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Background: Clinical studies have demonstrated platelet activation in inflammatory 
disorders including asthma and allergic rhinitis. This is distinct from platelet 
aggregation involved in the maintenance of haemostasis. Whilst signalling involved 
in platelet activation in haemostasis is well known, signalling pathways in activation 
responding to inflammatory stimuli remains unclear. 
Objectives: Here I investigated whether purinergic activation of platelets in allergic 
inflammation is distinct from purine involvement in platelet aggregation. In the 
second part, stimulation of platelets with a large range of both inflammatory and 
haemostatic stimuli was used to investigate potential distinct differences in platelet 
function 
Methods: Balb/c mice were sensitised to Ovalbumin (OVA) and subsequent OVA 
challenge. Bronchoalveolar lavage fluid was analysed for inflammatory cells and 
blood samples were collected and analysed for platelet activation. The role of 
platelet purinergic receptors and associated signalling mechanisms (RhoA) were also 
assessed. 
Additional in vitro experiments were performed on isolated human platelets to 
investigate the impact of a range of inflammatory and haemostatic stimuli on platelet 
function through measurements on P-selectin expression, platelet-leukocyte 
conjugation, aggregation and migration. 
Results: Allergen challenge induced significant increases in pulmonary leukocyte 
recruitment compared to sham controls (P<0.001).P2Y1 (P < 0.001), but not P2Y12 
or P2X1 antagonism inhibited allergen induced pulmonary leukocyte recruitment. 
The formation of platelet-leukocyte conjugates in vivo and platelet/P-selectin 
dependent polymorphonuclear cell migration in vitro was exclusively P2Y1 
dependent, furthermore allergen challenge induced significant increases in RhoA 
activity, a process which was inhibited exclusively through P2Y1 receptor 
antagonism. Leukocyte recruitment remained significantly suppressed in 
thrombocytopenic mice following reinfusion of platelets treated with a P2Y1 
antagonist or a Rho-associated kinase inhibitor confirming a crucial role for RhoA 
activity downstream of platelet P2Y1 receptors. 
Secondly, stimulation of platelets with chemotactic stimuli such as macrophage-
derived chemokine (P < 0.01) and stromal-cell derived factor 1α (P < 0.001) induced 
significant platelet migration without increases in P-selectin, platelet-leukocyte 
conjugates or aggregation. Conversely haemostatic stimuli induced increases in all 
measured parameters bar platelet migration 
Conclusion: RhoA signalling downstream of platelet P2Y1, but not P2Y12, 
represents a clear dichotomy in platelet activation during allergic inflammation 
versus haemostasis. Furthermore, platelet activation by different stimuli 
(inflammatory or haemostatic) can induce differences in platelet function further 
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1.1 Asthma and Allergic Inflammation 
 
"Asthma is a major non-communicable disease characterised by recurrent attacks of 
breathlessness and wheezing, which can vary in severity and frequency from person 
to person. During an asthma attack, the lining of the bronchial tubes swells, causing 
the airways to narrow and reducing the flow of air into and out of the lungs." 
The above quote is taken from the world health organisation (WHO). According to 
the WHO, some 235 million people currently suffer from asthma (WHO 2014). In 
the second half of the twentieth century worldwide prevalence of asthma has 
increased dramatically. However it is believed that asthma prevalence has plateaued 
since the late 1990s. Despite this, asthma rates in the UK remain amongst the highest 
across Europe, with an average of 3 deaths per day due to asthma in the UK alone 
(Asthma UK). Currently, the NHS spends £1.1 billion on asthma through treatment 
and care, whilst in 2008/2009 1.1 million working days were lost due to breathing or 
lung problems (Asthma UK). These figures clearly demonstrate a continued unmet 
need for effective long-term treatment. 
 Typically, asthma is characterised as a chronic disease, exacerbated by acute 
exposures to allergens or other irritants including cold air, exercise, particulates and 
chemical irritants, as well as some medications e.g. aspirin/β-blockers resulting in 
bronchoconstriction and subsequent inflammatory cell recruitment. Asthma is now 
recognised as a chronic inflammatory condition associated with changes to the 
architecture of the airways. The typical response to allergen provocation in asthma 
consists of the acute inflammatory response. This comprises of the early and late 
phase responses characterised by bronchospasm and contributes to the development 
of non-specific airway hyperresponsiveness, a state of heightened contraction of the 




airway wall and increased sensitivity to spasmogens. Following the acute phase, the 
chronic inflammatory response is initiated which is characterised by persistent 
inflammatory cell recruitment and structural changes to the airway architecture 
(airway wall remodelling), potentially contributing to the development of airway 
hyperresponsivess (AHR). 
The early phase response is the first stage of the allergic response following allergen 
provocation. Typically, this is characterised by interactions of IgE and the IgE 
receptor FcεRI on cells such as mucosal mast cells, dendritic cells, epithelial cells 
and basophils (Lambrecht and Hammad, 2010; Nakanishi, 2010; Barnes, 2011; 
Amin, 2012; Salazar and Ghaemmaghami, 2013), and normally occurs within the 
first 2 hours post provocation. This cross-linkage induces the release of pro-
inflammatory mediators including histamine, leukotrienes (LTC4), prostaglandins 
(PGD2), platelet activating factor (PAF), and reactive oxygen species (ROS) 
(Nakanishi, 2010; Barnes, 2011; Amin, 2012) leading to bronchoconstriction, mucus 
secretion and vasodilation (Barnes, 2011) (figure 1.1). 
 
Figure 1. 1 Pathogenesis of asthma and subsequent clinical consequences 
Early Asthmatic Response (EAR), Late Asthmatic Response (LAR), Airway 
Hyperresponsiveness (AHR), Forced Expiratory Volume (FEV1) 




6-9 hours post initial allergen challenge, the late phase of the acute response is 
initiated. The late phase response is typically characterised by early recruitment of 
inflammatory cells, in particular eosinophils to the lungs. Release of further pro-
inflammatory mediators and T-cell derived cytokine occurs, including IL-4 and IL-5 
(Hershey et al., 1997; Hogan et al., 1997; Moritani et al., 1998; Shi et al., 1998; 
Barnes, 2011). During this late phase response, inflammatory cells including 
eosinophils, basophils, neutrophils, macrophages and T-lymphocytes are all recruited 
(Wenzel et al., 1997). Once recruited, these inflammatory cells secrete further 
cytotxic mediators such as ROS, degradative enzymes, major basic protein (MBP), 
ecationic proteins, peroxidases and leukocyte derived neurotoxins. Furthermore, 
neutrophils, eosinophils, mast cells and basophils are all major sources of 
sulphidopeptide leukotrienes and PAF (Wardlaw et al., 2000), which can all 
contribute to further bronchospasm, vasodilation and mucus secretion. Indeed this 
extra bronchospasm can trigger non-specific AHR, as measured by heightened 
contraction of the airway wall and increased sensitivity to spasmogens (figure 1.1). 
The chronic inflammatory response associated with asthma is characterised by the 
immune response with increased secretion of the Th2 cytokines (IL-4, IL-5 etc) from 
Th2 cells (Lambrecht and Hammad, 2010; Nakanishi, 2010; Barnes, 2011), 
eventually leading to alterations in tissue architecture, tissue destruction, and 
inappropriate repair mechanisms that might modulate lung function, leading to a 
state of airway hyperresponsiveness (AHR). 
In patients with asthma, the CD4
+
 subset of T cells reside within the airways where 
they subsequently differentiate to form T helper 2 Cells (Th2) (Ying et al., 1997). 
Activation of Th2 cells by APCs such as mast cells and dendritic cells triggers the 
release of Th2 derived chemokines such as IL-4, IL-5, IL-13, eotaxin and RANTES 




(Regulated upon Activation, Normally T-cell Expressed and Secreted) (Moritani et 
al., 1998; Barnes, 2011; Bosnjak et al., 2011) involved in the initiation and 
maintenance of inflammatory cell recruitment. The importance of Th2 cells in 
allergic inflammation has been confirmed in murine models of allergic inflammation 
by the presence of severe eosinophilic airway infiltration and AHR development 
following adoptive transfer of TCR-transgenic Th2 cells, but not Th1 cells with 
subsequent challenge to the antigen Ovalbumin (OVA) (Cohn et al., 1998). 
Furthermore, CD4
+
 deficient mice demonstrate impaired AHR development in 
models of sheep red blood cell (SRBC) or OVA induced allergic inflammation 
combined with a decrease in Th2 cell derived IL-4 and IL-5 secretion resulting in 
impaired eosinophil recruitment (Gavett et al., 1994; Garlisi et al., 1995). The 
importance of Th2 cell activation in eosinophil recruitment has been demonstrated in 
a number of studies as the Th2 derived chemokines IL-4 and IL-5 have both been 
implicated in pulmonary eosinophil recruitment in asthmatics (Hershey et al., 1997; 
Hogan et al., 1997; Shi et al., 1998). Indeed IL-4 and IL-5 deficient mice 
demonstrate decreased leukocyte recruitment and AHR (Coyle et al., 1995; Foster et 
al., 1996; Hamelmann et al., 1997; Lampinen et al., 1999). Importantly however, IL-
12 has been shown to be capable of shutting down the Th2 response (Barnes, 2011). 
Interestingly, despite a decrease in both blood and sputum eosinophil numbers in 
response to allergen challenge, neither recombinant IL-12 or anti-IL-5 has shown 
any effect on BHR, demonstrating that the Th2 response alone is not the only 
process involved (Matsuse et al., 2003).  





Figure 1. 2. The Immune response to allergen 
 
 
During the chronic inflammatory phase, activated Th2 cells can also activate B cells 
inducing antibody secretion  (plasma cells, a cell type late in B cell development) 
(Drolet et al., 2010) (figure 1.2). Indeed, B cells have been previously been detected 
in the respiratory mucosa following exposure to allergen in a murine model of 
allergic inflammation (Singh et al., 2008; Drolet et al., 2010) and also demonstrate 
an ability to behave as APCs, allowing them to drive Th2 cell responses (Lindell et 
al., 2008). The most widely accepted role of B cells in allergic inflammation is their 
ability to produce IgE (Lack et al., 1995). This process is known as immunoglobulin 
switching of B cells and is processed by IL-4 and IL-13 (Lack et al., 1995; Barnes, 
2011). This production of IgE allows for further cross-linking of allergen with IgE 
on FcεRI expressing inflammatory cells inducing further release of histamine, 




leukotrienes and ROS leading to bronchoconstriction and tissue damage. IgE 
production also demonstrates an ability to induce eosinophil recruitment as the 
administration of IgE specific antibodies was able to inhibit antigen induced 
eosinophil recruitment (Coyle et al., 1995). Importantly, deficiencies in the low 
affinity IgE receptor FcεRII (CD23) showed no significant difference in eosinophil 
recruitment when compared to wild-type mice (Riffo-Vasquez et al., 2000). Thus, it 
would appear that at least in the case of murine models, IgE dependent pathways co-
exist with T cell dependent pathways demonstrating multiple pathways capable of 
inducing leukocyte recruitment and the development of AHR. 
Despite the abundance of research demonstrating the efficacy of anti-IL-5, IL-5 and 
IL-13 therapies in murine models, these antibodies have demonstrated very poor 
efficacy in clinical trials with patients with asthma, with a persistent state of AHR 
remaining (Leckie et al., 2000). Thus, there is a continued need to research the 
mechanisms involved in the inflammatory response. 
Current asthmatic therapies focus on combination therapies with corticosteroids e.g. 
fluticasone proprionate to provide inflammatory relief and long acting β2 agonists 
such as salmeterol to provide bronchodilation (GINA guidelines 2013). 
Unfortunately, not all asthmatic patients respond to corticosteroid treatment (patients 
who demonstrate no objective responses/improvements to FEV1 despite long term 
treatment with high doses of corticosteroids). There is clearly therefore a large unmet 
need for better treatments for asthmatic patients in dealing with excessive 
inflammation and AHR. Furthermore, current therapies are associated with unwanted 
side effects, depending on systematic or long term administration e.g. 
corticosteroids. 




1.2 Platelet Development and Maturation 
 
The platelet is a specialised component of the blood with a significant role in the 
cessation of bleeding following injury. The mammalian platelet is a sub cellular 
fragment approximately 0.5μm - 3μm in size with a resting discoid shape (Hartwig 
and Italiano, 2003). Platelets are produced within the cytoplasm of the 
megakaryocyte before being released into the circulation where they survive for 7-10 
days (Hartwig and Italiano, 2003). Under normal (resting) conditions, blood platelet 
concentration typically ranges between 1.5 and 3x10
8
 platelets/ml (Hartwig and 
Italiano, 2003). Furthermore under normal haemostasis these platelets demonstrate 
no interaction with either the vascular endothelium or other circulating platelets. 
Platelets are created through a process of maturation within the megakaryocytes, 
here pro-platelets are formed protuding out from the megakaryocytes. Whilst the 
precise mechanism remains unclear, Radley et al 1980 were the first to postulate the 
theory that long pro-platelet extensions from the megakaryocytes were intimately 
linked with the production and release of platelets (Radley and Scurfield, 1980). A 
more recent extension of the pro-platelet theory involves the production of platelets 
from the tips of the pro-platelets (Richardson et al., 2005). In this scenario, platelets 
form on the tip of the pro-platelet extrusion extending outwards from the 
megakaryocyte cell body. Importantly in this model the intracellular contents of the 
platelets must be moved from the regions of synthesis within the megakaryocytes 
cell body to the pro-platelets where the platelet organelles and granules can be 
assembled and packaged, thus completing platelet maturation and paving the way for 
subsequent release into the circulation (Leven et al., 1987; Tablin et al., 1990; 
Kosaki, 2005). It remains unclear where this process occurs as meegakaryocytes 




have also been detected within the vasculature including the lung, demonstrating the 
potential to provide an additional organ for thrombopoesis alongside the bone 
marrow. Indeed intact megakaryocytes have been observed in the lungs of rabbits, 
rats and mice, with cytoplasmic extensions consistent with the formation of pro-
platelets (Weyrich and Zimmerman, 2013), whilst platelets have been shown to be 
produced from circulating megakaryocytes within the pulmonary circulation 
(Trowbridge et al., 1982; Martin et al., 1983; Slater et al., 1985). In addition to 
animal models, megakaryocytes have been routinely detected in human lungs with 
elevated numbers observed in cases of acute lung injury (ALI), acute respiratory 
distress syndrome (ARDS), burns, asthma and thrombosis (Bozza et al., 2009). The 
potential for platelet production within the lung as a result of megakaryoycte 
fragmentation suggests a potential role for platelets as effector cells in a variety of 
pulmonary disorders (Weyrich and Zimmerman, 2013). 
1.2.2. Platelet Ultrastructure 
 
Platelets have a complicated structure which features an external and internal 
membrane system consisting of the surface-connected open canalicular system 
(OCS) (Bearer et al., 2002). The OCS acts as a reservoir of plasma membrane for 
platelet activation and the secretion of granular products. The spectrin membrane 
skeleton supports the OCS and plasma membrane through interactions with the actin 
cytoskeleton. The actin cytoskeleton controls the shape of the platelet, whilst closed 
channels of residual endoplasmic reticulum forms the dense tubular system (DTS) 
which is involved in calcium sequestration, and a vast array of additional different 
organelles are present including mitochondria, peroxisomes, lysosomes, α-granules 
and dense granules (Bearer et al., 2002). The α-granules and dense granules contain 




a wide range of important mediators involved in regulating haemostasis, 
inflammation and angiogenesis listed below in table 1.1 which are crucial in platelet 
function following activation. (Ciferri et al., 2000; White, 2002; Italiano and 
Battinelli, 2009; Smyth et al., 2009)  
Under normal physiological conditions, the platelet remains in its resting state 
indicated by it discoid shape. Upon activation the platelet undergoes a wide variety 
of structural and chemical changes. Following agonist induced activation, it is the 
ability of platelets to secrete mediators stored in their granules (table 1.1) allowing 
platelets to play important roles in the functional modulation of other cell types, 
















α-granules Dense granules Lysosomal granules 
Mulitmerin ATP †‡ CD63 (LAMP-3) † 
Adhesive glycoproteins ADP †‡ Cathepsin D 
Fibrinogen ‡ Calcium †‡ Cathepsin E 
von Willebrand Factor ‡ Serotonin †‡ 
Proline Carboxypeptidase 
A 
von Willebrand Factor propetide Pyrophosphate 
Proline Carboxypeptidase 
B 
Fibronectin ‡ GDP ‡ 
β-N-acetylhexos-
aminidase 
Thrombospondin-1 †‡ Magnesium β-D-glucuronidase 
Vitronectin †‡ Other secreted/released proteins β-D-galactosidase 
Coagulation Factors Protease nexin 1 ‡ α-D-mannosidase 
Factor V ‡ Gas6 ‡ α-L-arabinofuranosidase 
Protein S ‡ Amyloid β-protein precursor acid phosphatase 
Factor XI ‡ 
Tissue factor pathway 
inhibitor arylsulphatase 
Mitogenic Factors Factor XIII ‡   
Platelet-derived growth factor †‡ α2-Protease inhibitor   
Transforming growth factor-β † Complement 1 inhibitor †‡   
Endothelial cell growth factor • 
High molecular weight   
kininogen   
Epidermal growth factor α2-Macroglobin ‡   
Insulin-like growth factor-1 Vascular permeability factor   
Angiogenic factors Interlukin-1β †   
Vascular endothelial growth factor • Histidine-rich glycoprotein   
Platelet factor 4 (Inhibitor) • † Chemokines   
Fibrinolytic inhibitors MIP-1α (CCL3) †   
α2-Plasmin inhibitor ‡ RANTES (CCL5) †   
Plasminogen activator inhibitor-1 †‡ MCP-3 (CCL7) †   
Albumin Gro-α (CXCL1) †   
Immunoglobulins † Platelet factor 4 (CXCL4) †‡   
Granule membrane-specific proteins ENA-78 (CXCL5) †   
P-selectin (CD62P) †‡ NAP-2 (CXCL7) †‡   
GMP 33 Interlukin-8 (CXCL8) †•   
GPIb/IX/V ‡ TARC (CCL17) †   
GPIIb/IIIa ‡ CD63 (LAMP-3) †   
GPIV ‡     
   
   † - Granular contents involved in inflammation 
 ‡ - Granular contents involved in haemostasis 




Table 1. Platelet granular constituents (Adapted from Smyth et al. 2009) 




1.3 Mechanisms of Platelet Activation 
Platelet aggregation is an accepted function of platelets within the vasculature in 
response to exposed and damaged endothelium as a means to maintain hemostasis 
(Brass, 2010). Furthermore, inappropriate stimulation of platelet aggregation triggers 
thrombosis. The processes and mechanisms behind platelet activation stimulating 
aggregation have been extensively researched. However, more recently the role of 
platelets in the propagation of the inflammatory response has garnered more interest, 
including towards pathogen invasion, autoimmune and allergic diseases (Gresele et 
al., 1993; Moritani et al., 1998; Kowal et al., 2006; Pitchford et al., 2008; Boilard et 
al., 2010; Kraemer et al., 2010; Semple and Freedman, 2010). With regards to a 
range of inflammatory diseases including asthma, a key fundamental difference is 
the stimulation of platelet activation by inflammatory stimuli without subsequent 
platelet aggregation and thrombosis. Indeed, asthmatic patients actually demonstrate 
mild haemostatic defects (Maccia et al., 1977; Kowalska et al., 2000; Brown et al., 
2013).  
The mechanisms by which platelets become activated in response to different stimuli 
whilst sharing some similar signalling cascades and chemical events including 
granular secretion also demonstrate significant divergence in subsequent platelet 
function. For example, ADP acting via  the P2Y1 receptor and both Macrophage 
Derived Chemokine (MDC) acting via the CCR4 receptor and Stromal Derived 
Factor 1α (SDF-1α) via the CXCR4 receptor, signal through Gαq linked receptors 
with similar signalling cascades, as both trigger PLC stimulation and granular 
secretion. However whilst stimulation of the P2Y1 receptor with ADP triggers 
transient platelet aggregation (Fabre et al., 1999), activation with either MDC or 
SDF-1α stimulates platelet chemotaxis, thus demonstrating a potential divergence in 




platelet function (Kowalska et al., 2000; Kraemer et al., 2010).  Any mechanism of 
platelet activation requires stimulation of one or more of the exposed surface 
receptors. The surface of platelets express a large range of receptors and signalling 
molecules including receptors from the G-Protein Coupled Protein family of 
Receptors (GPCRS) (Purine Receptors, Thromboxane Receptor, Thrombin 
Receptors, Prostaglandin I2 (PGI2) receptor and the adrenergic receptor (α1R)), 
Ionotropic Receptors (P2X1), the single transmembrane domanin spanning non-
catalytic Toll-Like Receptors (TLR2, TLR4 and TLR9), integrins (αIIbβ3), 
Glycoprotein receptors (GPVI), Immunoglobulin receptors (i.e. FcεRI) and adhesion 
molecules (P-selectin, PSGL-1, CD40L, CD40 and ICAM-2) (Gear, 2001; Pitchford, 
2007a; von Hundelshausen and Weber, 2007; Gachet, 2008; Amison et al., 2012). 
Stimulation and signalling through any one of these receptors/molecules may 
contribute to different products of platelet activation including granule secretion, 
rolling, adhesion, leukocyte interactions, leukocyte recruitment, aggregation and 
pathogen recognition.  
One of the first measurable physiological responses following platelet stimulation is 
platelet shape change. Platelets change from a resting discoid shape into more 
rounded structures consisting of blebs and pseudopodia (Gear and Polanowska-
Grabowska, 2002) . Activation to induce shape change is through stimulation of Gαq 
coupled receptors for example the TP, PAR1, PAR4 and P2Y1 receptors (Brass, 
2010). Stimulation of Gαq coupled receptors triggers activation of phospholipase C-β 
(PLC-β) catalysing the production of Inositol triphosphate (IP3) and Diacyl-glycerol 
(DAG) from phosphatidylinositol 4,5-bisphosphate (PIP2) (figure 1.3). IP3 triggers 
Ca
2+
 mobilisation from intracellular stores whilst DAG triggers the activation of 
Protein Kinase C (PKC) which is responsible for the phosphorylation of subsequent 




downstream proteins, in particular actin (Jin et al., 1998; Kunapuli, 2003; Gachet, 




Figure 1. 3. Gq mediated induction of platelet shape change and granule secretion 
 
Actin is a highly conserved protein of 42kDa which when polymerised forms 
filaments. In platelets, actin exists in 2 forms, monomeric actin (G-actin) and 
polymeric filamentous actin (f-actin) (Bearer et al., 2002). The process of shape 
change occurs over a series of steps. Under resting conditions, the discoid shape of 
platelets is maintained through inhibition of actin polymerisation and the 
sequestration of actin monomers by monomer binding proteins (thymosin β4) 
(Hartwig, 1992; Bearer et al., 2002), thus increasing the concentration of actin 
required for polymerisation. However, following stimulation the platelet contracts 
losing its discoid shape and becomes more spherical and slightly smaller through 
actin filament disassembly controlled by gelsolin in the presence of Ca
2+
 and actin 




depolymerisation factors e.g. cofilin (Bearer et al., 2002). Platelet retraction is 
heavily dependent on interactions between Mysoin IIA and actin filaments. Platelet 
stimulation via either Gα13 inhibition of myosin phosphatase via RhoA activation, or 
via Ca
2+
 mobilisation results in increased myosin light chain kinase (MLCK) activity 
(Pleines et al., 2012; Aslan and McCarty, 2013). Both processes result in increased 
phosphorylation of myosin regulatory light chain (MRLC). MRLC phosphorylation 
allows the movement of myosin along actin filaments producing the contractile force 
involved in the rounding phase of platelet activation (Bearer et al., 2002; Li, 2002; 
Johnson et al., 2007). Breakdown of actin filaments presents 2 opportunities for 
platelet shape change. Firstly breakdown of the rigid cytoskeleton maintaining the 
discoid shape allows deformation of the membrane, and production of new structures 
within the platelet (Bearer et al., 2002). Secondly, breakdown of existing actin 
filaments increases the concentration of actin monomers present following their 
release from the ends of severed filaments (Bearer et al., 2002). These actin 
monomers can then bind to one of the 2 actin binding sites on the activated Arp2/3 
complex (actin related protein 2/actin related protein 3 complex) (Li, 2002). The 
Arp2/3 complex uses its second actin binding site to bind to the sides of the actin 
filaments. This process allows nucleation of the actin monomers and barbed-end 
elongation at 70 degree angles producing the pseudopodia extending out from the 
platelet following the rounding phase (Mullins et al., 1998; Welch, 1998; Pantaloni, 
2001; Li, 2002). As previously stated, platelet shape change is one of the first 
measurable physiological responses following platelet stimulation, however for 
continued platelet activation, release of a vast array of signalling and adhesion 
molecules from within the platelet granules occurs, all of which play different roles 




in the mediation and regulation of the involvement of platelets in processes such as 
haemostasis, inflammation and angiogenesis.  
In the process of granule secretion, molecules released from platelet granules, or the 
tissue environment provides the basis for platelet signalling. Indeed, defects in 
granular formation have been demonstrated in both patients and mice. Among them 
is Gray Patient Syndrome (GPS), a rare inherited disorder characterised by 
thrombocytopenia, enlarged platelets and a specific absence of α-granules (Nurden 
and Nurden, 2007; Blair and Flaumenhaft, 2009). Research suggests that α-granules 
fail to mature causing leakage of growth factors and cytokines leading to 
myelofibrosis as well as modification of thrombin/collagen-induced aggregation, 
resulting in a moderate to severe bleeding disorder (Nurden and Nurden, 2007). 
Other forms of α/δ-storage pool disorders (α/δ-SPD) include Hermansky-Pudlack 
syndrome (Cattaneo, 2002; Hurford and Sebastiano, 2008) and Chediak-Higashi 
syndrome (Cattaneo, 2002; Nagai et al., 2013), with both being disorders of dense 
granule (δ-granule) storage pool deficiency. 
Out of the 3 platelet secretory granules (α, δ and lysosomes) the α-granule is the 
most abundant with between 50-80 granules found per platelet and a diameter of 
approximately 200-500nm (Cattaneo, 2002; King and Reed, 2002; Blair and 
Flaumenhaft, 2009). α-granules can be identified through immunofluorescent 
labelling of constituents such as P-selectin and vWF. As listed in table 1.1 platelet α-
granules contain membrane bound proteins and proteins collected from receptor 
mediated endocytosis or stored following synthesis within the megakaryocyte, 
including the adhesion molecule P-selectin and platelet specific proteins including 
platelet factor 4 (PF4) and β-thromboglobulins (β-TG)  (Cattaneo, 2002; Smyth et 
al., 2009). Whilst platelets express a substantial number of these membrane proteins 




under resting conditions, platelet activation results in the release of the α-granule 
contents via exocytosis. This increases surface expression of the membrane proteins 
including integrins (αIIbβ3) and adhesion molecules (P-selectin), whilst also releasing 
substantial levels of soluble proteins such as PF-4, β-TG and growth factors (Blair 
and Flaumenhaft, 2009; Smyth et al., 2009) thus promoting cell-cell interactions and 
stimulating vascular repair.  
In contrast to α granules platelets contain substantially less dense (δ) granules, with 
only 3-9 present in human platelets (King and Reed, 2002). The contents of dense 
granules function primarily for the amplification of platelet activation through 
secretion of additional platelet agonists such as ADP, ATP, Ca
2+
 and 5-
Hydroxytryptomine (5-HT)  promoting platelet aggregation. They also include a 
large array of chemokines capable of stimulating further platelet activation and 
inducing platelet and leukocyte migration including Macrophage Inflammatory 
Portein-1α (MIP-1α), RANTES, Thymus- and activation-regulated chemokine 
(TARC) (Smyth et al., 2009). 
The final type of platelet secretory granule are the lysosomal (λ) granules, which 
have been shown to release their contents in humans post activation (Ciferri et al., 
2000). Indeed lysosomal granule release requires stimulation by strong platelet 
agonists such as thrombin and high doses of collagen (Ciferri et al., 2000). 
Lysosomal granule secretion has been detected by increased concentrations of β-N-
acetylhexosaminidases (HEX) (the main lysosomal glycohydrolase in blood 
platelets), in blood emerging from an experimental skin wound in comparison to 
venous blood. Importantly, levels of PF-4 and β-TG were increased demonstrating 
platelet activation in these regions (Ciferri et al., 2000) 




Platelet granules are normally secreted in response to stimulation of platelet surface 
receptors by their agonists, coupled to their second messengers. Exocytosis of 
granules requires Ca
2+
 mobilisation and Protein Kinase C (PKC) activation. 
Therefore many platelet receptors on the platelet surface are capable of inducing 
granule secretion through Gαq signalling via PLC-β activation, G13 stimulation of 
RhoA, Gi signalling through PI3K activation, TLR2 activation through PI3K 
activation and GPVI through Ca
2+
 mobilisation. (Hardy et al., 2004; Woulfe, 2005; 
Gachet, 2006; Brass, 2010; Cohen et al., 2011; Amison et al., 2012). PKC is one of 
the most important proteins involved in granular secretion, where the PKCθ isoform 
is particularly important. PKCθ activation downstream of Gαq
 
coupled receptors 
triggers the phosphorylation of syntaxin-4, a key component of the exocytotic 
machinery initiating the exocytosis of platelet granules via the SNARE hypothesis. 
This involves the soluble NSF attachment protein receptor (SNARE), a process by 
which vesicles relocate and fuse with the extracellular membrane allowing the 
release of their contents through coiled coil interactions of both vesicle membrane 
proteins, vSNARES (Synaptobrevin and synaptotagmin) and membrane associated 
proteins, t-SNARES (Syntaxin 1A, Soluble NSF Attachment Protein-25 (SNAP-25)) 
(Cattaneo, 2002; Hoylaerts, 2002; Cohen et al., 2011). Stimulation of Ca
2+
 
mobilisation also stimulates granular secretion through the promotion of PKC 
activity. 
Secretion of granular content contributes to activation through potentiation of 
platelet activation and reinforcing aggregation in haemostasis. Importantly, 
stimulation of granule secretion promotes an increase in mediators of platelet 
function in the vicinity of unactivated platelets propagating the process of platelet 
activation. 




1.4 A Possible Dichotomy in Platelet Function 
 
1.4.1 The Role of Platelets in Thrombosis and Haemostasis 
 
One of the most extensively described roles of platelets is the response to vascular 
injury. In their resting state, the platelets discoid shape is maintained by a highly 
specialised cytoskeleton of spectrin, actin and microtubules (White, 2002; 
Richardson et al., 2005). The traditional haemostatic response can be characterised 
by a 3 stage response: initiation, extension, and stabilisation (Brass, 2010). During 
the initiation phase, platelets are activated by collagen fibrils and thrombin release as 
a result of endothelial wall damage during vascular injury.  These fibrils form a 
complex with von Willebrand factor (vWF) which in turn interacts with exposed 
glycoprotein GPIbα on the surface of platelets circulating in the periphery of the 
blood vessel (Tsuji et al., 1997). These interactions mediated by vWF are promoted 
by exposure of the vWF A1 domain by high shear which promotes further 
interactions with GPIbα (Brass, 2010). The interaction of platelets and collagen 
fibres mediated by vWF slows platelet progression along the vessel long enough to 
induce platelet activation, triggering inside-out activation of the integrin αIIbβ3. 
Additionally, platelet agonists are secreted (ADP, thrombin, TxA2) into the local area 
coupled with increased adhesion molecule expression (i.e. P-selectin, PSGL-1) 
creating a monolayer of platelets over the damaged endothelium (Li et al., 2010). 
During the second extension phase, circulating platelets come into contact with the 
activated platelet monolayer resulting in further release of platelet agonists (Li et al., 
2010). The increased concentration of platelet agonists in the local region triggers 
activation of integrin αIIbβ3. αIIbβ3 is expressed at high densities on the platelets 
surface and is exposed to high μM concentrations of fibrinogen within the 




vasculature. However under resting conditions the receptor does not become even 
minimally occupied by fibrinogen; only after Ca
2+
 dependent inside-out signalling is 
αIIbβ3 converted from the low affinity to high affinity binding state for fibrinogen (Li 
et al., 2010). The coagulation cascade then leads to further interactions between 
fibrin and fibrinogen, fibrin formation is induced following exposure of 
subendothelial tissue factor to plasma factor VII. Platelet-platelet and platelet-
endothelium interactions are increased through interactions between 
fibrinogen/fibrin or vWF with αIIbβ3, GPVI or GPIb-IX-V, increasing platelet 
adherence to the damaged endothelium recruiting additional platelets thus extending 
the platelet plug. Platelet phospholipids also support factor Xase activity (a complex 
of FIXa, platelet bound FVIIIa and Ca
2+
), whilst prothrombinase complex formation 
is mediated by FXa, platelet bound FVa and Ca
2+
 leading to further thrombin 
generation. These additional pro-coagulant and clotting factors further stabilise the 
platelet plug.   
The third phase of stabilisation is described by the formation of additional close 
contacts between platelets within the platelet plug which is embedded with a cross-
linked fibrin mesh network. This is capable of withstanding the high shear forces 
generated by blood flow within the arterial circulation which further enhances the 
stabilisation of the platelet plug (Brass, 2010). Finally induction of outside-in 
signalling by αIIbβ3, αIIbβ3 triggers  contraction of the actin cytoskeleton leading to 
clot retraction which further helps to stabilise the platelet plug and prevent premature 








1.4.2 Platelet Involvement in Inflammatory Disorders 
The role of platelets in haemostasis and thrombosis has been well established. 
However, evidence now exists implicating the platelet as a cell type which can play 
important roles in inflammatory diseases including allergic inflammation, COPD, 
inflammatory bowel disease (IBD), atherosclerosis, rheumatoid arthritis, 
inflammation associated with cardiovascular diseases and the immune response to 
bacterial infections (Gresele et al., 1993; Moritani et al., 1998; Kowal et al., 2006; 
Pitchford, 2007b; Boilard et al., 2010; Semple and Freedman, 2010). 
Through the use of experimental models, platelets are thought to contribute to 
inflammatory disorders via numerous mechanisms. These include interactions with 
inflammatory leukocytes 'priming' them for migration into inflamed tissue where 
they can contribute to tissue damage and remodelling, and through the ability of 
platelets to provide a 'bridge' between the innate and the adaptive immune response. 
Interestingly, the direct migration of platelets into inflamed tissue might lead to a 
situation where release of pro-inflammatory mediators from platelet granules can 
contribute to tissue damage and impaired function. In this section the ability of 
platelets to modulate allergic inflammatory disorders will be discussed. 
 
1.4.2.1 Evidence of Platelet Activation in Allergic Inflammation 
Markers of platelet activation have been detected in patients with asthma following 
allergen provocation, and include elevated platelet derived RANTES, PF-4, β-TG 
and P-selectin (Moritani et al., 1998; Sullivan et al., 2000; Pitchford et al., 2003a; 
Kowal et al., 2006). Patients with asthma demonstrate altered platelet function ex 
vivo, because of higher states of platelet activation in vivo. For example, platelets 




taken from venous peripheral blood of patients with asthma during the allergy season 
respond poorly to a number of platelet activators (ADP, collagen, thrombin and 
adrenaline), as demonstrated by reduced secondary aggregation in vitro. This was 
found to correlate with elevated serum immunoglobulin (IgE) levels (> 250U/ml) 
(Gallagher et al., 1978). This state of 'platelet exhaustion' is believed to be a result of 
platelet activation by inflammatory stimuli in vivo inducing release and subsequent 
depletion of platelet granular contents. This results in an inability of the platelet to 
aggregate in response  to secondary stimuli ex vivo (Maccia et al., 1977; Gallagher et 
al., 1978; Gresele et al., 1993). Furthermore, it was shown that platelet function 
recovered in the experiments conducted outside of the allergy (pollen) season 
(Gallagher et al., 1978). This platelet activation in vivo may lead to the apparent mild 
haemostatic defects that some patients with asthma exhibit, as demonstrated by 
increased bleeding times (Szczeklik et al., 1986; Ind, 1991). 
Alterations in the lifespan of platelets have also been demonstrated. Healthy 
individuals typically show a platelet lifespan of around 8.9 days. However platelets 
from atopic asthmatic patients have a significantly decreased lifespan of only 4.7 
days, possibly as a result of chronic activation inducing a state of continual platelet 
consumption. This process could be reversed following corticosteroid treatment of 
these patients with asthma (Taytard et al., 1986). However, this observation has not 
been confirmed, as additional groups have failed to demonstrate any difference in the 
lifespan of platelets between healthy individuals and atopic asthmatic patients (Ind et 
al., 1985). Patients with asthma also demonstrate a mild thrombocytopenia (10-25%) 
observed within minutes following allergen exposure in patients with asthma 
(Sullivan et al., 2000; Kowal et al., 2006), potentially as a result of localised platelet 
recruitment to sites of inflammation. 




Inhibition of platelet derived bronchoactive mediator release (e.g. PAF) abolishes 
acute AHR in a baboon model of PAF induced bronchoconstriction (Arnoux et al., 
1988). Furthermore, platelets have been detected within the lung tissue and 
bronchoalveolar (BAL) lavage fluid of patients with asthma (Jeffery PK et al.,  
1989). Interestingly in addition to allergic inflammation, platelet migration towards 
sites of inflammation has also been detected in other inflammatory diseases 
including in the synovial fluid with rheumatoid arthritis patients and in the tissue of 
patients experiencing long periods of ischaemia (Boilard et al., 2010). Thus, the 
phenomenon of platelet migration and presence in extravascular sites suggests that 
they may interact directly with resident structural cells and modulate their function. 
Release of pro-inflammatory mediators such as β-TG, PAF, PF-4, RANTES, as well 
as increased surface expression of the adhesion molecule P-selectin are all elevated 
post allergen challenge in patients with asthma (Gresele et al., 1993; Moritani et al., 
1998; Tutluoglu, 2005; Kowal et al., 2006) providing evidence of platelet activation. 
PF-4 has been shown to stimulate histamine release from basophils, increase IgE 
receptor expression, induce bronchoconstriction, and provide chemotactic activity 
and subsequent activation of eosinophils, all of which propagate the inflammatory 
response (Coyle et al., 1996). Chemokines secreted by platelets, i.e. RANTES, 
TARC and MDC demonstrate chemotactic properties for inflammatory leukocytes 
including neutrophils, eosinophils and T cells contributing to the influx of 
inflammatory cells to the pulmonary tissue following allergen provocation (Lukacs 
et al., 1996; Lampinen et al., 1999; Sekiya et al., 2000) .  
In addition to the previously mentioned mediators released by platelets, 5-HT is also 
released from platelets. Platelets contain high levels of 5-HT, which is taken up from 
the plasma via 5-HT transporters (SERTs) and released from dense granules upon 




platelet activation  (Toh, 1956; Yoshida et al., 2002; Ni and Watts, 2006). Outside of 
the CNS, 5-HT is synthesised through the catalysation of L-tryptophan to 5-HT by 
tryptophan hydroxylase 1 (TPH1) (Dürk et al., 2013). 5-HT has been best 
characterised as a neurotransmitter involved in the regulation of physiologic 
functions including sleep and mood, but more recently it has emerged as an 
important inflammatory mediator in the peripheral nervous system. In asthma, 
elevated levels of plasma 5-HT have been detected, with plasma levels of 5-HT 
correlating with disease severity and pulmonary function (Malmgren et al., 1982; 
Lechin et al., 1996). Blockade of the 5-HT transporter through the use of 
pharmacological antagonists or 5-HT receptor blockade attenuate the development of 
allergic inflammation and airway wall remodelling in murine models of allergic 
inflammation (De Bie et al., 1998; Lechin et al., 1998; Lima et al., 2007). More 
recently, 5-HT synthesised by TPH1 has been shown to be critical in the 
development of allergic airway inflammation with significantly elevated levels of 5-
HT present in BAL fluid (Dürk et al., 2013). More importantly however, this study 
showed that platelet-derived and not mast-cell derived 5-HT was important in 
leukocyte infiltration and the development of BHR (Dürk et al., 2013), suggesting 
platelet derived 5-HT release as a potential future therapeutic target in the treatment 
of allergic inflammation. 
One of the key processes involved in leukocyte recruitment in inflammation is the 
formation of platelet-leukocyte conjugates, a process known to be P-selectin-PSGL-1 
dependent (Moritani et al., 1998; Hayward et al., 1999; Pitchford et al., 2005; 
Zarbock et al., 2006; Kornerup et al., 2010). Platelet P-selectin expression levels and 
circulating platelet-leukocyte conjugates are significantly elevated in asthmatic 
patients following allergen provocation as well as the frequency of conjugate 




formation (Gresele et al., 1993; Pitchford et al., 2003b, 2005; Kowal et al., 2006; 
Johansson et al., 2012). This function of platelets in allergic inflammation is of 
particular interest as leukocytes bound to platelets demonstrate increased integrin 
activation on the surface (Johansson et al., 2012; Johansson and Mosher, 2013; 
Johansson, 2014). Indeed, P-selectin interactions of platelets with blood eosinophils 
results in subjects with non-severe asthma expressing α4β1 and αMβ2 present in an 
intermediate-activity state. Eosinophils in this state are said to be pre-activated 
'primed' eosinophils ready to facilitate adhesion onto the endothelium (figure 1.4) 
(Johansson and Mosher, 2013). This has been confirmed with in vitro studies where 
platelet-induced adhesion of eosinophils to endothelium is enhanced with platelets 
isolated from asthmatic subjects when compared to platelets taken from healthy 
controls (Ulfman et al., 2003). These 'primed' eosinophils bound with platelets via P-
selectin-PSGL-1 interactions provide a link between platelet activation and 
eosinophilia in nasal secretions of infant and adolescent asthmatic patients (Benton 
et al., 2010). 
Evidently, the involvement of platelets in allergic inflammation adds to an already 
complex web of cellular interactions involved in propagating the allergic 
inflammatory response. In the next section, the different ways by which platelet 









1.4.2.2 Platelet Pulmonary Recruitment 
Platelets have been observed to undergo diapedisis in sections of lung from 
asthmatic patients as well as from lung samples obtained from mice, rabbits and 
guinea pigs sensitised and challenged to allergen (Jeffery PK et al., 1989; Pitchford 
et al., 2008). Indeed in allergic inflammation, a mild systemic thrombocytopenia (10-
25%) has been observed in asthmatic patients following allergen challenge 
(Maestrelli et al., 1990; Sullivan et al., 2000; Kowal et al., 2006). This migration of 
platelets towards allergen has also been confirmed  in vitro and has been shown to be 
dependent on allergen/allergen specific IgE interactions with the FcεRI receptor 
(Pitchford et al., 2008).  Further research has begun to show that in addition to 
asthma, platelet migration has also been seen to occur in other inflammatory 
diseases; including accumulation within the synovial fluid of joints in rheumatoid 
arthritis (Boilard et al., 2010), and recruitment to the vascular wall following periods 
of ischaemia (Kraemer et al., 2010). Platelets have been shown to express functional  
chemokine receptors (CCR1, CCR3, CCR4 and CXCR4) (Clemetson et al., 2000), 
and ligands of these receptors including SDF1α (CXCL4), MDC (CCL-17), and 
TARC (CCL-22) have all shown the capacity to activate platelets (Abi-Younes et al., 
2000; Kowalska et al., 2000). Indeed, platelets have previously been shown to 
migrate towards SDF-1α and f-MLP in vitro demonstrating that platelets are indeed 
motile cells (Czapiga et al., 2005; Kraemer et al., 2010). It is therefore possible that 
platelet migration is modulated by these chemokines. Indeed, evidence suggests that 
platelets can be recruited to the lungs immediately following allergen exposure in a 
murine model of ovalbumin induced pulmonary inflammation (Yoshida et al., 2002; 
Pitchford et al., 2008), demonstrating that allergen/chemokines may be capable of 
inducing platelet activation itself. 




1.4.2.3 Platelet Involvement in Chronic Inflammation 
Patients with chronic asthma demonstrate substantial remodelling of the pulmonary 
architecture, with thickening of the airway epithelium and smooth muscle combined 
with increased reticular-fibre deposition within the extracellular matrix resulting in 
impaired lung function. In animal models, these characteristics can be mimicked 
through chronic exposure to aerosolised allergen, and in platelet depleted mice, these 
remodelling processes observed following chronic allergen exposure are 
significantly reduced (Pitchford et al., 2004). This implies that platelets contribute to 
wound repair through the release of cellular mitogens such as insulin-like growth 
factor (IFG), transforming growth factor β (TGFβ), vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF) and platelet derived growth factor 
(PDGF).  
As platelets appear to possess the ability to migrate into inflammed tissues, a direct 
mechanism by which platelets can promote the inflammatory process is possible. In 
addition to chemokines and platelet agonists, platelet granules also contain numerous 
degradative enzymes including the matrix metalloproteinase's (MMP1, MMP2, 
MMP3, MMP14 and potentially MMP9) (Seizer and May, 2013). Their main 
function is the degradation of the extracellular matrix. In atherosclerosis this leads to 
destabilisation of the thrombi and the eventual rupturing of the atherosclerotic plaque 
with vascular wall rupture being the main cause of mortality in atherosclerotic 
patients (Agewall, 2006). 
Additionally, platelets from patients with asthma also release arachidonic acid 
metabolites and phospholipid metabolites (Plaza et al., 1995). 
Hydroxyaicosatetraenoic acid (12-HETE) production is stimulated by the release of 




the platelet specific enzyme 12-lipoxygenase. 12-HETE also demonstrates strong 
chemotactic activity for eosinophils (Marcus et al., 1984), and is taken up by 
neutrophils for the production of 20-diHETE. Neutrophils alone are incapable of 
producing 20-diHETE and require the uptake of platelet produced 12-HETE for its 
production (Marcus et al., 1984, 1987, 1988). 20-diHETE has chemoattractant 
properties for neutrophils but also stimulates the production of leukocyte 5-
lipoxygenase involved in the production of leukotrienes (LTC4, LTD4, LTE4 and 
LTB4) (Maclouf and Murphy, 1988). Leukotrienes are a potent family of 
inflammatory mediators capable of inducing bronchospasm, increased vascular 
permeability, mucus hyper secretion (Maclouf and Murphy, 1988), induction of 
AHR (Diamant et al., 1997) and inflammatory cell recruitment. Whilst the cysteinyl 
leukotrienes (LTC4 and LTD4) specifically induce eosinophil recruitment, LTB4 
demonstrates non-specific chemoattractant properties for leukocytes. Interestingly, 
platelets and neutrophils are capable of synergism in the metabolism of arachidonic 
acid, as leukocyte derived LTA4 can be converted to LTC4 by platelets through 
gluthathion-s-transferase (Maclouf and Murphy, 1988). However this requires direct 
contact between leukocytes and platelets through platelet p-selectin and PSGL-1 
(Maclouf and Murphy, 1988). 
 
1.4.2.3 Platelet Involvement in Bridging the Innate and Adaptive Immune 
Responses 
Platelets posses many receptors involved in the recognition of antigens including the 
toll-like receptors (TLRs) which recognise components of pathogens such as 
lipopolysaccharides (LPS) contained within the bacterial cell wall. Platelets express 
3 receptors of the TLR family, TLR2, 4 and 9 (Aslam et al., 2006; Semple and 




Freedman, 2010). Furthermore, platelets also express both the high (10
-7
 M) and low 
(10
-9
 M) affinity IgE receptors (FcεRI and FcεRII respectively) as well as IgG 
receptors (FcγRI, FcγRII) (Joseph et al., 1986, 1997). The first indication of IgE 
induced activation of platelets was observed by Benveniste in 1972, where leukocyte 
dependent histamine release was observed from rabbit platelets. Later identification 
of immunoglobulin receptors on platelets strongly implicated a potential role of 
platelets within the adaptive immune response. Platelet activation induced by 
stimulation of FcεRI can induce platelet release of 5-HT and RANTES, suggesting 
that platelet stimulation by IgE might affect the allergic inflammatory response 
(Hasegawa et al., 1999), given that similar cross-linking of allergen specific IgE with 
the FcεRI receptor on mast cells results in mast cell degranulation and the release of 
both preformed and newly synthesised mediators including ROS, eicosanoids, 5-HT, 
and histamine (Hogan and Schwartz, 1997). Importantly, in normal individuals, IgE 
binds approximately 20-30% circulating platelets, whilst in asthmatic patients, this 
binding increases to approximately 50% (Maccia et al., 1977; Joseph et al., 1986), a 
phenomenon also observed in circulating platelets obtained from allergen-sensitised 
mice (Pitchford et al., 2008). Furthermore platelets collected from atopic individuals 
were shown to have significantly elevated IgE stored within the platelet granules 
which correlated with increased serum IgE (Gallagher et al., 1978). In agreement 
with this, allergen-sensitised mice demonstrate increased platelet bound-IgE 
(Pitchford et al., 2008).  
The implication of platelets in bridging the innate and adaptive immune responses 
can be seen in patients of immune thrombocytopenia (ITP), a condition characterised 
by both accelerated clearance of autoantibody-sensitised platelets and suboptimal 
platelet production. Studies have demonstrated that patients with ITP suffer from 




disturbances to both the innate and adaptive immune responses (reviewed in Lazarus 
2013). Other studies have implicated platelets in a regulatory role for the 
maintenance of Th cell homeostasis, where platelet derived PF4 has been implicated 
in limiting Th17 cell differentiation (Shi et al., 2014).  
One of the key components of platelet activation and their contribution to immunity 
and inflammation lies in the interactions of granule released CD40 and CD40L 
present on activated platelets. CD40 is a phosphorylated membrane glycoprotein 
constitutively expressed on platelets (Inwald et al., 2003) which interact with 
leukocytes expressing CD40 ligand (CD40L) (Vanichakarn et al., 2008). Whilst the 
role of CD40 and CD40L has been extensively researched in atherosclerosis, it's role 
in inflammation is less well defined. Recent work has identified that vast numbers of 
CD40+ and CD40L+ cells are detectable in conditions of chronic inflammation and 
autoimmune disorders (Danese et al., 2004). Engagement of platelet CD40 with 
CD40L has been shown to induce platelet activation demonstrated by increased P-
selectin expression (Danese et al., 2004). Furthermore, activation induced through 
CD40 and T cell derived CD40L interactions triggered granule release of the 
leukocyte chemokine RANTES, enhancing T cell recruitment through endothelial 
cell activation. This produces an amplification loop of T cell recruitment mediated 
by platelet and T cell interactions (Henn et al., 1998; Danese et al., 2004). These key 
interactions between CD40 and CD40L of platelets and leukocytes potentially link 
the provocation of tissues with the adaptive immune response. Platelet activation by 
thrombin has been shown to increase levels of platelet CD40L inducing the 
maturation of dendritic cells as indicated by elevated surface expression of both 
CD8- and CD83 on dendritic cells and increased levels of IL-12 production (a 
process dependent on platelet-derived CD40L) (Czapiga et al., 2004). Platelet 




induced maturation of dendritic cells potentiates co-stimulatory signals from 
dendritic cells inducing T cell activation and survival (Czapiga et al., 2004). This 
suggests that platelet signalling can lead to the maturation of APCs and modulate 
their subsequent effects on the adaptive immune response. 
 
1.4.2.4 Platelet Involvement in Inflammatory Cell Recruitment 
A large amount of research has recently described the ability of platelets to interact 
with inflammatory leukocytes within the circulation, with platelet-leukocyte 
conjugates significantly elevated in asthma (Gresele et al., 1993; Pitchford et al., 
2003a, 2005; Kowal et al., 2006; Johansson et al., 2012). Other inflammatory 
disorders are also associated with heightened platelet activation including COPD, 
atherosclerosis and rheumatoid arthritis (Ott I, et al., 1996; Neumann et al., 1997; 
Joseph et al., 2001; Sarma, 2002; Huo et al., 2003; Pitchford et al., 2003b, 2005; 
Irving et al., 2008). As P-selectin bound leukocytes and the resulting contact-
dependent activation of leukocytes have been shown to induce the conversion of the 
αMβ2 and α4β1 integrins to the intermediary activity-state (Johansson and Mosher, 
2013), leading to increased adhesion of leukocytes to the vascular endothelium via 
P-selectin-dependent adhesion  (Jawieñ et al., 2002; Ulfman et al., 2003), it suggests 
a mechanism by which leukocytes can become activated and subsequently adhere to 
damaged endothelial cells prior to diapedisis into the tissue.  
The interaction of platelet derived P-selectin with its counter ligand PSGL-1 on the 
surface of leukocytes leads to leukocyte activation (Pitchford et al., 2005; Kornerup 
et al., 2010; Johansson et al., 2012; Page and Pitchford, 2013). The formation of 
platelet-leukocyte conjugates seen in the clinic has been replicated in a number of 




animal models (Sanctis et al., 1997; Broide et al., 1998; Lukacs et al., 2002; 
Pitchford et al., 2003a, 2005) with these platelet-leukocyte aggregates forming as a 
result of adhesion interactions without the induction of platelet aggregation (Figure 
1.3).  
 
Figure 1. 4. Identification of platelet-eosinophil complexes taken from allergen-
sensitised mice after allergen exposure 
Lung samples taken from allergen challenged mice were stained with rat anti-MBP for 
eosinophils (green fluorescence) and goat anti-CD41 for platelets (red fluorescence). A 
Image with green fluorescence filter only B Red and green fluorescence filters combined, 
showing eosinophils complexed with platelets C Individual platelets (red) attached to 
eosinophils (green). (Pitchford et al., 2005) 
 
P-selectin is an integral membrane glycoprotein expressed by platelets. In resting 
conditions, P-selectin is stored within the α-granules of the platelet. Cellular 
activation induces rapid relocation of P-selectin from the secretory α-granules to the 
plasma membrane of the platelet (Gachet, 2006). Here, P-selectin recognises its 
counter ligand; PSGL-1 expressed on the surface of polymorphonuclear (PMN) 
cells, initiating the reversible interaction of platelets and leukocytes increasing 
circulating platelet-leukocyte aggregate numbers (Joseph et al., 2001; Jawieñ et al., 
2002; Pitchford et al., 2003a, 2005; Zarbock et al., 2006; Irving et al., 2008; 
Kornerup et al., 2010) . These interactions then support contact-dependent activation 




of leukocytes and subsequent intergin expression, facilitating stable interactions 
between the 2 cell types. Platelet PSGL-1 expression then allows the tethering and 
subsequent rolling of platelet-leukocyte conjugates to endothelium through 
interactions with endothelial derived selectins. This rolling subsequently progresses 
to firm adhesion through integrin interactions via inside-out signalling from either 
platelets or leukocytes with the endothelium (Johansson et al., 2012; Johansson and 
Mosher, 2013) (figure 1.5). 
 
Figure 1. 5. Contribution of platelets to inflammatory processes 
Platelet activation results in granular secretion of inflammatory mediators and upregulation 
of adhesion molecules. Expression of P-selectin and PSGL-1 triggers platelet-leukocyte 
conjugation eventually targeting the P-L complex to the endothelium for firm adhesion 
through integrin activation. This allows the P-L complex to migrate across the endothelium 
into damaged tissue (Amison et al., 2012) 
 




The requirement of platelets for leukocyte recruitment has been confirmed in a 
variety of in vivo animal studies, in particular models of allergic inflammation, 
allergen induced eosinophil and lymphocyte recruitment is abolished in platelet 
depleted rabbits, guinea-pigs and mice (Lellouch-Tubiana et al., 1988; Coyle et al., 
1990; Pitchford et al., 2003a, 2005). This allergen induced eosinophilia was then 
restored following platelet reinfusion thus confirming the role of platelets (Pitchford 
et al., 2003b). Pitchford et al 2005, expanded on this through reinfusion of 
thrombocytopenic mice with platelets treated with the P-selectin blocking antibody 
RB40.34. When platelets treated with the anti-P-selectin antibody were reinfused, 
allergen induced eosinophilia remained suppressed (Broide et al., 1998; Lukacs et 
al., 2002; Pitchford et al., 2003b, 2005). This clear involvement of P-selectin in 
inflammatory cell recruitment has led to possible targeting of the P-selectin/PSGL-1 
interactions as a therapeutic target for inflammatory cell recruitment. The pan-
selectin antagonist Bimosiamose (TBC1269) can significantly reduce leukocyte 
recruitment in a variety of in vivo  assays including significant attenuation of 
neutrophil accumulation at infarction sites in a model of myocardial 
infarction/reperfusion injury (Onai et al., 2003) as well as attenuation of late 
asthmatic responses following allergen challenge (Beeh et al., 2006).  
It is important to consider that whilst P-selectin and PSGL-1 interactions are clearly 
important for leukocyte adhesion and transmigration, they are not the only adhesion 
molecules involved, and  there is probably both a sequential and time dependent 
interplay of molecules expressed on the platelets surface as well as the release of 
soluble mediators. For example, platelets have previously been reported to secrete 
soluble CD40L (sCD40L) upon activation as well as up-regulating membrane 
expression of CD40L (Henn et al., 1998; Vanichakarn et al., 2008; Chandler et al., 




2010). Vanicharkan et al. 2008 have reported that platelet derived CD40L can 
interact with CD40 expressed on neutrophils stimulating the release of ROS capable 
of activating platelets and enhancing sCD40L release through a positive feedback 
mechanism (Vanichakarn et al., 2008) propagating the inflammatory response. 
Additionally, the increased expression of CD40L on platelets enables interactions 
with endothelial cells expressing CD40 triggering production of pro-inflammatory 
cytokines and the upregulation of adhesion molecules (Henn, 2001; Danese et al., 
2011). This elevation in adhesion molecule expression generates increased signals 
involved in the recruitment and extravastion of leukocytes at the site of inflammation 
(Henn et al., 1998; Danese et al., 2004). Indeed, stimulation of endothelial cells by 
platelet derived CD40L has been shown to significantly enhance inflammatory cell 
recruitment in atherosclerosis (Büchner et al., 2003). Platelet also express CD40 on 
their surface, which allows for interactions with platelets expressing CD40L 
increasing the formation of platelet aggregates (Inwald et al., 2003), but also up-
regulated surface expression of platelet P-selectin, increased α- and dense-granule 
secretion, enhanced platelet-leukocyte adhesion and platelet integrin activation 
(Inwald et al., 2003), all of which continue to propagate the inflammatory response. 
Platelets also express intercellular adhesion molecule-2 (ICAM-2) (Diacovo et al., 
1994) which is capable of mediating leukocyte-platelet interactions via CD11a/CD18 
(Leukocyte function associated antigen-1, LFA-1) and firm adhesion following 
selectin mediated tethering (Kuijper et al., 1998). Additionally, platelet endothelial 
interactions can be mediated by platelet expressed platelet endothelial cell adhesion 
molecule 1 (PECAM-1) and junctional adhesion molecule 1-3 (JAM 1-3) (Chavakis 
et al., 2004). Indeed, antagonism of these interactions has been reported to 




significantly attenuate neutrophil emigration into inflamed tissue in a murine model 
of peritonitis (Chavakis et al., 2004). 
This demonstrates that whilst platelet-leukocyte interactions via P-selectin-PSGL-1 
interactions are important in the formation of platelet-leukocyte conjugation and 
subsequent contact-dependent activation of the leukocytes, additional adhesion 
molecules are upregulated on the platelet surface upon activation. These contribute 
to further platelet, leukocyte and endothelial cell activation propagating the 
inflammatory response through the production of pro-inflammatory mediators as 
well as enhancing inflammatory cell recruitment to sites of inflammation. 
 
1.6.1 Platelet Purinergic Receptors 
 
The Purines ATP and ADP have previously been implicated in parameters linked to 
inflammatory processes. Stimulation of platelets with ADP induces significant 
increases in P-selectin expression. Furthermore, antagonism of both the P2Y1 and 
P2Y12 receptors have previously been shown to inhibit P-selectin expression and the 
formation of these platelet-leukocyte conjugates within the circulation (Klinkhardt et 
al., 2002; Storey et al., 2002; Leon et al., 2003; Evangelista et al., 2005; Perneby et 
al., 2007). The ability of platelet purinergic receptors to modulate platelet function 
that is relevant to both haemostasis (platelet shape change, aggregation, integrin 
αIIbβ3 activation, thrombus stabilisation) and inflammation (P-selectin expression, 
Platelet-leukocyte conjugation) demonstrate possibilities by which purine 
stimulation of platelets may contribute to their role in inflammation. Whilst the 
effects of purine stimulation of the haemostatic functions of platelets are well 




documented, the role of the purines in the inflammatory setting of platelets clearly 
requires more detailed analysis.  
 
Figure 1. 6. Involvement of platelet receptors in the inflammatory response 
 
The platelet surface express a family of receptors activated by the purines, ADP or 
ATP, and have long been known to be capable of inducing platelet activation 
resulting in aggregation, granule secretion, adhesion molecule upregulation and 
interactions with inflammatory cells (Fabre et al., 1999; Léon et al., 1999; Storey et 
al., 2000; Eckly et al., 2001; Hechler et al., 2003; Leon et al., 2003, 2004; Cattaneo 
et al., 2004). Whilst the family of Purinergic receptors is extensive, only 3 receptor 
subtypes are expressed on the platelets surface, two from the GPCR P2Y family of 
receptors P2Y1 and P2Y12 and one from the ionotropic P2X family, P2X1 (Figure 
1.6). The P2X1 receptor is a ligand gated cation ion channel activated by endogenous 




ATP resulting in a rapid influx of Ca
2+
 ions, whilst both the P2Y1 and P2Y12 
receptors are stimulated by endogenous ADP initiating separate signalling cascades 
controlled by their respective linked G Proteins (Woulfe, 2005; Gachet, 2006, 2008; 
Mahaut-Smith et al., 2011) (Figure 1.6).  
During normal haemostasis, endothelial cells express the enzyme NTPDase1 (also 
known as CD39) which catalyses the breakdown of ATP to ADP and subsequently 
into inactive AMP, thus eliminating 2 major molecules resulting in the interaction of 
endothelial cells and blood platelets (Marcus et al., 2005). However, following 
vascular injury, endothelial cells become damaged exposing the sub endothelial 
matrix, whilst also decreasing the elimination of ATP and ADP through decreases in 
NTPDase1 availability, triggering platelet activation through purinergic stimulation 
(Marcus et al., 2005). 
 
1.6.2 Platelet P2X1 Receptor Signalling 
To date, 7 different subunits of the P2X receptor family have been identified, P2X1-7. 
Each of the different subunits possess the same topology which consists of 2 
transmembrane spanning domains (TMD1 and TMD2), a large extracellular loop 
domain and intracellular C and N termini. Under normal conditions a functional 
receptor exists as either homotrimers or heterotrimers varying in kinetics and 
pharmacology, however all P2X receptor subtypes are activated by ATP (Ralevic 
and Burnstock, 1998; North, 2002; Burnstock, 2007; Surprenant and North, 2009; 
Hu and Hoylaerts, 2010). Whilst P2X receptors do not appear to have common 
consensus ATP binding sequences it is suspected that ATP molecules interact with 
the extracellular loop between TMD1 and TMD2 enabling up to 3 molecules of ATP 
to bind to a single functional receptor (Roberts and Evans, 2007). The P2X1 receptor 




expressed in platelets, following stimulation by ATP increases cellular permeability 
to Ca
2+
 ions (although small levels of Na
2+
 ion permeability have also been 
observed) (Sun et al., 1998) providing a substantial source of direct Ca
2+
 influx into 
the platelet post activation. This rapid influx of Ca
2+
 can instigate a number of 
reactions including depolarisation of the platelet membrane to enhance signalling 
through the Gq coupled receptors including the P2Y1 receptor (Toth-Zsamboki et al., 
2003). Rapid influx of Ca
2+
 ions induced by ATP receptor stimulation of the P2X1 
receptor can trigger a rapid but reversible shape change peaking within seconds, and 
low level inside-out activation of integrin αIIbβ3 through either calmodulin (CaM) 
dependent activation of myosin light chain kinase (MLCK) or PKC activation (Toth-
Zsamboki et al., 2003) (Figure 1.6). Binding of Ca
2+
 with CaM results in a 
conformational change of CaM, inducing its dimerisation and remodelling of its 
active sites (Toth-Zsamboki et al., 2003). This alteration in CaM's structure causes 
the displacement of its auto-inhibitory domains of numerous target proteins 
including MLCK (Toth-Zsamboki et al., 2003), elevating levels of myosin light 
chain phosphorylation (MLCP). Alternatively, P2X1 mediated rises in intracellular 
Ca
2+
 can trigger PKC activation, which when combined with CaM activation triggers 
phosphorylation of ERK2 (Toth-Zsamboki et al., 2003; Oury et al., 2006). Both 
mechanisms increase phosphorylation of myosin light chain kinase resulting in 
platelet shape change, however ERK2 phosphorylation is much slower than shape 
change and is thus more likely to be involved in the amplification of aggregation, as 
demonstrated through impaired aggregation and dense granule secretion at low levels 
of GPVI stimulation in the presence of a blocker of ERK2 phosphorylation (Oury et 
al., 2001; Mahaut-Smith et al., 2011). Importantly, stimulation of P2X1 receptors 
alone appear to be capable only of inducing reversible platelet shape change without 




subsequent aggregation (Rolf et al., 2001). This Ca
2+
/CaM dependent regulation of 
MLC kinase may be fundamental in the regulation of platelet activation given the 
importance of MLCK in the regulation of actomyosin reorganisation and subsequent 
cytoskeleton reorganisation. A process involved in key stages of platelet activation 
such as shape change and granule secretion (Johnson et al., 2007) (Figure 1.6). 
Phosphorylation of the myosin regulatory light chain subunit produces an elevation 
of actin-activated myosin ATPase activity resulting in cross-bridging of both actin 
and myosin. Cross-bridging of actin and myosin instigates a number of events 
resulting in the centralisation of secretory granules within the platelet (Ikebes et al., 
1994; Toth-Zsamboki et al., 2003). P2X1 regulation of shape change and granule 
secretion may contribute to positive feedback of additional platelet agonists initiating 
subsequent platelet aggregation (Gachet, 2008; Mahaut-Smith et al., 2011).   
Studying the impact of the P2X1 receptor in platelet activation has proved difficult 
due to rapid desensitisation of the receptor following stimulation. However  
desensitisation can be prevented through the hydrolysis of excess ATP using apyrase 
(Sun et al., 1998; Rolf et al., 2001; Mahaut-Smith et al., 2011). When desensitisation 
of the P2X1 receptor has been suitably reduced the P2X1 receptor appears be to 
incapable of inducing platelet aggregation alone, although it has been implicated in 
collagen and shear induced aggregation (Hechler et al., 2005). Indeed collagen 
induced aggregation and secretion is decreased in P2X1 deficient platelets and 
selectively P2X1 desensitised platelets (Hechler et al., 2003). Furthermore, platelet 
adhesion and thrombus size was decreased in P2X1 deficient mice combined with a 
decrease in thrombus removal time (Oury et al., 2001; Hechler et al., 2003; Kahner 
et al., 2006). Stimulation of P2X1 receptors triggers initial platelet shape change and 
granular centralisation without secretion, potentially helping to amplify platelet 




responses mediated by lower concentrations of alternate platelet agonists (Mahaut-
Smith et al., 2011). Indeed, it appears that P2X1 receptor signalling is capable of 
priming Gq coupled receptors i.e. PAR receptors, TP receptors and P2Y1 receptors 
with significant potentiation of their responses observed in the presence of combined 
stimulation of the P2X1 receptor (Oury et al., 2001; Erhardt et al., 2006; Gachet, 
2006; Kahner et al., 2006). However this potential synergism between P2X1 
receptors and alternate Gq coupled receptors requires further investigation as 
conflicting studies exist for the role of P2X1 receptors in thrombin induced activation 
(Hechler et al., 2003). Whilst further clarification is required, it demonstrates a 
potential role for the potentiation of Gq stimulated activation of platelets, providing 
an important basis by which the platelets response can be amplified to achieve full 
activation and events including thrombus generation. 
The synergy between P2X1 receptors and Gq coupled receptors can be readily seen 
with the P2Y1 receptor. Whilst the P2Y1 receptor alone can only induce weak 
secretion of platelet granules, ATP released during these events can significantly 
enhance intracellular Ca
2+
 elevation and whilst P2X1 receptor blockade has no 
impact on ADP-induced platelet aggregation, the subsequent activation of the P2X1 
receptor accelerates the mobilisation of intracellular Ca
2+ 
(Mahaut-Smith et al., 
2011) a process which may benefit platelet adhesion to damaged vessel walls which 
may otherwise fail to adhere if not activated in a small time window (Mahaut-Smith 
et al., 2011). Thus, specific stimulation of P2X1 receptors alone are capable of 
inducing platelet activation but only to the level of reversible shape change and 
granule secretion but are capable of the modulation and potentiation of a number of 
additional platelet agonists. The P2X1 receptors have the potential to substantially 
modulate haemostatic functions under a variety of conditions through modulation of 




platelet shape change and intracellular Ca
2+
 mobilisation in platelets. Indeed, whilst 
the role of P2X1 receptor activation in inflammation hasn't been extensively 
researched, initial studies have begun to implicate it in a number of inflammatory 
parameters including the promotion of neutrophil migration by ATP induced P2X1 
receptor activation on neutrophils (Lecut et al., 2009). Later studies have also 
implicated a protective role for P2X1 receptor activation in endotoxemia through 
dampening of neutrophil activation (Lecut et al., 2012). Whilst the emerging area of 
P2X1 involvement in inflammation currently requires further research, it opens the 




1.6.3 Platelet P2Y Subfamily 
The second class of purinergic receptor present in platelets are the ADP sensitive 
metabotropic P2Y receptors. At present this subfamily is accepted to contain 8 
different human subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 
(table 1.2), with the missing numbers accounted for by either non-mammalian 
subtypes or receptors with similar sequence homology, but with no apparent 
functional sensitivity to the nucleotides (Ralevic and Burnstock, 1998; Burnstock, 
2007). All of the receptors demonstrate a similar molecular structure typical of the G 
protein coupled family of receptors (GPCRs) with an extracellular N-terminal 
domain and a intra-cellular C-terminal domain separated by 7 transmembrane 
spanning domains (figure 1.9) (Deupi and Kobilka, 2007).  Activation of the GPCR 
purinergic receptors occurs along the extracellular loop segment connecting 
transmembrane domains IV and V (Burnstock, 2007; Deupi and Kobilka, 2007). 




When an agonist binds to the receptor a conformational change is triggered within 
the receptor, through a twisting and rotating movement of transmembrane domain 
(TMD) VI around the rotomer toggle switch (relative to TMD III) or the release of 
the ionic lock freeing up the attached G protein for guanine exchange factors (GEFs) 
allowing the exchange of Guanine di-phosphate (GDP) for Guanine tri-phosphate 
(GTP). The G Protein itself consists of 3 domains α, β and γ. On activation (the 
exchange of GDP for GTP) the α subunit dissociates from the β/γ complex where 
both the α subunit and the β/γ complex can then further affect intracellular signalling 
proteins depending on the original G Protein (Wess, 1997). 
 
Figure 1. 7. Diagrammatic representation of P2Y receptor structure 
(Burnstock, 2007) 
The 2 P2Y receptors expressed on the surface of platelets, P2Y1 and P2Y12 respond 
to ADP as their endogenous ligand and synthetic agonists are available for both 
receptors such as MRS2365 (P2Y1) and 2-methylthio-ADP (2-MeSADP) (P2Y12). 
Whilst ATP activates the P2X1 receptor , it acts as an antagonist to both the P2Y1 




and P2Y12 receptors (Ingall et al., 1999; Kauffenstein et al., 2004). Extensive 
research has implicated both the P2Y1 and P2Y12 (formally P2T) receptors in the 
regulation of platelet aggregation since the 1960s (Born and Cross, 1964). In 
subsequent years, both the P2Y1 and P2Y12 receptors have been analysed extensively 
resulting in the elucidation of their roles in hemostasis. 
 
 
Table 2. Cellular distribution of the P2Y receptor subtypes 
 
 
1.6.3.1 Platelet P2Y1 Signalling 
The P2Y1 receptor is expressed on the surface of platelets in substantially lower 
levels compared to other platelet receptors, for example the PAR1 receptor. The 
PAR1 receptor is expressed in levels ranging between 1000-2000 receptors per 
platelet, whereas platelets only express between 100-150 P2Y1 receptors per 
individual platelet (Baurand et al., 2001) 




ADP induced activation of platelet P2Y1 receptors triggers activation of the Gq 
coupled G Protein initiating α subunit dissociation from the β/γ complex allowing 
phospholipase C beta (PLCβ) activation downstream of the P2Y1 receptor (Gachet, 
2006). Once activated, PLCβ mediates the formation of Inositol-3-phosphate (IP3) 
and Di-acylglycerol (DAG) from PIP2 (phosphoinositol-bis-phosphosphate). 
Elevation in intracellular IP3 as a result of PLCβ activation increases IP3 binding to 
the IP3 receptor on the walls of intracellular compartments initiating Ca
2+
 release 
from internal stores, thus mobilising intracellular Ca
2+ 
(Lian et al., 2005). Increases 
in intracellular Ca
2+
 promote rearrangement of the actin cytoskeleton initiating rapid 
platelet shape change. In addition to IP3 formation, PLCβ also results in the 
production of DAG. DAG triggers Protein Kinase C activation and combined with 
the elevation of intracellular Ca
2+
 produced through IP3 production results in the 
centralisation and secretion of platelet granules (Walker and Watson, 1993). An 
additional impact of P2Y1 receptor activation is the formation of the potent platelet 
agonist Thromboxane A2 (TxA2) (Samuelsson et al., 1978; Bhagwat et al., 1985; Jin, 
2002). DAG also triggers the synthesis of TxA2 through the synthesis of arachidonic 
acid (AA). AA is metabolised into endoperoxidases (PGG2 and PGH2) by 
cycloxygenase (COX), with TxA2 subsequently being produced from PGH2 by 
thromboxane synthatase (Samuelsson et al., 1978; Bhagwat et al., 1985; Jin, 2002). 
TxA2 is a very unstable agonist with a half life of only around 30-40 seconds 
(Samuelsson et al., 1978), however despite its short activity it has pronounced 
biological activity as a platelet agonist inducing aggregation via activation of the 
platelet TP receptor, amplifying platelet activation. 
The importance of P2Y1 signalling in platelet activation has become increasingly 
clear using a range of P2Y1 specific antagonists including MRS2179, MRS2500 and 




through the use of P2Y1
 
deficient mice. These studies have demonstrated that 
blockade of P2Y1 signalling induces a severe impairment of platelet activation with 
defects observed in shape change, Ca
2+
 mobilisation, P-selectin expression, ERK 
phosphorylation and aggregation (Jin, 1998; Fabre et al., 1999; Léon et al., 1999; 
Baurand et al., 2001; Leon et al., 2003; Hechler et al., 2006; Garcia et al., 2007). 
Fabre et al. 1999, demonstrated significantly increased bleeding time (~25 minutes) 
in P2Y1 deficient mice compared with a bleeding time of approximately 10 minutes 
in wild type mice (Fabre et al., 1999), this was coupled to a failure of P2Y1
 
deficient 
mice to increase intracellular Ca
2+
 levels following stimulation with 30μM ADP 
compared to WT mice or undergo shape change towards 0.3μM (Fabre et al., 1999). 
Stimulation of P2Y1
 
deficient mice with either U46619 (TxA2 analogue) or 1.5u/ml 
thrombin were capable of inducing normal platelet activation compared to WT mice 
demonstrating that the inability of ADP to induce platelet activation was a result of a 
lack of P2Y1 signalling rather than a defect in general platelet activation (Fabre et al., 
1999). Other studies have also demonstrated impaired platelet function in P2Y1
 
deficient mice with transient aggregation to 5μM ADP completely abolished in P2Y1 
deficient mice compared to WT mice. Once again however stimulation of P2Y1 
deficient mice with 1u/ml thrombin produced normal aggregation compared to WT 
mice (Léon et al., 1999). These P2Y1 deficient mice have also demonstrated 
protection against systemic intravascular thrombosis following intravenous injection 
of ADP or collagen with significant increases in survival rates observed (Fabre et al., 
1999; Léon et al., 1999), further demonstrating its critical role in platelet activation. 
Studies with selective low molecular weight inhibitors such as MRS2500 and 
MRS2179 have also demonstrated impaired platelet activation and aggregation, with  




attenuation of ADP induced aggregation similar to levels observed in P2Y1 deficient 
mice (Hechler et al., 2006) Baurand et al., 2001).  
In addition to impaired Ca
2+
 mobilisation, shape change and platelet aggregation, 
deficiencies in P2Y1 signalling also results in impaired adhesion molecule 
expression, demonstrating impaired granule secretion. Stimulation with ADP is 
known to result in increased P-selectin expression (Storey et al., 2000, 2002; Leon et 
al., 2003; Evangelista et al., 2005; Perneby et al., 2007). Blockade of the P2Y1 
receptor with MRS2500 and MRS2179 can attenuate this ADP-induced elevation in 
P-selectin expression (Leon et al., 2003, 2004). 
Whilst the P2Y1 receptor is clearly involved in platelet activation and hemostasis as 
demonstrated by its role in platelet activation and increased protection from 
thrombosis following antagonist treatment, stimulation of the P2Y1 receptor alone is 
insufficient for full aggregation and can only induce a transient and reversible level 
of aggregation (Hechler et al., 1998; Baurand et al., 2001). Therefore additional 
stimulation of the platelets must be involved. More recently, research has begun to 
implicate the P2Y1 receptor in the RhoA signalling pathway. RhoA is a small 
GTPase belonging to the family of Rho GTPases consisting of RhoA, Rac and 
cdc42. Under 'resting' inactive conditions, RhoA is bound to GDP but following 
activation through linked GPCRs, GDP is switched for GTP through increasing  
GEF function (Bos et al., 2007).  
Rho signalling has previously been implicated with a key role in linking surface 
receptors to the actin cytoskeleton and in turn, its organisation. Within the 
vasculature, Rho signalling has been demonstrated to play a regulatory role in a 
number of different functions, including inflammation, leukocyte migration across 




the endothelial barrier, platelet activation, thrombosis and oxidative stress (Eckly et 
al., 2001; Rolli-Derkinderen et al., 2010; Pleines et al., 2012; Aslan and McCarty, 
2013; Ridley, 2013b). Indeed, RhoA has also been implicated in a variety of markers 
of platelet activation including shape change, filopodia formation, cytoskeletal 
changes and granule centralisation prior to secretion (Eckly et al., 2001; Pleines et 
al., 2012). These RhoA mediated events are not followed by subsequent platelet 
aggregation, this suggests that RhoA mediated events could potentially play a key 
role in eliciting the inflammatory actions of platelets, whilst demonstrating a 
redundancy in platelet aggregation. 
1.6.3.2 Platelet P2Y12 Signalling 
 
The second P2Y receptor subtype present on the surface of platelets is the P2Y12 
receptor. Whilst the P2Y12 receptor is expressed at higher levels than the P2Y1 
receptor, with expression levels exceeding 1000 receptors per platelet, its systemic 
distribution is limited solely to platelets and glial cells (Burnstock, 2007).  
The P2Y12 receptor is coupled to Gi, with the dissociated α-subunit coupling to and 
negatively regulating the membrane bound protein adenylyl cyclase (AC). Under 
resting conditions, AC catalyses the production of cyclic adenosine monophosphate 
(cAMP), locking the platelet integrin αIIbβ3 in an inactive conformation preventing or 
placing a 'brake' on platelet aggregation (Kauffenstein et al., 2001). However, upon 
P2Y12 receptor stimulation and subsequent inhibition of AC, the resulting drop in 
intracellular cAMP levels removes the block on αIIbβ3 activation allowing the 
formation of cohesive interactions between platelets thus initiating platelet 
aggregation (Kauffenstein et al., 2001; Gachet, 2006; Brass, 2010). Furthermore, 
activation of the P2Y12 stimulates secretion of platelet dense granules which leads to 




local generation of thrombin and TxA2, thus amplifying platelet aggregation (Storey 
et al., 2000)  
Given its limited distribution, the P2Y12 receptor has been viewed as an attractive 
therapeutic target for some time, with P2Y12 specific thienopyridine compounds such 
as ticlopidine and clopidogrel being used extensively in antithrombotic therapy 
(Collaboration, 1994; Barer, 1997; Moussa et al., 1999; Perneby et al., 2007). The 
identification of specific targeting of P2Y12 receptors for anti-platelet therapy began 
a new wave of development of more potent and specific P2Y12 receptor antagonists. 
Clopidogrel is itself a prodrug, and due to liver enzyme polymorphisms some 
patients are less able to metabolise clopidogrel into its active form leaving them 
resistant to Clopidogrel therapy (Gachet, 2006). Therefore, subsequent drug research 
and development created the third generation of P2Y12 receptor antagonists including 
Prasugrel (LY640315), ticagrelor (AZD6140) and cangrelor (AR-C69931MX), all of 
which demonstrated greater inhibition of ADP induced platelet aggregation 
compared to Clopidogrel treatment (Wiviott, 2007; Högberg et al., 2010; Nawarskas 
and Clark, 2011; Tan et al., 2011; Olivier et al., 2013). These antagonists have all 
demonstrated clear anti-thrombotic effects, both in vivo, with P2Y12 blockade shown 
to significantly decrease P-selectin expression and platelet aggregation in response to 
a variety of stimuli (Ingall et al., 1999; Kauffenstein et al., 2001; Storey et al., 2002; 
Leon et al., 2003, 2004; Evangelista et al., 2005; Judge et al., 2010). They have also 
demonstrated improvements in the clinic including mortality from cardiovascular 
diseases, non-fatal myocardial infarction, non-fatal stroke, platelet aggregation, 
cAMP formation in vitro and  other ischemic events (Perneby et al., 2007; Wiviott, 
2007; Srinivasan et al., 2009; Högberg et al., 2010; Tan et al., 2011; Olivier et al., 
2013). Stimulation of the P2Y12 receptor also significantly elevates P-selectin 




expression (Storey et al., 2000, 2002; Leon et al., 2003; Evangelista et al., 2005; 
Perneby et al., 2007),. 
In addition to being coupled to AC signalling, the P2Y12 receptor also couples to the 
phosphoinositol-3-kinase (PI3-K) signalling pathway through the β/γ complex. One 
of the main outcomes of PI3-K signalling is mobilisation of cytosolic Ca
2+
 (Hirsch et 
al., 2001; Kauffenstein et al., 2001; Reséndiz et al., 2003; Hardy et al., 2004; Gachet, 
2006). Platelets express 4 different isoforms of PI3-K (PI3Kα, PI3Kβ, PI3Kγ and 
PI3Kδ) (Hirsch et al., 2001; Garcia et al., 2010), with the α and β isoforms identified 
as regulators of platelet aggregation (Gilio et al., 2009). In addition to the 
mobilisation of cytosolic Ca
2+
, PI3-K is also involved in the activation of the integrin 
αIIbβ3, where studies have demonstrated impaired platelet aggregation through the 
use of specific PI3Kβ inhibitors (TGX-221) (Garcia et al., 2010). Cosemans et al., 
2006 demonstrated that both PI3-Kβ and γ were required to perpetuate αIIbβ3 
activation and the maintenance of platelet aggregates (Cosemans et al., 2006).  
A potential role for P2Y12 receptor involvement in inflammation has recently been 
demonstrated through attenuation of LTE4 induced pulmonary inflammation in the 
mouse following treatment with P2Y12 receptor antagonists (Paruchuri et al., 2009). 
In contrast, additional studies have shown that LPS induced systemic inflammation 
becomes more severe in the absence of P2Y12 receptors (Liverani et al., 2014), with 
P2Y12 receptor blockade using Clopidogrel also potentiating inflammation in a rat 
model of peptidoglycan-polysaccharide (PG-PS) induced arthritis (Garcia et al., 
2011). This demonstrates a clear need to further investigate the role of the P2Y12 
receptor in inflammatory conditions. 
 
 




1.7 Aims and Objectives 
1) To investigate whether modulation of platelet purinergic signalling can 
influence leukocyte recruitment in a murine model of allergic pulmonary 
inflammation.  
Leukocyte recruitment is a critical event in the development of chronic inflammation 
in patients with asthma. Numerous animal models have highlighted the critical role 
platelets play in orchestrating this response following exposure to allergen. Given the 
importance purinergic receptor signalling plays in the haemostatic role of platelets 
and the ability of the purinergic receptors to modulate P-selectin expression and the 
formation of platelet-leukocyte conjugates, two processes key to the induction of 
leukocyte recruitment following allergen challenge, a murine model of ovalbumin-
induced pulmonary lung inflammation was used to evaluate the differential impact of 
each of the purinergic receptors on pulmonary leukocyte recruitment  
Furthermore, to confirm that any effect demonstrated by purinergic receptor 
modulation is platelet specific, mice sensitised to OVA were specifically depleted of 
platelets via a non-immunological method of platelet depletion using the bone 
marrow cell specific toxin busulfan, inducing a gradual, long term, non-immune 
thrombocytopenia that can be replenished through platelet reinfusion from donor 








2) Identify the effects of purinergic receptor blockade on parameters of platelet 
activation. Extending from the objectives described above, the impact of purinergic 
receptor signalling blockade on parameters of platelet function including P-selectin 
expression, platelet-leukocyte conjugation, platelet-induced leukocyte chemotaxis, 
and platelet aggregation was evaluated. Previous work has highlighted an importance 
of both the P2Y1 and P2Y12 receptors on platelet P-selectin expression and platelet 
aggregation. My aim was to evaluate the differential influence of purinergic receptor 
activation on parameters of platelet activation and to identify potential differences 
between pathways associated with thrombosis and haemostasis and pathways 
attributed to inflammation. 
 
3) Dissecting a possible dichotomy in platelet activation and function with 
relation to both haemostatic and inflammatory stimuli. Using a range of 
inflammatory (MDC, SDF-1α, f-MLP, 5-HT, IL-1β and LPS) and haemostatic 
stimuli (ADP, Adrenaline, TxA2 and TRAP), I have investigated the impact of 
stimulation of different platelet receptors on classical assays of platelet function 
including P-selectin expression, platelet-leukocyte aggregate formation, platelet 
migration and platelet aggregation. This was performed in an attempt to shed further 
light on the mechanisms underlying the dichotomy of platelet functions described by 











Materials and Methods 
 
  






Balb/C mice     Harlan Laboratories, Oxfordshire, UK. 
Chicken Egg Ovalbumin (Grade V)   Sigma-Aldrich Ltd, Dorset, UK. 
Aluminium Hydroxide   Sanofi Winthrop Ltd. Brazil. 
0.9% Saline     Baxter Healthcare Ltd. UK 
Urethane     Sigma-Aldrich, Dorset, UK. 
DMSO      Sigma-Aldrich Ltd, Dorset, UK 
Apyrase     Sigma-Aldrich Ltd, Dorset, UK 
MRS2179     Tocris Bioscience, Bristol, UK 
MRS2395     Sigma-Aldrich Ltd, Dorset, UK 
MRS2500     Tocris Bioscience, Bristol, UK 
AR-C66096     Tocris Bioscience, Bristol, UK 
NF-279     Tocris Bioscience, Bristol, UK 
AMD3100     Tocris Bioscience, Bristol, UK 
MRS2365     Tocris Bioscience, Bristol, UK 
GSK429286     Tocris Bioscience, Bristol, UK 
Clopidogrel     Tocris Bioscience, Bristol, UK 
C-021      Merck Chemicals, Hertfordshire, UK 
PEG400     Fischer Scientific, Loughborough, UK 
Busulfan     Sigma-Aldrich Ltd, Dorset, UK 
Citrate-Dextrose    Sigma-Aldrich Ltd, Dorset, UK 
Murine MDC     PeproTech EC, Ltd, London, UK 
Murine SDF-1α     PeproTech EC, Ltd, London, UK 
Human MDC     PeproTech EC, Ltd, London, UK 
Human SDF-1α    PeproTech EC, Ltd, London, UK 
f-MLP      Sigma-Aldrich Ltd, Dorset, UK 




LPS      Sigma-Aldrich Ltd, Dorset, UK 
adrenaline     Sigma-Aldrich Ltd, Dorset, UK 
TRAP      Tocris Bioscience, Bristol, UK 
5-HT      Sigma-Aldrich Ltd, Dorset, UK 
U46619     Tocris Bioscience, Bristol, UK 
IL-1β      PeproTech EC, Ltd, London, UK 
Adenosine bisphosphate   Sigma-Aldrich Ltd, Dorset, UK 
Adenosine Triphosphate   Sigma-Aldrich Ltd, Dorset, UK 
Thrombin     Sigma-Aldrich Ltd, Dorset, UK 
Fibrinogen     Sigma-Aldrich Ltd, Dorset, UK 
Prostaglandin E1    Sigma-Aldrich Ltd, Dorset, UK 
RB40.34 P-selectin blocking antibody BD Biosciences, Oxford, UK 
#561923 
rat anti-mouse CD45 FITC   Miltenyi Biotec, Surrey, UK 
#130-091-609 
rat anti-mouse CD62P FITC   BD Biosciences, Oxford, UK 
#561923 
rat anti-mouse CD41RPE   BD Biosciences, Oxford, UK 
#558040 
FITC  mouse anti-human CD41a  BD Biosciences, Oxford, UK 
#555466  
PE Mouse anti-human CD42a  BD Biosciences, Oxford, UK 
#558819 
FITC Mouse anti-human CD45  BD Biosciences, Oxford, UK 
#555482 
PE Mouse anti-human CD62P  BD Biosciences, Oxford, UK 
#555524 
PE Mouse IgG κ Isotype Control  BD Biosciences, Oxford, UK 
#555574 
 
FITC Mouse IgG κ Isotype Control  BD Biosciences, Oxford, UK 





ab74996 (rabbit anti-P2Y1)   Abcam Plc, Cambridgeshire, UK 
ab82725 (rabbit anti-P2Y12)   Abcam Plc, Cambridgeshire, UK 
Alexa Fluor 594 Goat anti-rabbit IgG Invitrogen Life Sciences, Paisley, UK 
A21223 
Rabbit anti-RhoA (phosphoS188)   Santacruz Biotechnology, Cambridge, 
      USA 
Rabbit IgG      Santacruz Biotechnology, Cambridge, 
      USA 
Optiylyse C     Beckman Coulter Inc,   
      Buckinghamshire, UK 
Dulbecco’s Modified Eagle Medium  Invitrogen Life Sciences, Paisley, UK 
RPMI 1640 Media    Invitrogen Life Sciences, Paisley, UK 
ChemoTx® Transwell Migration System NeuroProbe, Inc, USA 
101-3, 3µm Pores 
BD Falcon Transparent 3um Pet Insert  Becton Dickinson, Plymouth, UK 
BD Falcon 24 Well companion plate  Becton Dickinson, Plymouth, UK 
Flow-count Fluorospheres   Beckman Coulter Inc.   
      Buckinghamshire, UK 
Methylene Blue Stain    Sigma-Aldrich Ltd, Dorset, UK 
Stromatol Stain    Mascia Brunelli, Italy 













Animal handling, care and experimental use were conducted in accordance with 
regulations described by The Animals (Scientific Procedures) Act (ASPA) 1986. All 
animals were housed under standard conditions of 22 ± 2°C and a 12:12 light:dark 
cycle. Pelleted diet and water was provided ad libitum. Soft bedding of wood 
shavings and paper material was provided in addition to plastic domes for 
environmental enrichment. All animals were sacrificed through administration of 
terminal 25% urethane anaesthesisa. Female Balb/c mice (20-25g) were procured 
from Charles River or Harlan UK laboratories. All animals were provided with a 
minimum acclimatisation period of 3 days upon arrival. 
 
In vivo Animal studies 
2.3.1 Allergen Induced Pulmonary Leukocyte Recruitment 
 
In order to define optimal conditions for the induction of leukocyte recruitment 
following local allergen challenge to the lung, female Balb/C mice were exposed to 4 
different sensitisation protocols. 
The sensitisation protocols involved 3 intra-peritoneal doses of chicken egg 
ovalbumin (OVA) at either 10µg/mouse or 30µg/mouse dissolved in a solution 
saturated with AlOH2 over a 2 week period. Subsequently, animals were exposed to 
nebulised OVA (3%) for 30 minutes either once or twice daily for 3 consecutive 
days. Formulation of OVA sensitisation doses per mouse are described below in 
table 2.1 
 







   μl/mouse 




Table 3 OVA sensitisation formulation 
 
2.3.1.1 Sensitisation Protocol for Allergen Induced Pulmonary Leukocyte 
Recruitment  
Mice were sensitised to OVA (10µg or 30µg, 0.4ml, i.p.) on days 0, 4 and 10, with 
subsequent challenge to nebulised (DeVillbisS 99, HCE, UK) 3% OVA once or 





Figure 2. 1 Murine model of allergic pulmonary inflammation: A protocol for 
sensitisation 
 





2.3.2 Bronchoalveolar Lavage 
Twenty four hours post final challenge to OVA, mice were terminally anaesthetised 
with 25% urethane administered intra-peritoneally (i.p.) (in saline). Once 
anaesthetised, a small incision into the midline of the throat was made and the 
trachea exposed through blunt dissection, the trachea was subsequently cannulated. 
Once cannulated, three 0.5ml aliquots of warm saline were injected into the lung 
with the resulting fluid being withdrawn using a 1ml syringe and then placed on ice. 
 
2.3.3 Total Leukocyte Counts 
Total cell counts were counted from Broncho-alveolar lavage (BAL) fluid obtained. 
Each sample was diluted 1:1 with hemolysis solution (0.1% methyline blue in 1% 
acetic acid). Cell counts were then quantified using a Neubauer haemocytometer 
under a x20 objective. 
 
2.3.4 Differential Leukocyte Quantification 
150μl BAL fluid was placed into filters fixed onto cytospin slides and centrifuged in 
a Shandon Cytospin 3 at 1000rpm for 1 minute. The slides were allowed to dry and 
subsequently stained using a Reastain® Quick-Diff kit and coverslipped with DPX 
mountant. 200 cells were then counted over a representative area from each slide and 
the percentages of macrophages, neutrophils, lymphocytes and eosinophils 
determined. The total cell counts and the percentages of each differential cell type 
were then used to calculate the number of individual leukocytes per ml of BAL fluid. 
 




2.3.5 Effects of ADP on Allergen Induced Pulmonary Leukocyte Recruitment in 
Mice 
Experiments were carried out via the administration of systemic Apyrase (100u/ml, 
0.1ml/mouse) though intra-venous injection, thirty minutes prior to exposure to 
nebulised OVA on days 14, 15 and 16. 0.1ml intra-venous saline was administered 
to control mice. 24 hours post final exposure to nebulised OVA (day 17), BAL fluid 
was taken as described in 2.3.2 and processed as described in 2.3.3-2.3.4. 
 
2.3.6 Effects of Purinergic Receptor Antagonists on Pulmonary Leukocyte 
Recruitment in Mice 
Experiments investigating the impact of purinergic receptor antagonists on acute 
allergen induced pulmonary leukocyte recruitment were carried out through the 
administration of competitive P2Y1, P2Y12 and P2X1 receptor antagonists. The first 
P2Y1 antagonist, the ADP analogue MRS2179 was dosed at 3, 10 and 30mg/kg i.v, 
(N
6
-methyl-2'-deoxyadenosine 3',5'-bisphosphate). Phosphate substitutions at the 2' 
or 3' position results in a loss of agonist activity without impairing receptor affinity 
to the P2Y1, resulting in a highly selective P2Y1 receptor antagonist with a 
dissociation constant (KD) of 109 ± 18nM  and an IC50 value of 109 ± 22 nM towards 
ADP induced aggregation (Boyer et al., 1998; Baurand et al., 2001; Hechler et al., 
2006). The second P2Y1 receptor antagonist used was the second ADP analogue 
MRS2500 which was dosed at  0.1, 1, 3mg/kg i.v., (2-Iodo-N
6
-methyl-(N)-
methanocarba-2'-deoxyadenosine-3',5'-bisphosphate). Substitution of the ribose 
moiety with a methanocarba-ring system and with Iodo substitution of the 2' position 
significantly enhances affinity for the P2Y1 receptor demonstrated by a KD of 
0.78nM and an IC50 value of 0.95nM towards ADP induced aggregation (Kim et al., 
2003; Cattaneo et al., 2004). 




Further experiments investigated the administration of the competitive P2Y12 
receptor antagonists MRS2395 (1, 3 and 10mg/kg, i.p) and AR-C66096 (0.1, 1 and 
3mg/kg, i.v.). MRS2395 (2-2-Dimethyl-propionic acid 3-(2-chloro-6-
methylaminopurin-9-yl)-2-(2,2-dimethyl-propionuloxymethyl-propyl ester) is an 
acyclic analogue of ADP with substitution of the phosphate with di(phenylacetyl) 
groups specifying affinity for the P2Y12 meditated inhibition of adenylyl cyclase 
pathway over P2Y1 mediated activation of PLC, demonstrated by a Kd of 3.6μM and 
a IC50 value of 4.6μM towards ADP induced platelet aggregation (Burnstock and 
Verkhratsky, 2012). 
The second P2Y12 receptor antagonist used was the ATP analogue AR-C66096 (2-
(Propyltio) adenosine-5'-O-(β-γ-difluoromethylene) triphosphate), which provided 
strong and selective activity for the P2Y12 receptor demonstrated by a Kd value of 
2.5nM and a IC50 value of 8.16nM towards ADP induced platelet aggregation 
(Humphries et al., 1994; Ingall et al., 1999). Furthermore, subsitution of the 
anhydride link with a β-γ-methylene link in the phosphate chain prevents the 
conversion of the ATP analogue into ADP via activity of ectonucleotidase enzymes 
resulting in prolonged activity (Humphries et al., 1994; Ingall et al., 1999). 
The final P2Y12 receptor antagonist used was the thienopyridine Clopidogrel ((S)-
(+)-Methyl 2-(4,5,6,7-  tetrahydrothieno [3,2-c] pyridin-5-yl) - 2 - (2-chlorophenyl) 
acetate), known for its activity as a selective P2Y12 receptor antagonist, 
demonstrated by a KD value of 12μM and a IC50 value of 1.9 ± 0.3μM towards ADP 
induced platelet aggregation (Weber et al., 1999). In combination with studies using 
MRS2395, AR-C66096 and Clopidogrel, the effects of the P2Y12 on parameters of 
platelet activation can be reliably investigated. 




In addition to the P2Y1 and P2Y12 receptor antagonists, a final P2X1 specific receptor 
antagonist NF-279 was used (0.1, 1 and 3 mg/kg i.v.). NF-279 (8-8'-
[Carbonlylbis(imino-4,1-phenylenecarbonylimino-4,1-
phenylenecarbonyliminio)]bis-1,3,5-naphthalenetrisulfonic acid) is a novel suramin-
related compound which demonstrates high potency and selectivity for the P2X1 
receptor as demonstrated by a Kd of 19nM (Damer et al., 1998; Kügelgen and Bonn, 
2008). 
All drugs were administered 30 minutes before exposure to nebulised OVA on days 
14, 15 and 16. 0.1ml intravenous saline was administered as a control for all 
experiments except for MRS2395 where a vehicle of 0.1% DMSO was administered 
via  intra-peritoneal injection. BAL fluid was taken as described in 2.2.2 24 hours 
post final allergen exposure (day 17) and processed. 
 









2.4 Effects of Platelet Depletion on a Murine Model of Allergic Inflammation 
2.4.1 A Protocol of Murine Platelet Depletion 
The depletion of the population of circulating platelets was induced using the bone 
marrow specific toxin busulfan inducing a gradual, long term state of 
thrombocytopenia. This mechanism of platelet depletion allows the reversal of  the 
thrombocytopenia through platelet transfusion demonstrated in later experiments. 
Busulfan was prepared in PEG400 (20mg/ml) at 60°C for 1 hour then diluted 1/8 
with warm saline prior to intra-peritoneal injection (0.2ml) giving a final dose of 
0.1mg/kg. The following protocol was subsequently used to investigate the impact of 
platelet depletion on leukocyte recruitment (Pitchford et al., 2003b, 2005). 
 
Figure 2. 3 Busulfan Induced Platelet Depletion Protocol 
 
BAL fluid was taken 24 hours post final allergen challenge and processed as 
previously described. On day 14 prior to the first exposure to nebulised OVA, blood 
was collected through a tail vein bleed and diluted 1:100 in the haematological stain 
Stromatol. Circulating platelet numbers were quantified using a Neubauer 
haemocytometer under an x40 objective and phase contrast, on a Zeiss Axioskop 
upright microscope to ensure an adequate depletion of circulating platelets. 




2.4.2 Platelet Reinfusion of Thrombocytopenic Mice 
Platelet rich plasma (PRP) was isolated from previously sensitised mice via the 
collection of blood through cardiac puncture, mixing with acid-citrate dextrose 
(ACD) solution at a ratio of 1:9 parts blood. Blood was centrifuged at 100 g for 10 
minutes followed by a second additional centrifugation step at 120 g for 5 minutes to 
isolate PRP. PRP was then treated with a saturating concentration of PGE1 (10µl, 
2.5mM), and subsequently centrifuged again at 900 g for 6 minutes. The resulting 
platelet pellet was resuspended in PBS and injected into thrombocytopenic mice 
intravenously at a volume of 0.1ml on days 14 and 15, 30 minutes prior to allergen 
exposure. No platelet transfusion was performed on the third day of allergen 
exposure (day 16). Resulting transfusion of platelets was an accumulated dose of 
2.36x10
8
 platelets/ml.  
Experiments investigating the impact of P2Y1 and P2Y12 receptor antagonism or Rho 
Kinase antagonism were performed through pre-incubation of PRP with either 
100µM MRS2500, AR-C66096 or the Rho Kinase inhibitor GSK429286 for 20 
minutes. PRP was then treated with a saturating concentration of PGE1 (10µl, 
2.5mM), and subsequently centrifuged again at 900 g for 6 minutes. The resulting 
platelet pellet was resuspended in PBS and injected into thrombocytopenic mice 
intravenously at a volume of 0.1ml on days 14 and 15, 30 minutes prior to allergen 
exposure.  
 





Figure 2. 4 Platelet Transfusion protocol 
 
BAL fluid was collected 24 hours post the final exposure to nebulised OVA (day 17) 


















In Vitro Mouse Studies 
 
2.5 Cell Isolation 
 
2.5.1 Blood Collection 
Female Balb/c mice were terminally anaesthetised with 0.2ml 25% w/v Urethane. 
Once anaesthetised, blood was collected via cardiac puncture mixing with ACD at a 
ratio of 1 part ACD to 9 parts Blood. 
 
2.5.2 Washed Platelet Isolation 
Citrated blood was centrifuged at 100 g for 10 minutes and the resulting PRP 
isolated. Blood was then centrifuged again for a further 5 minutes at 120 g and the 
remaining PRP collected. Saturating concentrations of PGE1 (10µl, 2.5mM) were 
added to the PRP which was then centrifuged again at 900 g for 6 minutes. The 
resulting platelet pellet was resuspended in tyrodes buffer. Platelets were then 
stained in stromatol and quantified on a Neubauer haemocytometer under a x40 
objective and phase contrast, on a Zeiss Axioskop upright microscope and diluted to 
a final concentration of 1x10
8
plts/ml in tyrodes buffer. 
 
2.5.3.1 Sepharose Column Preparation  
Sepharose columns were prepared using Sepharose C12-B (Sigma-Aldrich, Dorset, 
UK). Sepharose was first washed in a Buchner filter with 100% acetone. After 
washing with acetone, the sepharose was placed in a beaker with distilled water and 
mixed on a magnetic stirrer. The sepharose was then washed with distilled water 
through the Buchner filter. This wash cycle was repeated untill the odour of acetone 




had been lost. After washing, the sepharose was stored in 10% ethanol (1 part 
sepharose: 2 parts ethanol) at 4°C.  
When required, washed sepharose was placed into a 30ml pre-fitted reservoir column 
and washed with 10% ethanol until the column was half full with settled sepharose. 
The column is then stored in 10% ethanol at 4°C. 
 
2.5.3.2 Gel Filtered Platelet Isolation 
On the day of the experiment, the sepharose column was washed with approximately 
40ml HEPEs tyrodes buffer (137mM NaCl, 2.3mM KCl, 1mM MgCl2.6H2O, 4mM 
NaH2PO4.H2O, 3.1mM HEPES, 4.6mM Glucose) with 1% BSA at pH7.4. 
Citrated blood was centrifuged at 100 g for 10 minutes and the resulting PRP 
isolated, blood was then centrifuged again for a further 5 minutes at 120 g and the 
remaining PRP collected. PRP was added to the top of the sepharose matrix (no less 
than 0.5ml, no more than 1.5ml) and small amounts of HEPES buffer added to the 
top of the column. Only the cloudy platelet containing media eluted from the base of 
the column was collected with attention paid to ensure no plasma was collected. 
Platelets were then stained in stromatol (1/100) and quantified on a Neubauer 
haemocytometer under a x40 objective and diluted to a final concentration of 
1x10
8
plts/ml in HEPES tyrodes buffer. 
 
2.5.4. Leukocyte Isolation 
Following collection of blood via cardiac puncture, femurs were extracted from the 
mice and washed through with DMEM with supplements (1g/L glucose, 2mM 
glutamine, 100u/ml penicillin, 100μg/ml streptamycin, 1mM sodium pyruvate) 
collecting the bone marrow. Bone marrow was mixed in 15ml DMEM and 




centrifuged at 300 g for 5 minutes producing a leukocyte pellet. Following 
centrifugation, excess DMEM was aspirated and the leukocyte pellet resuspended in 
1ml DMEM. Leukocytes were diluted 1/10 in hemolysis solution (0.1% methyline 
blue in 1% acetic acid) and quantified in a Neubauer haemocytometer under a x20 
objective. The concentration of the leukocyte suspension was then adjusted to a final 
working concentration of 5x10
6
cells/ml in DMEM. 
 
2.6.1 Platelet-Induced Leukocyte Chemotaxis in vitro 
In order to identify the correct conditions required for platelet-induced leukocyte 
chemotaxis, in vitro leukocyte chemotaxis was measured towards different 
chemokines including MDC and SDF-1α both in the absence and presence of 
platelets. The effect of OVA sensitisation was also investigated in these experiments, 





Figure 2. 5 Ex vivo allergen sensitisation protocol 
 
 




Following a 10 day sensitisation period involving 3 doses of 30µg OVA (0.4ml, 
intra-peritoneal), mouse washed platelets were isolated from blood and leukocyte 
populations isolated from femurs as described in sections 2.5.1-2.4.4. 
Platelet induced leukocyte chemotaxis was investigated using an assay based around 
the ChemoTx® Transwell Migration System supplied by Neuro Probe (Kornerup, et 
al. 2010). Chemotaxis plates with 3µm pores were blocked with 31μl tyrodes buffer 
+ 2% foetal bovine serum (FBS) for 1 hour. After blocking, the buffer was removed 
and replaced with 31μl 100nM chemokine (MDC, SDF-1α, f-MLP). Platelets 
prepared as described previously (2.5.2) were stimulated with 100nM ADP at 37°C 
and washed to remove any excess ADP. Following ADP incubation, platelets were 
mixed at a 1:1 volume ratio (20:1 cellular ratio) with leukocytes prepared as 
described in 2.5.2. The chemotaxis membrane containing the 3µm pores was placed 
over the bottom wells containing 100nM chemokine and the 20μl platelet/leukocyte 
mixture applied onto the top of the membrane (Figure 2.6) and incubated for 90 
minutes at 37°C. 
Post 90 minute incubation, the chemotaxis membrane was removed from the top of 
the plate and media was collected from the bottom chamber. 10μl of the media was 
mixed 1:1 with hemolysis solution (0.1% methyline blue in 1% acetic acid) and 
leukocytes subsequently quantified in a Neubauer haemocytometer under a x20 
objective. The number of leukocytes present in the bottom chamber post incubation 










Figure 2. 6 Diagrammatic representation of platelet-induced PMN chemotaxis 
 
2.6.2 Effects of CXCR4 and CCR4 Receptor Antagonists on Platelet-Induced 
Leukocyte Chemotaxis 
To investigate the impact of chemokine receptor antagonists on platelet-induced 
leukocyte chemotaxis, platelets were pre-incubated with either the CXCR4 
antagonist AMD3100 (1, 10, 100, 1000nM) or the CCR4 receptor antagonist C-021 
(1, 10, 100, 1000nM) for 10 minutes at room temperature. Platelets were then 
centrifuged at 900 g for 6 minutes and resuspended in tyrodes buffer. Drug treated 
platelets were subsequently stimulated with 100nM ADP and chemotaxis measured 
as previously described (2.5.3). 
 
 
2.6.3 Effects of Purinergic Receptor Antagonism on Platelet-Induced Leukocyte 
Chemotaxis 
Experiments investigating the impact of purinergic receptor antagonists on platelet-
induced leukocyte chemotaxis were performed by the pre-incubation of platelets 
with either the competitive P2Y1 receptor antagonists MRS2179 and MRS2500, the 
competitive P2Y12 receptor antagonists MRS2395 and AR-C66096 or the P2X1 




receptor antagonist NF-279. All drugs were treated at 1, 10, 100 and 1000nM for 10 
minutes at room temperature with a saline vehicle used as a control. Platelets were 
then centrifuged at 900 g for 6 minutes and resuspended in tyrodes buffer. Drug 
treated platelets were subsequently stimulated with 100nM ADP and chemotaxis 
measured as previously described (2.5.3). 
 
2.6.4 Effects of Rho Kinase Inhibition and P-selectin Blockade on Platelet-
Induced Leukocyte Chemotaxis 
Experiments investigating the impact of purinergic receptor signalling on platelet-
induced leukocyte chemotaxis were performed by the pre-incubation of platelets 
with the competitive Rho Kinase receptor antagonist GSK429286 or RB40.34 (A P-
selectin blocking antibody). Platelets were treated with 0.1, 1, 10, 100μM for 20 
minutes at room temperature with a 0.01% DMSO vehicle used as a control. 
Platelets were then centrifuged at 900 g for 6 minutes and resuspended in tyrodes 
buffer. Drug treated platelets were subsequently stimulated with 100nM ADP or 
1μM of the P2Y1 receptor specific agonist MRS2365 and chemotaxis measured as 
previously described (2.4.3). 
 
2.7 Platelet Activation Demonstrated Through P-selectin Expression 
Platelets were isolated from whole blood via gel filtration as described in section 
2.5.1 and 2.5.3. Gel filtered platelets were pre-treated with vehicle, 1, 10, 100, 
1000nM MRS2500 or 1, 10, 100, 1000nM AR-C66096 for 15 minutes at room 
temperature. Following antagonist treatment, platelets were stimulated with 10μM 
ADP for 30 minutes at room temperature. After incubation, 10μl stimulated platelets 
were added to FACs tubes containing 100μl PBS and 5μl anti-CD62P-FITC and left 




to incubate for a further 30 minutes at room temperature. Following incubation 
500μl PBS was added to each sample and analysed on a EPICS XL-MCL s/n 
Y48314 flow cytometer (Beckman Coulter) by the same operator throughout the 
study. Data was collected on FITC fluorescence at 515nm. Live gating was used to 
specifically identify platelets using forward and side scatter analysing 10 000 events. 
Events staining for CD62P were considered to represent P-selectin expressing 
platelets. 
 
Ex vivo Mouse Studies 
 
2.8 Analysis of Platelet-Leukocyte Conjugate Formation ex vivo 
Female Balb/c mice treated with Vehicle, 3mg/kg MRS2500 or 3mg/kg AR-C66096  
were sensitised and challenged to OVA as described in figure 2.7. 6 hours post 




Figure 2. 7 Ex Vivo OVA sensitisation and challenge protocol 
 




50μl murine whole  blood  were treated with saturating concentrations of the platelet 
specific monoclonal antibody CD41-PE and the leukocyte specific monoclonal 
antibody CD45-FITC were added to each sample. Blood samples were incubated 
with the respective antibodies for 30 minutes in the dark at 4°C. After incubation, the 
reaction was terminated through the addition of 500µl Optilyse C for 1 hr, used to 
lyse red blood cells, samples were kept for up to 1 day at 4°C before analysis. The 
quantification of platelet-leukocyte conjugates was then analysed on a EPICS XL-
MCL s/n Y48314 flow cytometer (Beckman Coulter) by the same operator 
throughout the study. Data was collected on FITC fluorescence at 515nm and PE 
fluorescence at 580nm. Live gating was used to include events of a similar size to 
leukocytes using either forward or side scatter. Events staining for two separate 
antigens (CD41 and CD45) were considered to represent platelets attached to 
leukocytes through measurements of CD41 emission on CD45 positive events.  
 
2.9 Allergen Induced Alterations in Surface Expression of Platelet P2Y1 and 
P2Y12 Receptors  
25µl of platelets taken from sham or OVA sensitised mice were added to tubes and 
fixed with 2% paraformaldehyde (PFA) for 10 minutes. Excess PFA was then 
removed through a washing cycle (Samples were centrifuged 3 times at 1000 g for 5 
minutes and resuspended in FACS buffer after each stage of centrifugation). 
Following the wash cycle, platelets were subsequently incubated with saturating 
concentrations of either rabbit P2Y1 or P2Y12 pAb in combination with saturating 
concentrations  (PE)- labelled CD42 MoAb and a Alexa Fluor 594 - labelled rabbit 
anti-goat IgG secondary antibody. The antibodies were left to incubate with platelets 
for 30 minutes in the dark at 4°C. Excess unbound antibody was then removed by 




repetition of the previously described wash cycle. Samples were analysed on a 
EPICS XL-MCL s/n Y48314 flow cytometer (Beckman Coulter) by the same 
operator throughout the study. Data was collected on PE fluorescence at 580nm and 
Alexa Fluor fluorescence at 615nm. Live gating was used to specifically identify 
CD41 expressing platelets using forward and side scatter analysing 10000 events. 
Events staining for two separate antigens (CD41 and P2Y1/P2Y12) were considered 
to represent platelets expressing either the P2Y1 or P2Y12 receptors. 
 
 
2.10 Platelet Aggregation 
 
2.10.1 In vitro Platelet Aggregation 
Gel filtered platelets (225µl) (2x10
8
 plts/ml) were prepared as described in section 
2.5.3 and were preincubated with varying concentrations of MRS3500, AR-C66096 
or clopidogrel in microcuvettes placed in holding wells for 10 minutes at 37°C. 
Small magnetic stir bars were added into each microcuvette and the stir speed set to 
1000rpm on the aggregometer. After incubation with drugs, platelets were placed 
into the recording wells. Platelet aggregation was then induced through stimulation 
of platelets with an appropriate agonist (i.e. ADP/thrombin). The effects of specific 
agonists and drug treatment on platelet aggregation was measured using a Bio/Data 
Corporation optical aggregometer, measuring platelet aggregation using the 
turbidometric method developed by Born (Born., 1963). 
 




2.10.2 The Effects of Allergen Challenge on Platelet Aggregation ex vivo 
Female Balb/c mice were sensitised and challenged to OVA as previously described 
(Figure 2.7). 30 minutes prior to allergen challenge mice were dosed intravenously 
with either 3mg/kg MRS2500 or AR-C66096. 6 hours post allergen challenge mice 
were anaesthetised with 0.3ml 25% urethane (in saline) and blood collected via 
cardiac puncture into a 1ml syringe, mixing with ACD at a 1:9 ratio with blood. 
Washed platelets were isolated as previously described in 2.5.3 and subsequent 
aggregation of washed platelets performed as described previously (2.10). 
 
2.11 Investigating the Role of the Small GTPase RhoA on Parameters of Platelet 
Activation 
 
2.11.1 In vivo Stimulation for RhoA Expression Quantification 
Female Balb/c mice were sensitised and challenged to OVA as described below in 
figure 2.8. 30 minutes before allergen challenges on days 14, 15 and 16 animals were 
treated with either vehicle, 3mg/kg MRS2500 or 3mg/kg AR-C66096. 6 hrs after the 
final allergen challenge, citrated blood was collected via cardiac puncture. Washed 
platelets were subsequently isolated from whole blood as described in 2.5.3. 
 
 




2.11.2 Preparation of Cell Extracts and Western Blot 
Platelet RhoA expression was investigated in platelets by immunoblotting with a 
rabbit anti-pRhoA Ab. Washed platelets isolated in 2.9.1 were lysed in RIPA buffer 
(1% Nonidet P40, 0.5% Sodiodeossicolato, 0.1% SDS, 1mM PMDF, 1mM Na2VO4, 
pH 7.4) for 30 minutes on ice. Lysates were subsequently cleared by centrifugation 
at 10000g for 10 minutes at 4°C. The protein contents were then quantified through a 
Bradford Protein assay (Bio-Rad Laboratories). Equal amounts of protein were then 
separated through 12% SDS-polyacrylamide gel electrophoresis and immunoblotting 
followed by enhanced chemiluminescence (ECL) detection, using anti-pRhoA S188 
(Abcam) diluted 1:1000 in 0.01% TBS tween and 5% BSA and the anti-rabbit HRP 














Human in vitro Studies 
2.12 Platelet Isolation  
 
2.12.1 Sepharose Column Preparation  
Sepharose columns were prepared using Sepharose C12-B (Sigma-Aldrich, Dorset, 
UK). Sepharose was first washed in a Buchner filter with 100% acetone. After 
washing with acetone, the sepharose was placed in a beaker with distilled water and 
mixed on a magnetic stirrer. The sepharose was then washed with distilled water 
through the Buchner filter. This wash cycle was repeated untill the odour of acetone 
had been lost. After washing, the sepharose was stored in 10% ethanol (1 part 
sepharose: 2 parts ethanol) at 4°C.  
When required washed sepharose was placed into a 60ml pre-fitted reservoir column 
and washed with 10% ethanol until the column was half full with settled sepharose. 
The column is then stored in 10% ethanol at 4°C. 
 
2.12.2 Platelet Isolation via Gel filtration 
On the day of the experiment, the sepharose column was washed with approximately 
70ml HEPEs tyrodes buffer (137mM NaCl, 2.3mM KCl, 1mM MgCl2.6H2O, 4mM 
NaH2PO4.H2O, 3.1mM HEPES, 4.6mM Glucose) with 1% BSA at pH7.4. 
Human citrated venous blood (isolated from volunteers who had not taken anti-
platelet drugs for 10 days prior to donation) was centrifuged at 120g for 10 minutes 
and resulting PRP was collected. If required a second centrifugation step at 120g for 
10 minutes was performed to isolate additional PRP. 




PRP was added to the top of the sepharose matrix (no less than 1ml, no more than 
3ml) and small amounts of HEPES buffer added to the top of the column. Only the 
cloudy platelet containing media eluted from the base of the column was collected 
with attention paid to ensure no plasma was collected. Platelets were then stained in 
stromatol (1/100) and quantified on a Neubauer haemocytometer under a x20 
objective and diluted to a final concentration of 1x10
8
plts/ml in HEPES tyrodes 
buffer. 
 
2.12.3 Washed Platelet Isolation 
Human venous blood was collected in a citrated syringe (1 ACD: 9 Blood) and 
centrifuged at 120g for 10 minutes at 25°C, the resulting PRP was collected and the 
remaining blood centrifuged for a further 10 minutes at 120g and 25°C, collecting 
any remaining PRP. 2.5mM PGE1 was added to PRP and subsequently centrifuged at 
1300 g for 10 minutes at 25°C. The supernatant was aspirated and the platelet pellet 
resuspended in 1ml tyrodes buffer. 25μM PGE1 and 50U/ml Heparin were added and 
the final volume made up to 10ml with tyrodes. The platelet suspension was then 
centrifuged at 1300 g for 10 minutes at 25°C. After centrifugation, the supernatant 
was aspirated and the platelet pellet resuspended in 1ml RPMI 1640 media. Platelets 
were then stained in stromatol (1/100) and quantified on a Neubauer 
haemocytometer under a x40 objective and phase contrast on a upright Zeiss 
Axioskop microscope and diluted to a final concentration of 1x10
8
plts/ml in RPMI 
1640 media. Platelets were left for 45-60 minutes to ensure the activity of PGE1 had 
worn off before used in subsequent experiments. 




2.13 Platelet Activation Demonstrated through P-selectin Expression in vitro 
Gel filtered platelets were treated with 2mM Ca
2+
 and then stimulated with different 
agonists (MDC, SDF-1α, 5-HT, IL-1β, f-MLP LPS, ADP, Adrenaline, U46619 or 
TRAP) for 30 minutes at room temperature. After incubation, 10μl stimulated 
platelets were added to FACs tubes containing 100μl PBS and 5μl CD62P-FITC and 
left to incubate for a further 30 minutes at room temperature. Following incubation 
500μl PBS was added to each sample and  analysed on a EPICS XL-MCL s/n 
Y48314 flow cytometer (Beckman Coulter) by the same operator throughout the 
study. Data was collected on FITC fluorescence at 515nm. Live gating was used to 
specifically identify platelets using forward and side scatter analysing 10 000 events. 
Events staining for CD62P were considered to represent P-selectin expressing 
platelets. 
 
2.14 Measurement of Platelet-Leukocyte Conjugate Formation in vitro 
50μl of whole blood  were stimulated with varying different agonists (MDC, SDF-1, 
5-HT, IL-1β, f-MLP LPS, ADP, Adrenaline, U46619 or TRAP) on a rotating 
platform (Rotatest Shaker R100, Ludcham, Speed setting 3.5) for 30 minutes at room 
temperature. Following stimulation, samples were treated with saturating 
concentrations of the platelet specific monoclonal antibody CD41-PE and the 
leukocyte specific monoclonal antibody CD45-FITC were added to each sample. 
Blood samples were incubated with the respective antibodies for 30 minutes in the 
dark at 4°C. After incubation, the reaction was terminated through the addition of 
500µl Optilyse C for 1 hr, also responsible for the lysing of red blood cells. Samples 
were kept for up to 1 day at 4°C before analysis. The quantification of platelet-
leukocyte conjugates was then analysed on a EPICS XL-MCL s/n Y48314 flow 




cytometer (Beckman Coulter) by the same operator throughout the study. Data was 
collected on FITC fluorescence at 515nm and PE fluorescence at 580nm. Live gating 
was used to include events of a similar size to leukocytes using either forward or side 
scatter. Live gating was also used to detect CD45+ also emmiting CD41+ emission, 
representing platelets attached to leukocytes. 
 
2.15 Measurement of Platelet Aggregation in vitro 
Gel filtered platelets were isolated from human blood as previously described in 
section 2.12.1.2. All platelet samples were treated with 2mg/ml fibrinogen prior to 
commencing aggregation. 225μl platelets were added to microcuvettes containing 
magnetic stir bars and allowed time to equibrilate to 37°C. Platelet samples were 
subsequently stimulated with either vehicle controls of pro-inflammatory/thrombotic 
agonists (MDC, SDF-1α, IL-1β, f-MLP, 5-HT, LPS, ADP, Adrenaline, U46619, 
TRAP) for 10 minutes. Aggregation was measured using a Bio/Data Corporation 
optical aggregometer, measuring platelet aggregation using the turbidometric method 
developed by Born (Born., 1963). 
 
2.16 Platelet Chemotaxis 
Washed platelets were isolated from human venous whole blood via centrifugation 
described in section 2.12.1.3. Individual wells on a BD falcon cell 24 well plate (BD 
Biosciences) were blocked for 1 hour using 1ml tyrodes + 1% BSA. Post incubation, 
the blocking buffer was removed and the wells washed with 1 ml PBS. 




450μl media containing each chemotactic stimuli (MDC, SDF-1α, IL-1β, f-MLP, 5-
HT, LPS, adrenaline, ADP, U46619, TRAP) was added to the bottom well and 3μm 
pore PET membrane inserts (BD Biosciences) added to each well. 200μl of 1x108 gel 
filtered platelets/ml were added into each of the transwell inserts and the entire plate 
incubated at 37°C for 90 minutes. 
Post incubation, the transwell inserts were carefully removed and discarded and 
100μl of the media in the bottom chamber incubated with 5μl of the platelet specific 
CD42b FITC labelled antibody for 30 minutes at room temperature. After incubation 
with the antibody, 500μl PBS and 100μl flow-count fluorospheres (Beckman 
Coulter, UK) were added to each sample. Samples were subsequently analysed for 
platelet quantification on a flow cytometer and used as a measure of platelet 
migration. 
2.17 Statistical Analysis 
Cell counts quantified from BAL fluid taken from allergic studies (total and 
differential cell counts) and blood samples (circulating platelets & leukocytes, FACS 
analysis, platelet aggregation) were expressed as mean ± SEM, and analysed using 
one way ANOVA followed by a subsequent Dunnet’s multiple comparison post tests 
between different groups. Differences were considered significant if P<0.05 between 
individual groups. 
In vitro chemotaxis data is expressed as a chemotactic index (CI). Data was analysed 
by means of one way ANOVA, followed by a subsequent Dunnet’s multiple 
comparison test between groups. Significance differences were accepted if P<0.05 
















3.1. An Investigation into Leukocyte Recruitment in Allergen Challenged Mice 
Validation studies were performed to establish a suitable sensitisation and challenge 
protocol for the induction of pulmonary leukocyte recruitment in mice.  The 
variables studied were the sensitising concentration of OVA (either 0.5mg/kg or 
1.5mg/kg) as well as the number exposures towards nebulised OVA (once or twice 
daily). 
Murine sensitisation via intra-peritoneal injections of an OVA concentration of 
0.5mg/kg induced significant total leukocyte recruitment to the lungs when exposed 
to either one or two periods of aerosolised OVA challenge daily compared to sham 
sensitised control mice (Sham: 0.99 ± 0.15x10
5
 cells/ml vs. 0.5mg/kg OVA once 
daily: 6.10 ± 0.83x10
5
 cells/ml, 0.5mg/kg OVA twice daily: 5.59 ± 1.32x10
5
 
cells/ml, fig 3.1A), a process that was replicated by elevations in individual 
inflammatory cell types including macrophages (Sham: 1.17 ± 0.10x10
5
 cells/ml vs. 
0.5mg/kg OVA once daily: 1.92 ± 0.44x10
5
 cells/ml; 0.5mg/kg OVA twice daily: 
2.28 ± 1.38x10
5
 cells/ml, fig 3.1B), neutrophils (Sham: 0.00 ± 0.00 cells/ml vs. 
0.5mg/kg OVA once daily: 0.02 ± 0.01x10
5
 cells/ml; 0.5mg/kg OVA twice daily: 
0.01 ±0.01x10
5
 cells/ml fig 3.1C), lymphocytes (Sham: 0.00 ± 0.00 cells/ml vs. 
0.5mg/kg OVA once daily: 0.19 ± 0.06x10
5
 cells/ml, P < 0.01; 0.5mg/kg OVA twice 
daily: 0.01 ± 0.01x10
5
 cells/ml fig 3.1D) and eosinophils (Sham: 0.00 ± 0.00 cells/ml 
vs. 0.5mg/kg OVA once daily: 3.82 ± 0.25x10
5
 cells/ml; 0.5mg/kg OVA twice daily: 
3.34 ± 0.79x10
5
 cells/ml, P < 0.05  fig 3.1E). 
In addition to sensitisation with 0.5mg/kg OVA groups of mice were also sensitised 
with 1.5mg/kg OVA, which induced significant total leukocyte recruitment to the 
lungs when exposed to either once or twice daily aerosolised challenge to 3% OVA 




when compared to sham sensitised controls (Sham: 0.99 ± 0.15x10
5
 cells/ml vs. 
1.5mg/kg OVA once daily: 7.41 ± 2.19x10
5
 cells/ml, ; 1.5mg/kg OVA twice daily: 
9.86 ± 1.10x10
5
 cells/ml, P < 0.01, fig 3.1A). This elevation in total leukocyte 
infiltration was replicated in the individual inflammatory cell types of macrophages 
(Sham: 1.17 ± 0.10x10
5
 cells/ml vs. 1.5mg/kg OVA once daily: 2.42 ± 0.47x10
5
 
cells/ml; 1.5mg/kg OVA twice daily: 2.16 ± 0.39x10
5
 cells/ml, fig 3.1B), neutrophils 
(Sham: 0.00 ± 0.00 cells/ml vs. 1.5mg/kg OVA once daily: 0.04 ± 0.03x10
5
 cells/ml; 
1.5mg/kg OVA twice daily: 0.00 ± 0.00x10
5
 cells/ml, fig 3.1C), lymphocytes (Sham: 
0.00 ± 0.00 cells/ml vs. 1.5mg/kg OVA once daily: 0.03 ± 0.03x10
5
 cells/ml; 
1.5mg/kg OVA twice daily: 0.03 ± 0.03x10
5
 cells/ml, fig 3.1D) and eosinophils 
(Sham: 0.00 ± 0.00 cells/ml vs. 1.5mg/kg OVA once daily: 4.89 ± 1.77x10
5
 cells/ml; 
1.5mg/kg OVA twice daily: 8.86 ±0.67, P < 0.001, fig 3.1E) 
Furthermore, no significant difference in leukocyte recruitment was observed 
between once or twice daily provocation with 3% aerosolised OVA in any of 
measured cell types (total cells, macrophages, neutrophils, lymphocytes or 
eosinophils). 
The data obtained from these experiments indicated that twice daily exposures to 
nebulised 3% OVA did not significantly increase leukocyte recruitment over once 
daily exposures, whilst sensitisation to a higher 1.5mg/kg dose of OVA produced a 
significantly larger leukocyte recruitment profile when compared with a 0.5mg/kg 
OVA sensitisation dose. Thus, further experiments recording the effects of various 
agents on the development of pulmonary leukocyte recruitment were performed 24 
hours post final challenge using a sensitisation and challenge protocol consisting of 3 
sensitisation doses of 1.5mg/kg on days 0, 4 and 10 followed by a single exposure 
towards 3% nebulised OVA for 30 minutes on days 14, 15 and 16. 





Figure 3. 1 Pulmonary Inflammatory cell recruitment using a sensitisation 
protocol in OVA 
Mice were immunised with either 0.5/1.5mg/kg OVA (i.p.) on days 0, 4 and 10 and 
then exposed to nebulised OVA (3% in saline) either once or twice daily on days 14, 
15 and 16. Lavage fluid was collected on day 17, 24 hours post final OVA exposure. 
A Total Leukocyte counts B Eosinophils.  Data: Mean ± SEM. N = 4 animals per 
group. * = P < 0.05, ** = P < 0.01, *** = P < 0.001 compared to sham controls 




3.2 An Investigation into the Effects of Allergen Challenge of Circulating 
Platelet Dynamics over 24 hours 
A number of groups have previously demonstrated that platelets are a crucial 
component of the machinery involved in pulmonary leukocyte recruitment following 
provocation in a variety of animal models including the murine model of allergic 
inflammation (Pitchford et al. 2003, 2005), in an allergic rabbit model (Coyle et al. 
1990) and also in guinea pigs (Lellouch-Tubiana et al., 1988) with a state of mild 
systemic thrombocytopenia observed in asthmatic patients (Sullivan et al., 2000; 
Kowal et al., 2006). Given this additional parameter of platelets the impact of 
allergen challenge in this model of pulmonary leukocyte challenge on circulating 
platelet numbers were analysed from blood isolated from the tail veins at 1, 3, 6 and 
24 hours post allergen challenge and compared to circulating platelet numbers prior 
to allergen provocation. 
Circulating platelet numbers in sham-sensitised animals were unchanged throughout 
the time course and remained comparable to platelet numbers prior to allergen 
challenge. (Pre: 1.68 ± 0.06x10
9
 plts/ml; 1hr: 1.63 ± 0.03x10
9
plts/ml; 3hrs: 1.53 ± 
0.08x10
9
plts/ml; 6hrs: 1.37 ± 0.08x10
9
plts/ml; 24hrs: 1.51 ± 0.08x10
9
plts/ml) 
(Figure 3.2). In contrast a mild systemic thrombocytopenia was observed in allergen 
challenged OVA sensitised mice over the 24 hour time course with a significant 
decrease in circulating platelet numbers observed at all measured time points (Pre: 
1.69 ± 0.07x10
9
plts/ml; 1hr: 1.45 ± 0.04x10
9
plts/ml, P<0.01; 3hrs: 1.18 ± 
0.08x10
9
plts/ml, P<0.01; 6hrs: 1.03 ± 0.03x10
9
plts/ml, P <0.01; 24hrs: 1.19 ± 
0.06x10
9
plts/ml, P<0.05) (Figure 3.2). By 24 hours post challenge it appeared as 
though the circulating platelet numbers had begun to return to levels seen pre-
exposure to nebulised OVA. 





































Figure 3. 2. The effects of allergen challenge on circulating platelet dynamics 
over 24 hours 
Mice were immunised with 1.5mg/kg OVA or vehicle (i.p.) on days 0, 4 and 10 and 
then exposed to nebulised OVA (3% in saline) or sham controls once daily on days 
14, 15 and 16. Circulating blood was collected via tail bleeds from both OVA and 
sham challenged groups and circulating platelets assessed pre challenge and at 1, 3, 6 
and 24 hours post allergen challenge. Data: Mean ± SEM, N = 4-5 animals per 
group. ** = P < 0.01 compared to sham controls. 
 
 
3.3 Validating an in vitro Model of Platelet P-selectin Expression 
Experiments were performed to identify the most suitable protocol for the 
quantification of platelet P-selectin expression post stimulation following platelet 
isolation from whole blood. 
 
3.3.1 ADP Induced P-selectin Expression in Washed Platelet Preparations 
Washed platelet preparations isolated from whole blood via centrifugation 
demonstrated significant elevations in P-selectin expression following stimulation 




with increasing concentrations of the platelet agonist ADP when compared to sham 
controls (Vehicle: 19.84 ± 0.87% vs. 0.1μM ADP: 21.45 ± 1.57%; 1μM ADP: 24.22 
± 4.42%; 10μM ADP: 36.95 ± 3.95%, P < 0.05; 100μM ADP: 42.23 ± 3.91%, P < 
0.05, fig 3.3A). This was also reflected by ADP induced increases in platelet MFI on 
platelet P-selectin expression compared to vehicle controls (Sham: 0.94 ± 0.02 vs. 
0.1μM ADP: 0.91 ± 0.02; 1μM ADP: 1.50 ± 0.19; 10μM ADP: 2.00 ± 0.17, P < 
0.01; 100μM ADP: 2.17 ± 0.24, P < 0.01, fig 3.3B). It is important to note that P-
selectin is not constitutively expressed on the surface of platelets and is only 
expressed upon platelet activation. As a result, the relatively high basal levels of 
platelet P-selectin expression suggests that the platelets may have become activated 
during the centrifugation steps required for platelet isolation from the plasma. 
Therefore subsequent experiments measuring P-selectin following ADP stimulation 
on platelets isolated through gel filtration, (a platelet isolation protocol with minimal 
centrifugation steps capable of inducing high levels of basal platelet P-selectin 










Figure 3. 3 ADP Induced P-selectin expression in Gel Filtered Platelet 
Preparations 
Washed platelets were isolated from human blood via centrifugation and stimulated 
with 0.1, 1, 10 and 100μM ADP. Platelet P-selectin expression was measured via 
flow cytometry using a CD62P FITC labelled antibody as either the percent of 
platelets expressing P-selectin (A) or as the platelet MFI on P-selectin expression 
(B). Data expressed as Mean ± SEM. N = 3, * = P < 0.05, ** = P < 0.01 indicates 
significance compared to vehicle controls. 
 
 
3.3.2 ADP Induced P-selectin Expression in Gel Filtered Platelet Preparations 
Using platelets isolated from whole blood via gel filtration, platelet P-selectin 
expression was measured following stimulation with increasing concentrations of 
ADP. ADP induced a significant increase in surface P-selectin expression (Vehicle: 
2.05 ± 0.61% vs. 0.1μM ADP: 12.08 ± 8.10%; 1μM ADP: 21.33 ± 2.15%; 10μM 
ADP: 32.86 ± 3.44%, P < 0.01; 100μM ADP: 41.46 ± 2.99%, P < 0.01, figure 3.4A) 
as well as inducing increases in MFI on platelet P-selectin expression (Vehicle: 0.43 
± 0.05 vs. 0.1μM ADP: 1.20 ± 0.61; 1μM ADP: 1.77 ± 0.53; 10μM ADP: 2.54 ± 
0.42; 100μM ADP: 3.15 ± 0.40, P < 0.05, figure 3.4B) compared to sham controls. 




Importantly, basal levels of P-selectin expression were significantly lower in 
platelets isolated via gel filtration when compared to platelets isolated via 
centrifugation (WP: 19.84 ± 0.87% vs. GFP: 2.05 ± 0.61%, P < 0.001 ), this 
observation was replicated in platelet MFI on P-selectin expression (WP: 0.94 ± 0.02 
vs. GFP: 0.43 ± 0.05, P < 0.05).  This indicates that there is significantly lower basal 
platelet activation in platelets isolated via gel filtration, therefore in future 




Figure 3. 4 ADP induced P-selectin expression in gel-filtered platelet 
preparations 
Gel-filtered platelets were isolated from human blood via separation in a sepharose 
column and stimulated with 0.1, 1, 10 and 100μM ADP. Platelet P-selectin 
expression was measured via flow cytometry using a CD62P FITC labelled antibody 
as either the percent of platelets expressing P-selectin (A) or as the platelet MFI on 
P-selectin expression (B). Data expressed as Mean ± SEM. N = 3, * = P < 0.05, ** = 
P < 0.01 indicating significance compared to vehicle controls. 
 




3.4 Validating an in vitro Model of Platelet-Induced Leukocyte Chemotaxis 
Chemotaxis assays were performed on platelets and PMN cells (90% neutrophils) 
isolated from cardiac blood and bone marrow respectively, of allergen sensitised 
mice. To validate this in vitro model of platelet induced PMN migration, chemokines 
known to activate platelets were used, SDF-1α and MDC. 
3.4.1 Investigating the Effects of CCR4 Receptor Antagonism on Platelet 
Induced PMN Chemotaxis towards MDC and SDF-1 
Chemotaxis assays were performed on platelets and PMNs isolated from blood and 
bone marrow of allergen sensitised mice. Platelets were incubated with the CCR4 
receptor antagonist C-021 prior to stimulation with 100nM ADP to confirm that 
migration was the result of platelet CCR4 receptor activation. Post ADP stimulation, 
platelets were added to PMN cells to induce their migration towards a source of 
MDC. No significant migration was observed with leukocytes alone (0.65 ± 0.07), 
leukocyte migration towards 100nM MDC (1.31 ± 0.24) or leukocytes in the 
presence of platelets (1.00 ± 0.15), however in the platelets and leukocytes at a 1:1 
volumetric ratio (20:1 cellular ratio), platelet induced leukocyte migration was 
significantly enhanced (2.49 ± 0.12, P < 0.001, figure 3.5A). 
Pre-incubation of platelets with 1, 10, 100 and 1000nM of C-021 resulted suppressed 
PMN migration towards MDC in a concentration dependent manner (Veh:2.49 ± 
0.12 vs. 1nM: 2.24 ± 0.10, 10nM: 2.22 ± 0.12, 100nM: 2.04 ± 0.25, 1000nM: 1.24 ± 
0.13 P<0.001, figure 3.5A) confirming that co-stimulation of platelets with MDC 
and ADP triggered PMN migration across the chemotactic membrane. 
In contrast however the CCR4 antagonist C-021 failed to inhibit platelet-induced 
leukocyte migration towards SDF-1α (Veh: 1.96 ± 0.63; 1nM C-021: 2.15 ± 0.67; 




10nM C-021: 2.13 ±0.54; 100nM: 2.96 ± 0.23; 1000nM C-021: 2.42 ± 0.12, figure 
3.5B). 
 
Figure 3. 5 The Effects of the CCR4 Receptor Antagonist C-021 on Platelet 
Induced PMN chemotaxis in vitro 
Platelets and PMNs were isolated from citrated blood and bone marrow from female 
Balb/c mice. Platelets were treated with 1, 10, 100 and 1000nM C-021 and 
stimulated with 100nM ADP before mixing with PMN cells. The cell mixture was 
added to the top well of a chemotaxis chamber. PMN chemotaxis towards either 
100nM MDC (A) or 100nM SDF-1α (B) was then quantified after a 90 minute 
incubation and analysed as a chemotactic index. Data are expressed as mean ± SEM. 
*** = P < 0.001 where indicated to column 3, ### = P < 0.001 where indicated to 
column 4, n =4. 
 
 
3.4.2 Investigating the Effects of CXCR4 Receptor Antagonism on Platelet 
Induced PMN Chemotaxis Towards SDF-1α and MDC 
Platelets were incubated with the CXCR4 receptor antagonist AMD3100 prior to 
stimulation with 100nM ADP. Post ADP stimulation, platelets were added to PMN 
cells to induce their migration towards a source of SDF-1α. No significant migration 
was observed with leukocytes alone (0.93 ± 0.12), leukocyte migration towards 
100nM SDF-1α (1.04 ± 0.09) or leukocytes in the presence of platelets (1.00 ± 0.05), 
however in the platelets and leukocytes at a 1:1 volumetric ratio (20:1 cellular ratio), 




platelet induced leukocyte migration was significantly enhanced (2.38 ± 0.09, P < 
0.001, figure 3.6A). Pre-incubation of platelets with 1, 10, 100 and 1000nM of 
AMD3100 resulted suppressed PMN migration towards SDF-1α in a dose dependent 
manner (Veh: 2.38 ± 0.17 vs. 1nM: 2.06 ± 0.09, 10nM: 1.62 ± 0.09 P < 0.001, 
100nM: 1.42 ± 0.11 P < 0.001, 1000nM: 1.03 ± 0.13 P<0.001, figure 3.6A) 
confirming that co-stimulation of platelets with SDF-1α and ADP triggered PMN 
migration across the chemotactic membrane. In contrast however AMD3100 failed 
to inhibit platelet-induced leukocyte migration towards MDC (Veh: 2.38 ± 0.17; 




Figure 3. 6 The Effects of the CXCR4 Receptor Antagonist AMD3100 on 
Platelet Induced PMN Chemotaxis in vitro 
Platelets and PMNs were isolated from citrated blood and bone marrow from female 
Balb/c mice. Platelets were treated with 1, 10, 100 and 1000nM C-021 and 
stimulated with 100nM ADP before mixing with PMN cells. The cell mixture was 
added to the top well of a chemotaxis chamber. PMN chemotaxis towards either 
100nM SDF-1α (A) or 100nM MDC (B) was then quantified after a 90 minute 
incubation and analysed as a chemotactic index. Data are expressed as mean ± SEM. 
*** = P < 0.001 where indicated to column 3, ### = P < 0.001 where indicated to 







Purine Involvement in Pulmonary Leukocyte 
















4.1 An Investigation into the Involvement of ADP in Pulmonary Leukocyte 
Recruitment 
Platelets have previously been reported as a critical cellular component in pulmonary 
leukocyte recruitment after allergen challenge in animal models of allergic 
inflammation (Lellouch-Tubiana et al., 1988; Coyle et al., 1990; Pitchford et al., 
2003a). Furthermore, purinergic receptor stimulation has been reported to induce 
platelet activation, resulting in granular release of pro-inflammatory cytokines such 
as RANTES and PF-4 and upregulation of surface P-selectin expression and the 
formation of platelet-leukocyte conjugates (Leon et al., 2003, 2004; Straub et al., 
2011), in addition to the well characterised process of aggregation (Hechler et al., 
1998, 2006; Fabre et al., 1999; Léon et al., 1999; Baurand et al., 2001; Kauffenstein 
et al., 2001; Oury et al., 2001; Nylander et al., 2003, 2004). The elevation in P-
selectin expression and the formation of platelet-leukocyte conjugates suggests a 
potential role of platelet purinergic stimulation in the platelet P-selectin dependent 
process of pulmonary leukocyte recruitment (Pitchford et al., 2003a, 2005). 
Therefore experiments were performed investigating the impact of purinergic 
receptor stimulation in this murine model of allergic inflammation. 
The enzyme Apyrase which is responsible for the degradation of active ATP and 
ADP into inactive AMP was used in order to evaluate the impact of the purines on 
pulmonary leukocyte recruitment using this murine model of allergic pulmonary 
inflammation validated in section 3.1. Apyrase (100u/ml), dosed daily, intravenously 
30 minutes before each exposure to nebulised OVA significantly suppressed allergen 
induced total leukocyte infiltration into the BAL (Sham: 20.00 ± 2.08x10
4
 cells/ml; 
OVA: 61.33 ± 18.30 x10
4
 cells/ml vs. 100u/ml Apyrase: 27.00 ± 2.02x10
4
 cells/ml, 
P < 0.001) (Figure 4.1A). 




Allergen induced elevations in total leukocyte infiltration and subsequent attenuation 
of infiltration following apyrase treatment was replicated in the differential cell 
count numbers of macrophages (Sham: 19.87 ± 2.08x10
4
 cells/ml; OVA:29.67 ± 
1.87x10
4
 cells/ml, P < 0.001 vs. Apyrase: 20.55 ± 1.41, P < 0.001), neutrophils 
(Sham: 0.09 ± 0.05x10
4
 cells/ml; OVA: 1.80 ± 0.59x10
4
 cells/ml, P < 0.001 vs. 
Apyrase: 1.29 ± 0.74, P < 0.001), lymphocytes (Sham: 0.04 ± 0.04x10
4
 cells/ml; 
OVA: 1.07 ± 0.29x10
4
 cells/ml, P < 0.001 vs. Apyrase: 0.04 ± 0.04, P < 0.001) and 
eosinophils (Sham: 0.00 ± 0.00 cells/ml; OVA: 34.29 ± 4.02x10
4
 cells/ml, P < 0.001 
vs. Apyrase: 5.12 ± 1.07, P < 0.001) (Figure 4.1B)  
This attenuation of total and differential cell infiltration into the BAL fluid following 
nebulised provocation to OVA strongly implicates both ATP and ADP as necessary 
in pulmonary leukocyte recruitment. Given that previous studies have reported that 
pulmonary leukocyte recruitment in this model is also platelet dependent the impact 

















Figure 4. 1 The Effects of Apyrase of Pulmonary Leukocyte Recruitment 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and allergen 
exposure protocol. Apyrase was administered prior to allergen exposure on days 14, 
15 and 16 (100u/ml intravenously). Lavage fluid was collected 24 hours post final 
allergen Exposure (day 17). A Total BAL Leukocytes B Differential Cell counts. 
Data: Mean ± SEM, N= 4 animals per group. * = P < 0.05, ** = P < 0.01, *** = P < 
0.001 compared to sham control, # = P < 0.05, ## = < 0.01, ### = P < 0.001 
compared to OVA challenged mice. 
 




4.2 An Investigation into the Effects of Purinergic Receptor Antagonism on 
Pulmonary Leukocyte Recruitment in a Murine Model of Allergic 
Inflammation 
In 4.1, experiments involving the treatment of mice with Apyrase demonstrated 
significant attenuation of pulmonary leukocyte recruitment in a murine model of 
allergic inflammation thus implicating the purines in the initiation of pulmonary 
leukocyte recruitment. Therefore, the roles of antagonists specific for each of the 
purinergic receptors stimulated by adenosine phosphates on the platelet surface, 
including the P2Y1 (MRS2179, MRS2500) and P2Y12 (MRS2395, AR-C66096) 
receptors whose endogenous agonist is ADP and the ATP sensitive P2X1 receptor 
(NF-279) were investigated, given that leukocyte recruitment is platelet dependent in 




4.2.1.An Investigation into the Effects of the P2Y1 Receptor Antagonist 
MRS2179 on Pulmonary Leukocyte Recruitment 
Female Balb/c mice were sensitised to OVA using a sensitisation protocol involving 
3 intra-peritoneal injections of 30µg/mouse OVA or sham sensitised controls on days 
0, 4 and 10. OVA sensitised mice were then pre-treated with vehicle or 3, 10 and 
30mg/kg MRS2179 i.p. (an ADP analogue demonstrating selective and competitive 
antagonism for the P2Y1 receptor) 30 minutes prior to allergen challenge on days 14, 
15 and 16. Twenty-four hours post final challenge (Day 17) all animals were culled 
and BAL fluid collected.  
Sensitisation and subsequent challenge to OVA resulted in significant elevation in 
total leukocyte recruitment into BAL fluid (Sham: 1.33 ± 0.01x10
5
 cells/ml vs. 




OVA: 3.58 ± 0.25x10
5
 cells/ml, P < 0.001) which was significantly attenuated by 
daily intravenous administration of MRS2179 in a dose-dependent manner when 
treated before exposure to nebulised OVA, as demonstrated by the top concentration 
of 30mg/kg MRS2179 (Vehicle: 3.58 ± 0.25x10
5
 cells/ml vs. 30mg/kg MRS2179: 
1.73 ± 0.11x10
5
 cells/ml, P < 0.001) (Figure 4.2A). At 30mg/kg of MRS2179, 
differential leukocyte analysis of cell infiltrate revealed a significant reduction in 
macrophages counts (13.25 ± 1.04x10
4
 cells/ml vs. OVA: 22.06 ± 4.80x10
4
 cells/ml, 
P < 0.001; 30mg/kg MRS2179: 15.38 ± 0.84x10
4
 cells/ml P < 0.001), neutrophil 
counts (Sham: 0.08 ± 0.03x10
4
 cells/ml vs OVA: 1.21 ± 0.21x10
4
 cells/ml P < 0.001; 
30mg/kg MRS2179: 0.57 ± 0.17x10
4
 cells/ml, P < 0.05), lymphocyte counts (Sham: 
0.00 ± 0.00 cells/ml vs. OVA: 0.48 ± 0.08x10
4
 cells/ml, P < 0.001; 30mg/kg 
MRS2179: 0.04 ± 0.03x10
4 
cells/ml, P < 0.001) and eosinophil counts (Sham: 0.00 ± 
0.00 vs. OVA: 13.54 ± 4.12x10
4
 cells/ml, P < 0.001; 30mg/kg MRS2179: 3.29 ± 
0.94x10
4


















Figure 4. 2 The Effects of MRS2179 of Pulmonary Leukocyte Recruitment 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and allergen 
exposure protocol. MRS2179 was administered prior to allergen exposure on days 
14, 15 and 16 (3, 10 & 30mg/kg intravenously). Lavage fluid was collected 24 hours 
post final allergen exposure (day 17). A Total BAL Leukocytes B Differential Cell 
counts. Data: Mean ± SEM, N= 4 animals per group. * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001 compared to sham control, # = P < 0.05, ## = < 0.01, ### = P < 
0.001 compared to OVA challenged mice. 




4.2.1.2 An Investigation into the Effects of the P2Y1 Receptor Antagonist 
MRS2500 on Pulmonary Leukocyte Recruitment 
Given the ability of MRS2179 to significantly inhibit leukocyte recruitment, a 
second more potent antagonist was used to confirm the phenomenon. MRS2500 [2-
Iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-biphosphate], the 
combination of the ring-constrained (N)-methanocarbo modification of adenine 
nucleotides combined with an substitution of the 2-position functionalities with a 2-
iodo substitution significantly increased the antagonistic potency (Kim et al., 2003). 
OVA sensitised mice were pre-treated with either vehicle or the ADP analogue 0.1, 1 
or 3mg/kg MRS2500 30 minutes prior to allergen challenge. Twenty-four hours post 
final challenge all animals were culled and BAL fluid collected. 
Sensitisation and subsequent challenge to OVA resulted in significant elevation in 
total leukocyte lung recruitment (Sham: 1.81 ± 0.32x10
5
 cells/ml vs. OVA: 4.23 ± 
0.24x10
5
 cells/ml, P < 0.001), treatment with MRS2500 as demonstrated, induced a 
dose-dependent inhibition of leukocyte recruitment (OVA: 4.23 ± 0.24x10
4 
vs. 
3mg/kg MRS2500: 2.25 ± 0.15x10
4
 cells/ml, P < 0.05) (Figure 4.3A). Similarly to 
MRS2179, Intravenous dosing of MRS2500 at 3mg/kg inhibited allergen induced 
BAL differential cell leukocyte recruitment compared to vehicle controls as seen in 
macrophage counts (Sham: 16.00 ± 2.79x10
4
 cells/ml vs OVA: 22.80 ± 1.65x10
4
 
cells/ml; 3mg/kg MRS2500: 17.96 ± 1.99x10
4
 cells/ml), neutrophil counts (Sham: 
0.00 ± 0.00 cells/ml vs. OVA: 0.80 ± 0.21x10
4
 cells/ml, P < 0.05; 3mg/kg 
MRS2500: 0.08 ± 0.08x10
4
 cells/ml, P < 0.05), lymphocyte counts (Sham: 0.00 ± 
0.00 cells/ml vs OVA: 2.00 ± 0.38x10
4
 cells/ml, P < 0.01; 3mg/kg MRS2500: 0.56 ± 
0.33x10
4
 cells/ml, P < 0.05) and eosinophil counts in the lavage (Sham: 0.00 ± 0.00 
cells/ml vs. OVA: 16.23 ± 2.45x10
4
 cells/ml, P < 0.01; 3mg/kg MRS2500: 3.92 ± 






 cells/ml, P < 0.01) (Figure 4.3B). Through the use of MRS2179 and 
MRS2500 this data heavily implicates the P2Y1 receptor in the modulation of 


















Figure 4. 3 The Effects of MRS2500 on Pulmonary Leukocyte Recruitment 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and allergen 
exposure protocol. MRS2500 was administered prior to allergen exposure on days 
14, 15 and 16 (0.1, 1 & 3mg/kg intravenously). Lavage fluid was collected 24 hours 
post final allergen exposure (day 17). ). A Total BAL Leukocytes B Differential Cell 
counts. Data: Mean ± SEM, N= 4 animals per group. * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001 compared to sham control, # = P < 0.05, ## = < 0.01, ### = P < 
0.001 compared to OVA challenged mice. 




4.3.2. An Investigation into the effect of P2Y12 Antagonism on Pulmonary 
Leukocyte Recruitment in a Murine Model of Allergic Inflammation 
 
4.3.2.1. An Investigation into the Effect of the P2Y12 Specific Receptor 
Antagonist MRS2395 on Pulmonary Leukocyte Recruitment in vivo 
The ADP acyclic analogue MRS2395 which is a highly selective and competitive 
antagonist for the P2Y12 receptor was dosed intravenously on days 14, 15 and 16 30 
minutes prior to allergen challenge. Twenty-four hours post final challenge (Day 17) 
all animals were culled and BAL fluid collected. 
Similarly to the studies performed with the P2Y1 receptor antagonists MRS2179 and 
MRS2500, sensitisation and subsequent challenge to nebulised 3% OVA induced 
significant total leukocyte recruitment to the lungs compared to sham sensitised 
samples (Sham: 15.35 ± 1.52 x10
4
 cells/ml vs. OVA: 34.00 ± 1.19x10
4
 cells/ml, 
P<0.001), this allergen induced increase in total leukocyte recruitment was 
unaffected by any tested dose (1, 3 or 10mg/kg) of the P2Y12 receptor antagonist 
MRS2395 (Veh: 34.00 ± 1.19x10
4
 cells/ml vs. 10mg/kg [top dose] MRS2395: 41.75 
± 4.16x10
4
 cells/ml) (Figure 4.4A). This allergen induced rise in total leukocyte 
recruitment was mirrored by an allergen induced rise in pulmonary differential 
leukocyte numbers with MRS2395 treatment failing to modulate any of either 
macrophage counts (Sham: 18.07 ± 3.14x10
4
 cells/ml vs. OVA: 20.98 ± 4.07x10
4
 
cells/ml; 10mg/kg [top dose] MRS2395: 21.20 ± 1.81x10
4
 cells/ml), neutrophil 
counts (Sham: 0.00 ± 0.00 cells/ml vs. 1.53 ± 0.51x10
4
 cells/ml; 10mg/kg [top dose] 
MRS2395: 2.36 ± 0.49x10
4
 cells/ml), lymphocyte counts (Sham: 0.00 ± 0.00 
cells/ml vs. OVA: 1.53 ± 0.51x10
4
 cells/ml, 10mg/kg [top dose] MRS2395: 2.36 ± 
0.49x10
4
 cells/ml) or eosinophil counts within the lavage (Sham: 0.00 ± 0.00 




cells/ml vs. OVA: 9.35 ± 2.58x10
4
 cells/ml, P < 0.001; 10mg/kg MRS2395: 14.00 ± 
1.52x10
4
 cells/ml) (Figure 4.4B). 
Doses of MRS2395 were selected from previous in vivo based publications, however 
to ensure that the observed phenomenon was accurate and not an issue of the 
efficacy of the antagonist used, the experiment was repeated using an additional 






















Figure 4. 4 The Effects of MRS2395 on Pulmonary Leukocyte Recruitment 
.Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and allergen 
exposure protocol. MRS2395 was administered prior to allergen exposure on days 
14, 15 and 16 (0.1, 1 & 3mg/kg intravenously). Lavage fluid was collected 24 hours 
post final allergen exposure (day 17). A Total BAL Leukocytes B Differential Cell 
counts. Data: Mean ± SEM, N= 4 animals per group. * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001 compared to sham controls. 




4.3.2.2 An Investigation into the Effect of the P2Y12 Specific Receptor 
Antagonist AR-C66096 on Pulmonary Leukocyte Recruitment in vivo 
In addition to the adenosine diphosphate acrylic analogue MRS2395, the adenosine 
triphosphate analogue AR-C66096, which also demonstrates highly selective 
antagonist properties for the P2Y12 receptor, was administered to mice 30 minutes 
prior to allergen challenge at 0.1, 1 and 3 mg/kg. Twenty-four hours post final 
challenge all animals were culled and BAL fluid collected. 
Sensitisation and subsequent challenge to OVA induced a significant elevation in 
total leukocyte pulmonary recruitment, which remained significantly elevated in all 
animals treated with AR-C66096 (Sham: 12.13 ± 2.12x10
4
 cells/ml vs. OVA: 136.00 
± 13.68x10
4
 cells/ml, P<0.001; 3mg/kg AR-C66096: 126.75 ± 21.11x10
4
 cells/ml) 
(Figure 4.5A). This elevation of total cell counts in response to allergen as well as 
the failure of AR-C66096 to inhibit this pulmonary recruitment was reproduced in 
all inflammatory differential cell counts including macrophages (Sham: 12.13 ± 
2.12x10
4
 cells/ml vs. OVA: 52.05 ± 18.48x10
4
 cells/ml, P < 0.001, 3mg/kg AR-
C66096: 49.55 ± 18.48x10
4
 cells/ml), neutrophils (Sham: 0.00 ± 0.00 cells/ml vs. 
OVA: 2.96 ± 1.60x10
4
 cells/ml; 3mg/kg AR-C66096: 1.52 ± 0.70x10
4
 cells/ml), 
lymphocytes (Sham: 0.00 ± 0.00 vs. OVA: 5.10 ± 1.28x10
4
 cells/ml; 3mg/kg AR-
C66096: 7.50 ±.51x10
4 
cells/ml, P < 0.05) and eosinophils (Sham: 0.00 ± 0.00 
cells/ml vs. OVA: 69.41 ±18.96x10
4
 cells/ml, P < 0.001; 3mg/kg AR-C66096: 68.18 
± 23.92x10
4
 cells/ml) (Figure 4.5B). 
Additionally, experiments performed by collaborators at the Institute of Internal and 
Vascular Medicine at the University of Perugia in Italy demonstrated a failure of 
75mg/kg Clopidogrel (the P2Y12 specific thienopyridine antagonist) to inhibit 
allergen induced total leukocyte (Sham: 0.73 ± 0.06x10
5
 cells/ml vs. OVA: 3.89 ± 






 cells/ml, P < 0.001; 75mg/kg Clopidogrel: 3.69 ± 0.28x10
5
 cells/ml, Figure 
4.6A) and eosinophil (Sham: 0.04 ± 0.04x10
5
 cells/ml vs. OVA: 2.29 ± 0.07x10
5
 
cells/ml, P < 0.001; 75mg/kg Clopidogrel: 1.77 ± 0.12x10
5
 cells/ml, FIgure 4.6B)  
recruitment in the same murine model of allergic inflammation.  
Using the 3 distinct P2Y12 receptor antagonists MRS2395, AR-C66096 and 
Clopidogrel, there is substantial evidence indicating a failure of P2Y12 receptor 
signalling to modulate allergen induced pulmonary leukocyte recruitment within this 
murine model of allergic inflammation, in stark contrast to the results obtained 
through the use of the P2Y1 receptor antagonists MRS2179 and MRS2500 which 



















Figure 4. 5 The Effects of AR-C66096 on Pulmonary Leukocyte Recruitment 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and allergen 
exposure protocol. AR-C66096 was administered prior to allergen exposure on days 
14, 15 and 16 (0.1, 1 & 3mg/kg intravenously). Lavage fluid was collected 24 hours 
post final allergen exposure (day 17). A Total BAL Leukocytes B Differential Cell 
counts. Data: Mean ± SEM, N= 4 animals per group. * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001 compared to sham controls. 





Figure 4. 6 The effects of Clopidogrel of Pulmonary Leukocyte Recruitment 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and allergen 
exposure protocol. 75mg/kg Clopidogrel was administered i.v. prior to allergen 
exposure on days 14, 15 and 16. Lavage fluid was collected 24 hours post final 
allergen exposure (day 17). A Total BAL Leukocytes B Differential Cell counts. 




4.4 An Investigation into the Effect of the P2X1 Receptor Antagonist NF-279 on 
Pulmonary Leukocyte Recruitment in a Murine Model of Allergic 
Inflammation 
The final receptor present on the platelets surface sensitive to purine stimulation is 
the P2X1 receptor sensitive to ATP. Whilst this receptor is not sensitive to ADP it 
has previously been shown to be involved in platelet shape change and Ca
2+
 
mobilisation, two processes involved in the initial stages of platelet activation (Sun 
et al., 1998; Toth-Zsamboki et al., 2003). The involvement of this receptor in 
allergen induced pulmonary leukocyte recruitment was subsequently evaluated using 
the P2X1 suramin analogue NF-279. 
OVA sensitised mice were pre-treated with intravenous vehicle or 0.1, 1 or 3mg/kg 
NF-279, 30 minutes prior to 3% nebulised OVA exposure on days 14, 15 and 16. 




Twenty-four hours post final challenge (Day 17) all animals were culled and BAL 
fluid collected. 
Sensitisation and challenge to nebulised OVA induced a significant elevation in total 
pulmonary leukocyte numbers compared to sham sensitised mice which was 
unaffected following treatment of NF-279 at all tested doses (Sham: 12.00 ± 
2.29x10
4
 cells/ml vs. OVA: 33.3 ± 4.41x10
4
 cells/ml, P < 0.001; 3mg/kg NF-279: 
38.50 ± 2.86x10
4
 cells/ml) (Figure 4.7A). This allergen induced increase in 
pulmonary leukocyte recruitment, combined with the persistent elevation of 
leukocyte recruitment following treatment with all doses of NF-279 was also 
replicated within the differential cells present in the lungs including macrophages 
(Sham: 11.92 ± 0.32x10
4
 cells/ml vs. OVA: 22.86 ± 5.14x10
4
 cells/ml; 3mg/kg NF-
279: 19.43 ± 10.07x10
4
 cells/ml), neutrophils (Sham: 0.06 ± 0.03x10
4
 cells/ml vs. 
OVA: 0.94 ± 0.46x10
4
 cells/ml, 3mg/kg NF-279: 1.31 ± 0.74x10
4
 cells/ml, P < 
0.05), lymphocytes (Sham: 0.00 ± 0.00 cells/ml vs. OVA: 0.43 ± 0.10x10
4
 cells/ml; 
3mg/kg NF-279: 0.36 ± 0.20x10
4
 cells/ml, P < 0.05) and eosinophils (Sham: 0.00 ± 
0.00 cells/ml vs. OVA: 5.77 ± 0.26x10
4
 cells/ml, P < 0.001; 3mg/kg NF-279: 4.56 ± 
0.30x10
4
 cells/ml, P < 0.001) (Figure 4.7B). 
Experiments with antagonists for the P2Y1, P2Y12 and P2X1 receptors suggests that 
the P2Y1 receptors but not the P2Y12 or P2X1 receptors are important in the induction 
of pulmonary leukocyte recruitment in OVA sensitised mice following provocation 
to nebulised OVA. 
 
 







Figure 4. 7 The Effects of NF-279 on Pulmonary Leukocyte Recruitment 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and allergen 
exposure protocol. NF-279 was administered prior to allergen exposure on days 14, 
15 and 16 (0.1, 1 & 3mg/kg intravenously). Lavage fluid was collected 24 hours post 
final allergen exposure (day 17). A Total BAL Leukocytes B Differential Cell 
counts. Data: Mean ± SEM, N= 4 animals per group. * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001 compared to sham controls. 
 
 




4.5 An Investigation into the Purinergic Modulation of Platelet Aggregation 
The inability of platelet P2Y12 receptor blockade to modulate platelet-dependent 
leukocyte recruitment demonstrated a clear difference in function from the P2Y1 
receptor; however it was important to investigate if the absence of an effect through 
the P2Y12 receptor was a result of poor efficacy or inadequate doses of both 
MRS2395 and AR-C66096. Therefore the activity of both the P2Y1 and P2Y12 
receptor antagonists were tested using an ex vivo assay of platelet aggregometry. 
Female Balb/c mice were sensitised to OVA using the previously described 
sensitisation protocol and 30 minutes before challenge, mice were then treated with 
either 3mg/kg MRS2500 (Figure 4.8A & 4.8B), 3mg/kg AR-C66096 (Figure 4.8C) 
or 75mg/kg Clopidogrel as a positive control (Figure 4.8D). Platelets (2x10
8
 plts/ml) 
were isolated from murine blood 6 hours post allergen challenge and platelet 
aggregation towards 2-10μM ADP measured ex vivo. 
Platelet aggregation towards 2-10µM ADP was unaltered following sensitisation and 
exposure to allergen compared to sham controls (Sham: 50.82 ±4.36% vs. OVA: 
55.91 ± 4.31%) (Figure 4.8). Platelet samples pre-treated with 3mg/kg of the P2Y1 
receptor antagonist MRS2500 inhibited platelet aggregation at 1hr post treatment 
(Vehicle: 79.93 ± 6.62% vs. 3mg/kg MRS2500: 47.77 ± 4.71%, P < 0.05) but not 6 
hours post challenge (Veh: 52.50 ± 7.50% vs. 3mg/kg MRS2500: 40.75 ± 4.01%) 
(Figure 4.8A & 4.8B). 
Platelets taken from mice administered with either 3mg/kg AR-C66096 (Veh: 57.85 
± 5.54% vs. AR-C66096: 31.29 ± 6.98%, P<0.05, (Figure 4.8C) or 75mg/kg 
Clopidogrel (Veh: 50.00 ± 12.60% vs. 75mg/kg Clopidogrel: 14.00 ± 2.10% P<0.05, 
Figure 4.8D) demonstrated significant suppression of ADP induced aggregation, 




confirming their activity in this murine model of inflammation. This is critical in 
being able to conclude that pulmonary leukocyte recruitment was P2Y12 insensitive 




















Figure 4. 8 The Effects of P2Y1 and P2Y12 receptor antagonism on platelet 
aggregation 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and single 
allergen exposure protocol. Prior to allergen exposure, mice were treated with either 
3mg/kg MRS2500 at 1hr (A), 3mg/kg MRS2500 at 6hrs (B), 3mg/kg AR-C66096 at 
6hrs (C) or vehicle control and 75mg/kg Clopidogrel at 6 hrs (D) Platelets were 
collected 6 hours later and aggregation monitored to 10µM ADP. E/F Example 
traces of purinergic antagonism of ADP induced platelet aggregation. Data: Mean ± 
SEM, N= 4 animals per group. * = P < 0.05. 




4.6 An Investigation into the Effects of P2Y1 and P2Y12 Receptor Antagonism in 
Platelet-Depleted Mice 
Through the use of the specific P2Y1 (MRS2179, MRS2500) and P2Y12 (MRS2395, 
AR-C66096) receptor antagonists the P2Y1 receptor was identified to be the only 
platelet expressed purinergic receptor involved in pulmonary leukocyte recruitment 
as no suppression of allergen induced leukocyte recruitment was observed following 
treatment with P2Y12 or P2X1 receptor antagonists.  
P2Y1 receptor expression however is not solely located to the platelets surface with 
systemic expression detected in epithelial, endothelial, kidney and leukocyte 
subtypes (Burnstock et al 2007). It is therefore conceivable that the phenomenon of 
leukocyte recruitment was the result of leukocyte activation by ADP and not solely 
as a result of platelet activation. Therefore using a model of platelet depletion and 
subsequent reinfusion of washed platelets, the importance of platelet specific P2Y1 
receptors in allergen induced pulmonary leukocyte recruitment was investigated. 
 
4.6.1 An Investigation into the Effects of Busulfan Treatment on Circulating 
Platelet Levels 
Using the murine model of allergic inflammation as previously described, a 
significant elevation in total leukocyte numbers as well as macrophage, neutrophils, 
lymphocytes and eosinophil numbers (P<0.001) detected in the lungs was observed 
compared to sham controls.  
Pre-treatment of mice with a dosing regimen of 25mg/kg busulfan (days -5, -3, 0), a 
bone marrow depleting toxin (figure 2.3) induced a severe state of thrombocytopenia 
compared to vehicle treated control mice (Veh: 4.22 ± 0.31x10
8 
platelets/ml vs. 
Busulfan: 1.18 ± 0.03x10
9
 platelets/ml, P<0.001) thus demonstrating a decrease in 




circulating platelet numbers of 64% (figure 4.9). Whilst busulfan treatment rendered 
mice thrombocytopenic, no effect on circulating leukocyte numbers, including 
mononuclear cells, neutrophils or eosinophils was induced by busulfan treatment 












Figure 4. 9 Effects of Busulfan Treatment On Circulating Platelet and 
Leukocyte Numbers 
Mice were treated with busulfan (25mg.kg ip) on days 0, 3, and 5 and blood was 
collected via cardiac bleed on day 19. BAL and analysed for  platelets (A), total cell 
counts (B),  mononuclear cells (C), neutrophils (D), and eosinophils (E),  
lymphocytes (C), macrophages (D), and neutrophils (E). n=4.  Data are expressed as 
mean± SEM. *** P < 0.001.  
 
 




4.6.3 An investigation into the Role of Platelets on Pulmonary Leukocyte 
Recruitment in vivo 
Mice rendered thrombocytopenic through Busulfan treatment demonstrated 
significantly reduced total leukocyte recruitment to the lungs of allergen challenged 
mice compared to OVA sensitised controls (Sham: 13.92 ± 1.56x104 cells/ml; Veh: 
103.77 ± 17.91x10
4 
cells/ml vs. Busulfan: 37.35 ± 7.91x10
5 
cells/ml, P<0.05) 
(Figure 4.10A). This attenuation of allergen induced total leukocyte recruitment was 
replicated in all the differential cell counts including macrophages (Sham:  13.80 ± 
1.54x10
4
 cells/ml; Vehicle: 35.28 ± 6.25x10
4
 cells/ml vs. Busulfan: 15.19 ± 2.62x10
4
 
cells/ml, P < 0.01, figure 4.10B), lymphocytes (Sham: 0.01 ± 0.01x10
4
 cells/ml; 
Vehicle: 2.94 ± 0.79x10
4
 cells/ml vs. Busulfan: 0.67 ± 0.20x10
4
 cells/ml, P < 0.05, 
figure 4.10C), neutrophils (Sham: 0.19 ± 0.08x10
4
 cells/ml; Vehicle: 1.03 ± 
0.46x10
4
 cells/ml vs. Busulfan: 0.28 ± 0.18x10
4
 cells/ml, figure 4.10D) and 
eosinophils (Sham: 0.00 ± 0.00 cells/ml; Vehicle:71.05 ± 12.31x10
4
 cells/ml vs. 
Busulfan: 18.78 ± 5.55x10
4
 cells/ml, P < 0.05, figure 4.10E) 
Busulfan induced suppression of pulmonary total leukocyte recruitment was restored 
through the reinfusion of washed platelets (WP) from donor mice also sensitised to 
allergen (Busulfan: 37.35 ± 7.91x10
4
 cells/ml vs. WP: 82.95 ± 18.75x10
4
 cells/ml, 
figure 4.10A), a process that was replicated in all cell types: macrophages (Busulfan: 
15.19 ± 2.62x10
4
 cells/ml vs. WP: 27.48 ± 4.87x10
4
 cells/ml, figure 4.10B), 
lymphocytes (Busulfan: 0.67 ± 0.20x10
4
 cells/ml vs. WP: 2.26 ± 0.50x10
4
 cells/ml, 
figure 4.10C), neutrophils (Busulfan: 0.28 ± 0.18x10
4
 cells/ml vs. WP: 1.20 ± 
0.86x10
4
 cells/ml, figure 4.10D) and eosinophils (Busulfan: 18.78 ± 5.54 vs. WP: 
59.91 ± 16.70, figure 4.10E) confirming previous work demonstrating the critical 
role of platelets in pulmonary leukocyte recruitment as described previously 
(Pitchford et al., 2003a, 2005). 




4.6.4 An Investigation into the Impact of Platelet Specific P2Y1 Receptors on 
Pulmonary Leukocyte Recruitment 
On days 14 and 15 of the immunisation and challenge protocol for the current model 
of allergic inflammation, platelets were isolated from donor mice sensitised to OVA 
and subsequently treated in vitro with concentrations in excess of those required to 
inhibit platelet aggregation (100μM) of either MRS2500 or AR-C66096. After 
incubating for 15 minutes at room temperature any free unbound drug was removed 
from the platelet suspension through centrifugation before being reinfused into 
thrombocytopenic mice at a concentration of 1.40x10
8
 platelets/mouse before 
allergen challenge on days 14 and 15. 
As previously stated, reinfusion of WP into thrombocytopenic mice restored allergen 
induced leukocyte recruitment which was abolished following busulfan treatment. A 
significant attenuation remained with platelets treated with 100µM of the P2Y1 
antagonist MRS2500 of total leukocyte recruitment (OVA: 103.77 ± 17.91x10
4
 
cells/ml vs. MRS2500: 41.15 ± 9.82x10
4
 cells/ml, P<0.05, Figure 4.10A) as well as 
all differential cell types:  macrophages (OVA: 35.28 ±6.25x10
4
 cells/ml vs 
MRS2500:  18.71 ± 3.14 x10
4 
cells/ml, P < 0.01, figure 4.10B), lymphocytes (OVA: 
2.94 ± 0.79x10
4
 cells/ml vs. MRS2500: 0.69 ± 0.32x10
4
 cells/ml, P < 0.05, figure 
4.10C), neutrophils (OVA: 1.03 ± 0.46x10
4
 cells/ml vs. MRS2500: 0.09 ± 0.05x10
4
 
cells/ml, figure 4.10D) and eosinophils (OVA: 71.05 ± 12.31x10
4
 cells/ml vs. 
MRS2500: 21.22 ± 8.20x10
4
 cells/ml, P < 0.05, figure 4.10E). 
In contrast however, reinfusion with platelets treated with saturating concentrations 
of AR-C66096 failed to inhibit total leukocyte recruitment when compared to OVA 
challenged mice with normal circulating platelet levels (OVA: 103.77 ± 17.91x10
4
 
cells/ml vs. AR-C66096: 84.95 ± 19.37x10
4
 cells/ml, figure 4.10A) and also failed 




to inhibit the recruitment of the additional differential cell numbers; macrophages 
(OVA: 103.77 ± 17.91x10
4
 cells/ml vs. AR-C66096: 84.95 ± 19.38x10
4
 cells/ml, 
figure 4.10B), lymphocytes (OVA: 2.94 ± 0.79x10
4
 cells/ml vs. AR-C66096: 1.92 ± 
0.69x10
4
 cells/ml, figure 4.10C), neutrophils (OVA: 1.03 ± 0.46x10
4
 cells/ml vs. 
AR-C66096: 1.37 ± 0.64x10
4
 cells/ml, figure 4.10D) and eosinophils (OVA: 71.05 ± 
12.32x10
4
 cells/ml vs. AR-C66096: 56.64 ± 16.97x10
4
 cells/ml, figure 4.10E). This 
confirms that the modulation of pulmonary leukocyte recruitment via P2Y1 receptors 
in the earlier studies was mediated specifically by platelet expressed P2Y1 receptors 





























Figure 4. 10 The Effects of 
MRS2500 and AR-C66096 
treated Platelets on Pulmonary 
Leukocyte Recruitment 
Mice were rendered 
thrombocytopenic through a 
dosing protocol involving the 
bone marrow depleting agent 
Busulfan. During this process 
mice were subjected to a two 
week sensitisation (1.5mg/kg 
OVA) and allergen exposure 
protocol. Washed platelets 
isolated from allergen sensitised 
mice were pre-treated with either 
vehicle or 100µM MRS2500 or 
AR-C66096. Treated platelets 
were subsequently reinfused in 
thrombocytopenic mice prior to 
allergen exposure on days 14 and 
15. Lavage fluid was collected 24 
hours post final allergen exposure 
(day 17). A Total BAL 
Leukocytes B Macrophages C 
Lymphocytes D Neutrophils E 
Eosinophils.  Data: Mean ± SEM, 
N= 10-12 animals per group. * = P 








4.7 An Investigation into the Role of Purinergic Receptors in Adhesion 
Molecule Expression and Platelet-Leukocyte Interactions 
 
4.7.1. An Investigation into the Role of the P2Y1 and P2Y12 Receptors on ADP 
Induced P-selectin Expression 6 hours Post Allergen Challenge  
P-selectin is an adhesion molecule stored within the platelet α-granules. Upon 
platelet activation, these α-granules fuse with the platelet membrane secreting its 
contents. This triggers an upregulation of surface expressed P-selectin. This allows 
the quantification of surface P-selectin expression to be used as a marker of platelet 
activation. 
Using the in vitro assay of P-selectin expression described and validated in section 
3.2, ADP-induced P-selectin expression was measured in platelet populations treated 
with either 1, 10, 100 or 1000nM MRS2500 or AR-C66096 in platelets isolated from 
either sham or OVA-sensitised mice. 
MRS2500 failed to inhibit ADP-induced increases in either percent surface 
expression of P-selectin in either sham (PBS: 45.07 ± 3.05% vs. 10μM ADP: 63.09 ± 
1.11%; 1000nM MRS2500 [top dose]: 51.01 ± 6.95%) or OVA-sensitised platelets 
(PBS: 25.14 ± 8.15% vs. 10μM ADP: 58.63 ± 4.20%; 1000nM MRS2500 [top dose]: 
20.02 ± 7.92%, figure 4.11A). Neither did MRS2500 demonstrate any significant 
inhibition on ADP-induced elevations in platelet MFI in either sham (PBS: 1.63 ± 
0.08 vs. 10μM ADP: 2.43 ± 0.33, 1000nM MRS2500 [top dose]: 1.83 ± 0.16) or 
OVA-sensitised samples (PBS: 1.09 ± 0.23 vs. 10μM ADP: 2.05 ± 0.14; 1000nM 
MRS2500 [top dose]: 0.33 ± 0.19, figure 4.11B). 
In contrast, pre-treatment of platelets with AR-C66096 demonstrated significant 
attenuation of the percent P-selectin expression in both sham (PBS: 24.13 ± 0.23% 




vs. 10μM ADP: 60.43 ± 4.18, P < 0.01; 1000nM AR-C66096 [top dose]: 29.08 ± 
5.23, P < 0.01) and OVA sensitised samples (PBS: 25.58 ± 7.30% vs. 10μM ADP: 
74.59 ± 13.19%, P < 0.01; 1000nM AR-C66096 [top dose]: 54.62 ± 5.09%, P < 0.01, 
figure 4.11C). AR-C66096 treatment also inhibited ADP-induced elevations in 
platelet P-selectin MFI in both sham (PBS:1.00 ± 0.09 vs. 10μM ADP: 2.14 ± 0.23, 
P < 0.05; 1000nM AR-C66096 [top dose]: 1.11 ± 0.15, P < 0.05) and OVA-
sensitised samples (PBS: 1.09 ± 0.23 vs. 10μM ADP: 2.05 ± 0.14, P < 0.05; 1000nM 
AR-C66096: 0.86 ± 0.19, P < 0.01, figure 4.11D). 
Sensitisation to allergen had no impact on ADP induced elevations in percent platelet 
P-selectin expression (Sham-sensitised: 61.76 ± 2.03% vs. OVA-sensitised: 66.61 ± 
7.14%) when compared to unstimulated controls (Sham-sensitised: 36.60 ± 6.17% 
vs. OVA-sensitised: 25.36 ± 4.47%) allergen sensitisation also had no effect on 
ADP-induced changes in MFI on platelet P-selectin samples (Sham-sensitised: 2.29 
± 0.19 vs. OVA-sensitised: 2.05 ± 0.09) when compared to unstimulated controls 
(Sham-sensitised: 1.32 ± 0.19 vs. OVA-sensitised: 1.09 ± 0.13). It is possible that 
this apparent failure of the P2Y1 receptor to inhibit allergen induced P-selectin 
expression 6 hours post allergen challenge is an artifact of the platelet isolation 
procedure. Basal levels of P-selectin expression of nearly 40% suggests that the 













Figure 4. 11 The Effects of MRS2500 and AR-C66096 on ADP Induced Platelet 
P-selectin in vitro 
Platelets were isolated from blood of mice either sham or 1.5mg/kg OVA sensitised. 
Platelets were treated with 1, 10, 100 or 1000nM MRS2500 or AR-C66096 and P-
selectin expression measured following stimulation with 10μM ADP. Data expressed 








4.7.2 An Investigation into the Role of the P2Y1 and P2Y12 Receptors on ADP 
Induced Platelet-Leukocyte Conjugation 6 hours Post Allergen Challenge 
Platelet P-selectin is a necessary component of membrane interactions between 
platelets and leukocytes in allergic inflammation and is believed to be critical in the 
formation of circulating platelet-leukocyte complexes which are suspected to be 
responsible for the 'priming' of inflammatory leukocytes, a process suspected to be 
required for efficient leukocyte adhesion to endothelial cells. Indeed, a number of 
studies have shown elevated levels of circulating platelet-leukocyte complexes both 
in asthmatic patients following allergen challenge, and in a murine model of allergic 
inflammation, known to be P-selectin-dependent (Pitchford et al. 2003; 2005). 
Given the inconclusive data produced through the measurement of platelet surface P-
selectin expression, the occurrence of these platelet-leukocyte complexes were used 
as an alternate marker of platelet activation following the administration of either the 
P2Y1 (MRS2500) or P2Y12 (AR-C66096) receptor antagonists at 6 and 24 hours post 
allergen challenge. A significant increase in circulating platelet-leukocyte complexes 
(Sham: 18.73 ± 2.61% vs. OVA: 35.75 ± 4.30, P<0.01 figure 4.12), and the relative 
number of platelets (CD41 MFI) attached per individual leukocyte observed (Sham: 
0.92 ± 0.08% vs. OVA: 1.85 ± 0.35%, P<0.05 figure 4.12) was measured in 
allergen-sensitised mice over sham controls 6 hours post allergen challenge.  
OVA-sensitised mice pre-treated with 3mg/kg MRS2500 failed to show any increase 
in the percent of  circulating platelet-leukocyte conjugates at 6 hours post allergen 
challenge (Sham: 18.73 ± 2.61% vs. MRS2500: 28.15 ± 2.64%, figure 4.12A), 
neither did MRS2500 treated mice demonstrate a significant increase in the MFI on 
platelet-leukocyte complexes (Sham: 0.92 ± 0.08 vs. MRS2500: 1.23 ± 0.12, figure 
4.12B). In contrast, OVA-sensitised mice treated with 3mg/kg AR-C66096 




demonstrated a significant elevation in both the percent of circulating platelet-
leukocyte complexes (Sham: 18.73 ± 2.61% vs. AR-C66096: 32.21 ± 3.22%, P < 
0.05, figure 4.12A) and platelet MFI on platelet-leukocyte complexes (Sham: 0.92 ± 
0.08 vs. AR-C66096: 1.76 ± 0.29, P < 0.05, figure 4.12B) at 6 hours post allergen 
challenge. 
By 24 hours post allergen challenge, the significant elevation in the percent of 
circulating platelet-leukocyte complexes (Sham: 24.38 ± 2.30% vs. OVA: 29.54 ± 
1.30%, figure 4.12C) or platelet MFI on platelet-leukocyte complexes (Sham: 1.46 ± 
0.17 vs. OVA: 1.80 ± 0.20, figure 4.12D) had returned to levels similar to sham 
sensitised mice. Furthermore no significant differences were noted in mice pre-
treated with either 3mg/kg MRS2500 or 3mg/kg AR-C66096 compared sham levels 
in either the percent of circulating platelet-leukocyte complexes (Sham: 23.38 ± 
2.30% vs. MRS2500: 29.54 ± 1.30% or AR-C66096: 27.79 ± 1.62%, figure 4.12C) 
or platelet MFI on platelet-leukocyte complexes (Sham: 1.46 ± 0.17 vs. MRS2500: 



















Figure 4. 12 The Effects of MRS2500 and AR-C66096 on the Formation of 
Circulating Platelet-Leukocyte Conjugates 6 and 24 Hours Post Allergen 
Challenge 
Mice were subjected to a two week sensitisation (1.5mg/kg OVA) and single allergen 
exposure protocol. Prior to allergen exposure, mice were treated with vehicle control, 
3mg/kg MRS2500 or 3mg/kg AR-C66096. Whole blood was isolated at 6 (A & B) and 24 
(C & D) hours later and circulating platelet-leukocyte conjugates measured by flow 
cytometry. Data expressed as either % circulating conjugates (A & C) or MFI (B & D). 
Data: Mean ± SEM, N= 6-8 animals per group. * = P < 0.05, ** = P < 0.01 compared to 
sham controls. 
 





4.7.3 An Investigation into the Impact of Purinergic Receptor Antagonism on 
Circulating Platelet and Leukocyte Numbers  
Extensive research shows that stimulation of both the P2Y1 and P2Y12 receptors are 
capable of inducing P-selectin expression (Leon et al. 2003, 2004; Straub et al. 
2011), Thus it was surprising to observe a P2Y1 specific mediation of platelet-
leukocyte aggregate formation. It was therefore important to see if the suppression of 
platelet-leukocyte aggregate formation through treatment with the P2Y1 antagonist 
MRS2500 was a result of thrombocytopenia or changes in haematopoiesis. 
Circulating platelet numbers demonstrated a modest thrombocytopenia (albeit 
insignificant) in OVA-sensitised animals compared to sham controls (Sham: 10.77 ± 
1.76x10
8
 platelets/ml vs. OVA: 8.89 ± 0.83x10
8
 platelets/ml) (Figure 4.13A). 
Platelet numbers were also unaffected following either P2Y1 or P2Y12 pre-treatment 
(MRS2500: 11.48± 1.27 x10
8
 platelets/ml; AR-C66096: 9.43± 0.42x10
8
 
platelets/ml). Similarly to circulating platelet numbers, circulating leukocyte 
numbers were also measured. Allergen sensitisation failed to modulate leukocyte 
numbers compared to sham controls (Sham: 4.80 ± 1.73 x10
6
 cells/ml vs. OVA: 7.80 
± 1.31 x10
6
 cells/ml) (Figure 4.13B). Circulating leukocyte numbers also remained 
unaffected following pre-treatment MRS2500 or AR-C66096 (MRS2500: 6.30 ± 
1.51x10
6
 cells/ml; AR-C66096: 7.09 ± 1.97x10
6
 cells/ml). 
Given that treatment with the purinergic agents MRS2500 and AR-C66096 failed to 
alter circulating platelet or leukocyte numbers in allergen-challenged mice the 
observed suppression of platelet-leukocyte complex formation by MRS2500 was not 
a result of thrombocytopenia or any changes to haematopoiesis. 






Figure 4. 13 The Effects of OVA Sensitisation and MRS2500/AR-C66096 
Administration On Circulating Platelet and Leukocyte Numbers 
Mice sensitised to 1.5mg/kg OVA were treated with 3mg/kg MRS2500 or AR-C66096 and 
subsequently challenged to 3% aerosolised OVA on day 14. Blood was taken at 6 hours post 
allergen challenge and subsequently circulating platelet and leukocyte numbers quantified 
using a Zeiss axioscope microscope under a x20 objective. Data: Mean ± SEM, N=6-11 
animals per group. 
 




4.7.4 An Investigation into the Effects of Allergen Sensitisation on Platelet 
Surface Expression of P2Y1 or P2Y12 Receptors  
After the discovery that purinergic receptor treatment had no effect on circulating 
platelet or leukocyte numbers, the possibility of altered surface expression of platelet 
P2Y1 or P2Y12 was considered, as a possible cause of the P2Y1 specific suppression 
of platelet-leukocyte complex formation through elevated levels of P2Y1 expression 
in comparison to P2Y12 receptor expression. Expression of surface P2Y1 and P2Y12 
was measured by flow cytometry with representative scatter plots of P2Y expression 
on CD41 stained platelets in figure 4.14. 
P2Y1 receptor expression remained unaffected by allergen sensitisation and 
challenge compared to sham controls (Sham: 9.38 ± 0.64% vs. OVA: 9.19 ± 0.89%) 
(Figure 4.15A),  this was replicated by the relative number of receptors expressed 
per individual receptors (Sham: 1.00 ± 0.04% vs. OVA: 1.03 ± 0.03%) (Figure 
4.15), culminating in a binding index of 0.095 ± 0.01 for sham against 0.095 ± 0.012 
for OVA sensitised samples (Figure 4.15C). Similar to that of P2Y1 receptor 
expression, both the percentage expression of P2Y12 receptors (Sham: 45.90 ± 1.19% 
vs. OVA: 42.91 ± 1.74%) (Figure 4.16A) and the relative number of P2Y12 
receptors expressed per individual platelet (Sham: 2.85 ± 0.11% vs. OVA: 2.73 ± 
0.08%) (Figure 4.16B) were unaffected by allergen sensitisation, demonstrating a 
binding index of 1.312 ± 0.08 for sham controls against 1.174 ± 0.081in OVA 
sensitised platelets (Figure 4.16C), thus indicating that the suppression of platelet-
leukocyte conjugation by MRS2500 but not AR-C66096 treatment was not a result 
of altered surface expression of P2Y1 or P2Y12 receptors on platelets. 
 




Figure 4.17 depicts a single band for the ab74996 anti-P2Y1 antibody approximately 
56-58kDa and a single band for the anti-P2Y12 antibody ab82725 at approximately 




Figure 4. 14 The Effects of OVA Sensitisation on Platelet P2Y1 and P2Y12 
Receptor Expression 
Mice sensitised to 1.5mg/kg OVA were treated with 3mg/kg MRS2500 or AR-C66096 and 
subsequently challenged to 3% aerosolised OVA on day 14. Blood was taken  6 hours post 
allergen challenge and platelet P2Y1 and P2Y12 receptor expression was assessed by flow 
cytometry. Representative scatter plots are shown: (A) anti-CD41-FITC + control IgG-PE, 
(B) anti-CD41-FITC + anti-P2Y1-PE, (C) anti-CD41-FITC + anti-P2Y12-PE. 
 





Figure 4. 15 The Effects of OVA Sensitisation on Platelet P2Y1 Receptor 
Expression 
Mice sensitised to 1.5mg/kg OVA were treated with 3mg/kg MRS2500 and subsequently 
challenged to 3% aerosolised OVA on day 14. Blood was taken  6 hours post allergen 
challenge and platelet P2Y1 receptor expression was assessed by flow cytometry. The % of 
platelets expressing platelets (A) and the relative number of receptors expressed per platelet 
(B) and binding index (C) was quantified in platelets isolated from sham and OVA 












Figure 4. 16 The Effects of OVA Sensitisation on Platelet P2Y12 Receptor 
Expression 
Mice sensitised to 1.5mg/kg OVA were treated with 3mg/kg AR-C66096 and subsequently 
challenged to 3% aerosolised OVA on day 14. Blood was taken  6 hours post allergen 
challenge and platelet P2Y12 receptor expression was assessed by flow cytometry. The % of 
platelets expressing platelets (A) and the relative number of receptors expressed per platelet 
(B) and binding index (C) was quantified in platelets isolated from sham and OVA 
sensitised mice. Data expressed as mean ± SEM, N=4. 
 





Figure 4. 17 Specificity Profile of the P2Y1 and P2Y12 Receptor Antibodies 
Human derived PBMCs or Platelets were isolated and lysed with western blot 
analysis performed to identify the specificity of the P2Y1 antibody ab74996 or the 
P2Y12 antibody ab82725 for each receptor as depicted by the number of bands 
present. 
 
4.8 An Investigation into the Impact of the P2Y1 and P2Y12 Receptors in 
Platelet-Induced Leukocyte Chemotaxis, a P-selectin Dependent Process 
The formation of platelet-leukocyte complexes after allergen challenge is known to 
be a P-selectin dependent process (Pitchford et al., 2005), and has been shown to be 
affected by P2Y1 signalling (Figure 4.13).  It was hypothesised that the engagement 
of platelets with leukocytes in vivo, and in turn their dependency on P2Y1 signalling 
may stimulate leukocyte activation and motility necessary for diapedesis from the 
vasculature into the tissue. Polymorphonuclear (PMN) cells have previously been 
shown to require the presence of platelets to undergo chemotaxis towards either 
MDC or TARC (Kornerup et al 2010). These chemokines have been heavily 
implicated in the asthmatic phenotype with high expression of both MDC and TARC 
in the lungs of human asthmatic patients (Hirata et al. 2003; Leung et al 2004). 




Furthermore, both MDC and TARC have also been shown to activate platelets via 
the chemokine receptor CCR4 in an ADP dependent process (Kowalska et al 2000; 
Clemetson et al 2000; Gear et al 2001). It was therefore of interest to investigate 
whether the ability of platelets to induce the chemotaxis of bone marrow derived 
PMN cells towards MDC was a P-selectin dependent process and if a similar impact 
of P2Y1 receptor modulation was observed. 
Using the in vitro model of platelet-induced leukocyte chemotaxis validated in 
section 3.3, chemotaxis assays were performed to identify the importance of P-
selectin in platelet-induced leukocyte migration as well as the role of the platelet 
P2Y1 and P2Y12 receptors. 
 
4.8.2 An Investigation into the Role of P-selectin in Platelet-Induced PMN Cell 
Migration in vitro 
Previous research has demonstrated a requirement of pulmonary leukocyte 
recruitment to be P-selectin dependent in a similar murine model of allergic 
inflammation (Pitchford et al., 2005). Furthermore extensive work has demonstrated 
a critical role of P-selectin in the formation of platelet-leukocyte aggregates, a 
process thought to be a prerequisite for platelet induced leukocyte migration. It was 
therefore important to confirm whether this in vitro model of platelet-induced PMN 
cell migration towards MDC was also P-selectin dependent. As such, platelets were 
pre-treated with a specific anti-P-selectin antibody known to block P-selectin 
adhesion. Pre-treatment with the anti-P-selectin antibody significantly attenuated 
platelet dependent PMN migration (Veh: 3.40 ± 0.42 vs. anti-P-selectin: 2.15 ± 0.38, 
P<0.01, Figure 4.18). This demonstrates that the requirement for platelets in the 
induction of PMN migration towards MDC was a P-selectin dependent phenomenon.  






Figure 4. 18 Platelet Induced PMN chemotaxis in vitro is P-selectin Dependent 
Platelets and PMNs were isolated from citrated blood and bone marrow from 
1.5mg/kg OVA sensitised mice. Platelets were then pre-incubated with an anti-P-
selectin mAb before subsequent stimulation with 100nM ADP before mixing with 
PMN cells. The cell mixture was added to the top well of a chemotaxis chamber. 
PMN chemotaxis towards MDC (bottom well 100nM) was then quantified after a 90 
minute incubation and analysed as a chemotactic index. Data are expressed as mean 
± SEM. ** = P < 0.01 where indicated to column 4, ### = P < 0.001 compared to 
column 3, n = 5. 
 
4.8.3 An Investigation into the Impact of Allergen Sensitisation on Platelet 
Induced PMN Cell Migration in vitro  
Patients with asthma demonstrate an elevation in the incidence of circulating 
platelet-PMN aggregates after allergen exposure (Gresele et al., 1993; Pitchford et 
al., 2003a; Johansson et al., 2012). Therefore, the impact of allergen-sensitisation on 
platelet-induced PMN chemotaxis towards MDC in vitro was assessed. Chemotaxis 
assays were prepared using platelets and PMNs isolated from blood and bone 




marrow of sham- and allergen-sensitised mice. Incubation of platelets with PMNs 
produced significant PMN chemotaxis towards MDC compared to negative controls, 
whilst allergen sensitised samples demonstrated a significant elevation in PMN 
migration towards MDC compared to platelets isolated from sham-sensitised mice 
(sham: 9.06 ± 1.01 vs. OVA: 16.23 ± 1.62, P < 0.001, Figure 4.19).  
 
 
Figure 4. 19 The Effects of Allergen Sensitisation on Platelet Induced PMN 
Chemotaxis in vitro 
Platelets and PMNs were isolated from citrated blood and bone marrow from either sham or 
1.5mg/kg OVA sensitised mice. Platelets were then stimulated with 100nM ADP before 
mixing with PMN cells. The cell mixture was added to the top well of a chemotaxis 
chamber. PMN chemotaxis towards MDC (bottom well 100nM) was then quantified after a 
90 minute incubation and analysed as a chemotactic index. Data are expressed as mean ± 
SEM. *** = P < 0.001 where indicated to column 4, ### = P < 0.001 where indicated to 
column 3 or 7,  
n =4.  




4.8.4 An Investigation into the Role of the P2Y1 and P2Y12 Receptors in Platelet 
Induced PMN Cell Migration towards MDC 
Given the previous experiments demonstrating a critical role for platelet P2Y1 
receptors in pulmonary leukocyte recruitment in a murine model of allergic 
inflammation, platelets were incubated with either the P2Y1 receptor antagonists 
MRS2179 or MRS2500, the P2Y12 receptor antagonists MRS2395 or AR-C66096 or 
the P2X1 receptor antagonist NF-279 prior to stimulation with 100nM ADP. 
Stimulated platelets were subsequently isolated from either sham or OVA sensitised 
mice added to PMN cells to stimulate their chemotaxis in response to 100nM MDC. 
In all experiments, migration was achieved only when platelets were incubated with 
PMN cells (Figures 4.20 & 4.21). Prior to stimulation with ADP, platelets were pre-
incubated with 1, 10, 100 or 1000nM of the P2Y1 receptor antagonists MRS2179 or 
MRS2500. MRS2179 demonstrated a dose-dependent attenuation of platelet induced 
PMN cell migration towards MDC compared to vehicle controls (Veh: 3.65 ± 0.26 
vs. 1nM: 3.26 ± 0.24, 10nM: 2.35 ± 0.36 P<0.01, 100nM: 2.00 ± 0.26 P<0.001, 
1000nM: 1.46 ± 0.27 P<0.001, Figure 4.20A). This dose dependent attenuation of 
PMN cell migration was replicated with MRS2500 treatment (Veh:2.21 ± 0.12 vs. 
1nM: 2.50 ± 0.20, 10nM: 2.45 ± 0.28, 100nM: 2.34 ± 0.35, 1000nM: 1.58 ± 0.15 
P<0.01, Figure 4.20B). Furthermore, supporting the observations of the previous in 
vivo models, pre-treatment with the P2Y12 receptor antagonist MRS2395 failed to 
affect platelet induced PMN chemotaxis at any measured dose (Veh: 2.35 ± 0.22, 
1nM: 1.66 ± 0.26, 10nM: 1.86 ± 0.21, 100nM: 1.82 ± 0.18, 1000nM: 1.80 ± 0.32, 
Figure 4.20C), a lack of efficacy on PMN chemotaxis also replicated with AR-
C66096 (Veh: 2.21 ± 0.12 vs. 1nM: 1.81 ± 0.11, 10nM: 2.63 ± 0.31, 100nM: 2.31 ± 
0.29, 1000nM: 2.08 ± 0.11, Figure 4.20D).  




These results further support the observations concluded from the model of allergic 
inflammation in vivo that the P2Y1 but not the P2Y12 receptor is critical in platelet 
induced PMN migration both in vitro and in vivo.  
Significant platelet-induced leukocyte migration was also observed towards the 
chemokines f-MLP (Veh: 1.00 ± 0.46 vs. 100nM f-MLP: 3.00 ± 0.53, P < 0.001, 
figure 4.21A) and SDF-1 (Veh: 1.00 ± 0.11 vs. 100nM SDF-1: 2.01 ± 0.17, P < 
0.001, figure 4.21B). In agreement with data observed for platelet-induced leukocyte 
migration towards MDC, inhibition of the P2Y1 receptor with the antagonists 
MRS2179 and MRS2500 significantly inhibited platelet-induced PMN migration 
towards f-MLP compared to vehicle controls (Veh: 3.00 ± 0.53 vs.1000nM 
MRS2179: 1.10 ± 0.10, P < 0.001; 1000nM MRS2500: 1.16 ± 0.18, P < 0.001) 
whilst no effect was observed with either of the P2Y12 receptor antagonists (Veh: 
3.00 ± 0.53 vs. 1000nM MRS2395: 2.48 ± 0.20; AR-C66096: 3.06 ± 0.11, figure 
4.21A).  
Surprisingly however, neither P2Y1 nor P2Y12 receptor antagonism was capable of 
inhibiting platelet induced PMN migration towards SDF-1α (Veh: 2.01 ± 0.17 vs. 
1000nM MRS2179: 1.91 ± 0.15; 1000nM MRS2500: 2.09 ± 0.19; 1000nM 
MRS2395: 1.80 ± 0.16; 1000nM AR-C66096: 2.52 ± 0.17, figure 4.21B). 
Finally, pre-incubation of platelets with the P2X1 receptor antagonist NF-279 failed 
to modulate PMN cell chemotaxis towards MDC in the presence of platelets at any 
measured concentration compared to the positive controls (Veh: 3.46 ± 0.23 vs. 
1nM: 3.02 ± 0.26, 10nM: 3.34 ± 0.26, 100nM: 2.90 ± 0.24, 1000nM: 3.14 ± 0.14) 
supporting the earlier in vivo observations (figure 4.22). 
 





Figure 4. 20 The Effects of P2Y1 and P2Y12 Receptor Antagonism on Platelet 
Induced PMN Chemotaxis in vitro 
Platelets and PMNs were isolated from citrated blood and bone marrow from 
1.5mg/kg OVA sensitised mice. Platelets were then  pre-incubated with 1, 10, 100 
and 1000 of the P2Y1 receptor antagonists MRS2179 (A) and MRS2500 (B), or the 
P2Y12 receptor antagonists MRS2365 (C) and AR-C66096 (D) before subsequent 
stimulation with 100nM ADP before mixing with PMN cells. The cell mixture was 
added to the top well of a chemotaxis chamber. PMN chemotaxis towards MDC 
(bottom well 100nM) was then quantified after a 90 minute incubation and analysed 
as a chemotactic index. Data are expressed as mean ± SEM. *** = P < 0.001 towards 
sham controls, # = P < 0.05, ## = P < 0.01, ### = P < 0.001 towards positive 
controls. n = 6-9. 





Figure 4. 21 The Effects of P2Y1 and P2Y12 Receptor Antagonism on Platelet 
Induced PMN Chemotaxis in vitro 
Platelets and PMNs were isolated from citrated blood and bone marrow from 
1.5mg/kg OVA sensitised mice. Platelets were then pre-incubated with 1000nM of 
either the P2Y1 receptor antagonists MRS2179, MRS500 or the P2Y12 receptor 
antagonists MRS2395 or AR-C66096 before subsequent stimulation with 100nM 
ADP and mixing with PMN cells. The cell mixture was added to the top well of a 
chemotaxis chamber. PMN chemotaxis was measured towards either 100nM f-MLP 
(A) or 100nM SDF-1 (B) after a 90 minute incubation and analysed as a chemotactic 
index. Data are expressed as mean ± SEM. *** = P < 0.001towards sham controls, 


















































Figure 4. 22 The Effects of P2X1 Receptor Antagonism on Platelet Induced 
PMN Chemotaxis in vitro 
Platelets and PMNs were isolated from citrated blood and bone marrow from 
1.5mg/kg OVA sensitised mice. Platelets were then pre-incubated with 1, 10, 100 
and 1000 NF-279 before subsequent stimulation with 100nM ADP before mixing 
with PMN cells. The cell mixture was added to the top well of a chemotaxis 
chamber. PMN chemotaxis towards MDC (bottom well 100nM) was then quantified 
after a 90 minute incubation and analysed as a chemotactic index. Data are expressed 
as mean ± SEM. *** = P < 0.001 where indicated to column 3,n = 6-9. 
 
4.9. An Investigation into the Role of RhoA in Inflammatory Processes 
Downstream of Purinergic Receptors   
In the previously described experiments, the role of platelet P2Y1 receptor signalling 
has been shown to be critical in the inflammatory actions of platelets, whilst the 
P2Y12 receptor signalling has been shown to only be implicated in thrombotic 
process of platelets. It was therefore important to try to identify differences in the 
downstream signalling of the purinergic receptors that separates this role from that of 
platelet aggregation.  




RhoA is a small GTPase that belongs to the Rho family of GTPases, a family of GTP 
binding proteins critically involved in the regulation of the platelet cytoskeleton and 
platelet function (Sakumura et al 2005). In its active form RhoA binds to and 
activates Rho-associated coiled-coil forming kinases (ROCKs) (Ridley, 2013b). 
Once activated, ROCK phosphorylates and inactivates myosin light chain (MLC) 
phosphatase resulting in an overall increase in MLC phosphorylation initiating 
platelet shape change (Zhu et al 2011). Indeed RhoA has been shown to be involved 
in platelet shape change, filopodia formation and granule secretion (Aslan et al 2013, 
Bustelo et al 2007, Pleines et al 2012). Similar processes also appear to be necessary 
in leukocytes for cell adhesion whilst in conjunction with other GTPases of the Rho 
family (Rac1, cdc42) coordinates cell movement (Aslan et al 2013, Sakumura et al 
2005). However, RhoA appears to be redundant in platelet aggregation (Eckly et al., 
2001; Pleines et al., 2012). Therefore, given that P2Y1 activation of platelets in the 
context of allergic inflammation does not increase aggregation per sé, the 
significance of this redundant pathway in the context of the allergic response to 
allergen was investigated. 
In addition to the described role of RhoA in platelet function, activation of Rho 
kinase isoforms has been demonstrated in lung endothelial cells during inflammation 
(Mong et al 2009), whilst inhibition of Rho-Kinase through the use of 
pharmacological antagonists inhibits airway hyperresponsiveness, inflammation, 
extra-cellular matrix remodelling and decrease neutrophil accumulation to the lungs 
in models of abdominal sepsis and chronic inflammation (Palani et al 2012, Souza 
Possa et al 2012). Given these previously described roles of RhoA signalling for 
inflammatory cell recruitment; the possibility of a role for RhoA in platelet function 
during inflammatory events was investigated. 




4.9.1 An Investigation into the Impact of RhoA Phosphorylation at S188 
Following Allergen Challenge 
RhoA phosphorylation was used as a biomarker of activity within the RhoA system. 
Female Balb/c mice were sensitised and challenged to OVA as described in figure 
2.2. Animals were treated with either vehicle, 3mg/kg MRS2500 or AR-C66096. 6 
hours post final allergen challenge, citrated blood was collected via cardiac puncture. 
Platelets were isolated and phosphorylated RhoA was measured through western blot 
using the anti-pRhoA S188 antibody. Allergen sensitisation and challenge resulted in 
RhoA phosphorylation at S188, a process that was not observed in sham sensitised 
controls. Interestingly, RhoA S188 phosphorylation was specifically suppressed 
through pre-treatment with MRS2500 but not AR-C66096, providing a possible 
basis for modulation of RhoA signalling in the P2Y1 specific role in the 













Figure 4. 23 Effects of P2Y1 and P2Y12 Antagonism on RhoA Phosphorylation 
at S188 
Female Balb/c mice were sensitised and challenged to OVA as described in figure 
2.2. Animals were treated with either vehicle or 3mg/kg MRS2500 or AR-C66096. 6 
hours post final allergen challenge, citrated blood was collected via cardiac puncture. 
Platelets were isolated and phosphorylated RhoA was measured through western blot 
















4.9.2 An Investigation into the Role of Platelet RhoA Signalling in Pulmonary 
Leukocyte Recruitment in vivo  
Pre-treatment of some groups of mice with 20mg/kg Busulfan induced significant 
thrombocytopenia (Veh:1.68 ± 0.06x10
9
 plts/ml vs. 20mg/kg Busulfan: 0.50 ± 
0.02x10
9


































Figure 4. 24 Busulfan Induced Thrombocytopenia 
Female Balb/c mice were treated with either vehicle or 20mg/kg Busulfan. 10 days 
post final dosing, circulating platelet counts were quantified under 40X 
magnification on a light microscope. Data expressed as mean ± SEM, N = 5, *** = P 
< 0.001. 
 
Busulfan induced thrombocytopenia significantly attenuated allergen-induced total 
leukocyte recruitment which was restored following reinfusion of 2.36x10
8
 washed 
platelets per mouse (OVA: 406.50 ± 51.33x10
4
 cells/ml vs. OVA + Busulfan: 134.50 
± 24.19x10
4
 cells/ml, P < 0.001; WP: 309.00 ± 23.87x10
4
 cells/ml, figure 4.25A). 
This attenuation of leukocyte recruitment in thrombocytopenic mice and subsequent 
restoration with WP was restored in macrophage counts (OVA: 91.01 ± 16.58x10
4
 
cells/ml vs. OVA + Busulfan: 54.13 ± 16.05x10
4
 cells/ml; WP: 50.04 ± 5.56x10
4
 
cells/ml, figure 4.25B), infusion with WP restored lymphocyte counts (OVA: 9.65 ± 






 cells/ml vs. OVA + Busulfan: 3.68 ± 1.49x10
4
 cells/ml; WP: 5.70 ± 1.43, 
figure 4.25C), neutrophil counts (OVA: 47.52 ± 13.65x10
4
 cells/ml vs. OVA + 
Busulfan: 8.35 ± 2.82x10
4
 cells/ml, P < 0.05; WP: 50.20 ±9.63x10
4
 cells/ml, figure 
4.25D) and eosinophil counts (OVA: 258.52 ± 25.03x10
4
 cells/ml vs. OVA + 
Busulfan: 38.49 ± 19.28x10
4




Reinfusion with platelets pre-treated with 100μM of the Rho kinase inhibitor 
GSK429286 reinstated suppression of total leukocyte recruitment (OVA: 406.50 ± 
51.33x10
4
 cells/ml vs. GSK429286: 174.50 ± 32.23x10
4
 cells/ml, P < 0.001 figure 
4.25A), a process which was not replicated in macrophages (OVA: 91.01 ± 
16.58x10
4
 cells/ml vs. GSK429286: 86.64 ± 16.18x10
4
 cells/ml, figure 4.25B), but 
in lymphocytes (OVA: 9.65 ± 3.48x10
4
 cells/ml vs. GSK429286: 0.20 ± 0.20x10
4
 
cells/ml, P < 0.01 figure 4.25C), neutrophils (OVA: 47.32 ± 13.65x10
4
 cells/ml vs. 
GSK429286: 25.47 ± 7.34x10
4
 cells/ml, figure 4.26D) and eosinophil numbers 
(OVA: 258.22 ± 25.03x10
4
 cells/ml vs. GSK429286: 62.01 ± 11.91x10
4
 cells/ml, P 
< 0.001 figure 4.25E). This demonstrates a significant role of platelet RhoA 
signalling in pulmonary leukocyte recruitment in this murine model of allergic 
inflammation. 
Given the similarity of the results obtained through inhibition of RhoA with 
GSK429286 and the inhibition of P2Y1 receptors with MRS2179 and MRS2500, 
further studies investigated if RhoA signalling was downstream of the P2Y1 receptor 
in platelet signalling. 
 
 











Figure 4. 25 The Effects of 
GSK429286 Treated Platelets on 
Pulmonary Leukocyte Recruitment 
Mice were rendered thrombocytopenic 
through a dosing protocol involving the 
bone marrow depleting agent Busulfan. 
During this process mice were 
subjected to a two week sensitisation 
(1.5mg/kg OVA) and allergen exposure 
protocol. Washed platelets isolated 
from allergen sensitised mice were pre-
treated with either vehicle or 100µM 
GSK429286. Treated platelets were 
subsequently reinfused in 
thrombocytopenic mice prior to 
allergen exposure on days 14 and 15. 
Lavage fluid was collected 24 hours 
post final allergen exposure (day 17). 
A Total BAL Leukocytes B 
Macrophages C Lymphocytes D 
Neutrophils E Eosinophils.  Data: 
Mean ± SEM, N= 5 animals per 
group. * = P < 0.05, ** = P < 0.01, 
*** =  P < 0.001. 
 




4.9.3 An Investigation into the Role of RhoA Signalling Downstream of the 
P2Y1 Receptor in Platelet Induced PMN Cell Migration 
The ability of RhoA signalling downstream of platelet P2Y1 receptor activation to 
induce the activation and motility of murine bone marrow PMN cells to MDC was 
investigated. Stimulation of platelets with 100nM ADP or 1000nM of the P2Y1 
receptor agonist MRS2365 induced significant PMN cell migration towards 100nM 
MDC (Vehicle: 1.32 ± 0.26 vs. 100nM ADP: 3.16 ± 0.14, P<0.001; 1000nM 
MRS2365: 2.52 ± 0.43, P<0.01, Figure 4.26). ADP induced increases in platelet-
induced PMN cell migration were attenuated by treatment with the RhoA antagonist 
GSK429286 (100µM GSK: 1.52 ± 0.43, P<0.01, Figure 4.26). This was replicated 
in groups stimulated with the specific P2Y1 agonist (MRS2365) with subsequent 
treatment with GSK429286 (100µM GSK: 1.32 ± 0.49, P<0.05, Figure 4.26).   
This collection of data confirms that platelet induced PMN migration towards MDC 
is a ADP-dependent process, furthermore the suppression of either ADP or 
MRS2365 induced PMN cell migration by GSK429286 suggests that RhoA 
signalling downstream of the P2Y1 receptor is necessary. 











































Figure 4. 26 RhoA Signalling Downstream of P2Y1 Stimulation is Necessary in 
Platelet Induced PMN Cell Migration 
Platelets and PMNs were isolated from citrated blood and bone marrow from 
1.5mg/kg OVA sensitised mice. Platelets were then pre-incubated either vehicle, 
20µg/ml apyrase or 100µM GSK429286 before subsequent stimulation with either 
100nM ADP or 1000nM MRS2365 before mixing with PMN cells. The cell mixture 
was added to the top well of a chemotaxis chamber. PMN chemotaxis towards MDC 
(bottom well 100nM) was then quantified after a 90 minute incubation and analysed 
as a chemotactic index. Data are expressed as mean ± SEM. * = P < 0.05, ** = P < 
0.01, *** = P < 0.01 where indicated to column 1, # = P < 0.05, ## = P < 0.01 n 4. 
 
Given that GSK429286 is a ROCK inhibitor. To further investigate the impact of 
RhoA signalling downstream of the P2Y1 receptor a second known direct inhibitor 
of RhoA signalling was used. Botulinum ADP-ribosyltransferase (C3 exoenzyme), is 
known to directly inhibit RhoA activity in human platelets (Morii et al., 1992), this 
C3 exoenzyme was therefore used to determine if RhoA specific activity was 
involved in platelet induced leukocyte chemotaxis in vitro to ADP or specific 
activation of the P2Y1 receptor using the agonist MRS2365 (Figure 4.27). 






Figure 4. 27. The effects of C3 exoenzyme on platelet induced leukocyte 
chemotaxis in vitro 
Platelets and PMNs were isolated from citrated blood and bone marrow from Balb/c 
mice. Platelets were then pre-incubated either vehicle, 1, 10 or 100nM C3 
Exoenzyme before subsequent stimulation with either 100nM ADP (A) or 1000nM 
MRS2365 (B) before mixing with PMN cells. The cell mixture was added to the top 
well of a chemotaxis chamber. PMN chemotaxis towards MDC (bottom well 
100nM) was then quantified after a 90 minute incubation and analysed as a 
chemotactic index. Data are expressed as mean ± SEM. * = P < 0.05, ## = P < 0.01, 
### = P < 0.01 where indicated to column 1, n 4. 
 
Initial chemotaxis assays were performed on platelets and PMNs isolated from blood 
and bone marrow of female balb/c mice. Platelets were incubated with the RhoA 
inhibitor C3 exoenzyme prior to stimulation with either 100nM ADP (figure 4.27A) 
or 1μM of the P2Y1 specific agonist MRS2365 (figure 4.27). Post stimulation with 
ADP or MRS2365, platelets were added to PMN cells to induce migration towards 
100nM MDC. No significant migration was observed to leukocytes alone following 
either ADP stimulation ( 1.40 ± 0.68) or MRS2365 stimulation (0.94 ± 0.30), 
leukocyte migration towards MDC alone following either ADP stimulation (1.40 ± 
0.26) or MRS2365 stimulation (0.81 ± 0.31) or leukocytes in the presence of 




platelets following ADP stimulation (1.00 ± 0.00) or MRS2365 stimulation (1.00 ± 
0.00). 
When platelets were mixed with PMNs, significant migration to 100nM MDC was 
observed following stimulation by both ADP (2.36 ± 0.43, P < 0.05, figure 4.27A) 
and MRS2365 stimulation (1.57 ±0.22, P < 0.05, figure 4.27B). Pre-incubation of 
platelets with C3 exoenzyme significantly attenuated platelet induced leukocyte 
migration towards MDC following ADP stimulation (Veh: 2.36 ± 0.43 vs.1nM: 0.56 
± 0.10, P<0.01; 10nM: 0.84 ± 0.19, P<.0.05; 100nM: 0.82 ± 0.27, P<0.05, figure 
4.27A). Importantly, this inhibition of platelet induced PMN migration by C3 
exoenzyme was also observed downstream of specific P2Y1 receptor activation using 
the P2Y1 specific receptor agonist MRS2365 (Veh: 1.56 ± 0.22 vs. 1nM: 0.92 ± 
0.34; 10nM: 0.54 ± 0.02; 100nM:0.53 ± 0.06, P<0.05, figure 4.27B). In agreement 
with inhibition of platelet induced PMN migration with pre-treatment with the 
ROCK inhibitor GSK429286, this demonstrates that RhoA signalling downstream of 
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5.1 An investigation into the Regulation of the Apparent Dichotomy of Platelet 
Function in Hemostasis and Inflammation  
As has been previously described, platelets are capable of being activated by a 
number of different 'platelet agonists', for example the classical agonists of ADP, 
Thrombin and TxA2 and adrenaline. However platelets also express a number of 
receptors for inflammatory mediators, including SDF-1α, MDC, IL-1β and LPS. 
Indeed, Clemetson et al 2000 have demonstrated functional expression of the SDF-
1α receptor CXCR4 and the MDC receptor CCR4 on the surface of platelets 
(Clemetson et al., 2000) and the LPS receptors TLR2 and TLR4 (Semple and 
Freedman, 2010), whilst more recent studies have identified the IL-1β specific 
receptor IL-1R1 on the platelets surface (Brown et al. 2013). 
Given the dichotomy in platelet activation leading to pro-inflammatory events 
compared to aggregation described in Chapter IV, and in numerous inflammatory 
conditions such as asthma, COPD, atherosclerosis, rheumatoid athritis and ezcema, 
platelet activation leads to the formation of circulating platelet-leukocyte aggregates 
via adhesion molecule interactions  which do not lead to platelet aggregation per sé 
(Ott I, Neumann FJ, Gawaz M, Schmitt M, 1996; Neumann et al., 1997; Joseph et 
al., 2001; Sarma, 2002; Huo et al., 2003; Bunescu et al., 2004; Pitchford et al., 2004, 
2005; Irving et al., 2008), this body of evidence suggests that platelet activation as a 
result of inflammatory stimuli may result in different parameters of platelet function. 
In this chapter, using platelets isolated from human venous blood a series of in vitro 
assays of platelet function covering aspects of inflammation and hemostasis (platelet 
migration, platelet-leukocyte conjugate formation, platelet P-selectin expression and 
platelet aggregation) are used to investigate the impact of both inflammatory and 
haemostatic stimuli (SDF-1α, MDC, f-MLP, 5-HT, LPS, IL-1β, Adrenaline, the 
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TxA2 analogue U46619, TRAP and ADP) on platelet function to elucidate the 
differential signalling mechanisms involved. 
5.2 An Investigation into the Effects of the Stimulation of Platelets by 
Inflammatory Mediators on Platelet Function 
 
SDF-1α (CXCL12) is a chemokine known to activate platelet expressed CXCR4 
receptors. Activation of the CXCR4 receptor activates a complex cascade of 
intracellular signalling pathways regulating and promoting cell migration, adhesion, 
survival and proliferation. Indeed, platelet migration has previously been observed 
towards SDF-1α in a CXCR4 dependent fashion, as well as inhibiting cAMP 
production (Kowalska et al., 2000; Gear, 2001; Kraemer et al., 2010). Using the 
aforementioned assays of platelet function (both haemostatic and inflammatory), the 
role of SDF-1 on platelet function was investigated. 
Stimulation with SDF-1α failed to induce any change in platelet P-selectin 
expression compared to sham controls in either percent expression (Veh: 6.49 ± 
2.08% vs. 0.1µg/ml SDF-1α: 7.25 ± 3.22%; 1µg/ml SDF-1α: 8.72 ± 2.40% and 
10µg/ml SDF-1α: 7.04 ± 0.01, figure 5.1A) or MFI on P-selectin expression (Veh: 
0.47 ± 0.09 vs. 0.1µg/ml SDF-1α: 0.39 ± 0.01; 1µg/ml SDF-1α: 0.50 ± 0.10 and 
10µg/ml SDF-1α: 0.46 ± 0.00, figure 5.1B). 
Furthermore, SDF-1α failed to significantly enhance the formation of platelet 
leukocyte conjugates in human venous whole blood when compared to sham 
controls, either in a fold increase in the incidence of conjugates (Veh: 1.04 ± 0.04 vs. 
0.1µg/ml SDF-1α: 1.26 ± 0.15; 1µg/ml SDF-1α: 1.19 ± 0.13 and 10µg/ml SDF-1α: 
1.53 ± 0.22, figure 5.1C) or MFI on conjugate formation (Veh: 3.63 ± 0.62 vs. 
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0.1µg/ml SDF-1α: 3.15 ± 0.57; 1µg/ml SDF-1α: 3.16 ± 0.58 and 10µg/ml SDF-1α: 
3.18 ± 0.61, figure 5.1D).  
SDF-1α stimulation was also not capable of inducing platelet aggregation in gel 
filtered isolated platelets in vitro (Veh: 0.77 ± 0.53% vs. 0.1µg/ml SDF-1α: 1.30 ± 
0.90; 1µg/ml SDF-1α: 3.15 ± 1.76% and 10µg/ml SDF-1α: 3.67 ± 1.90%, figure 
5.1E). 
In contrast, whilst SDF-1α stimulation had no effect on P-selectin expression, the 
formation of platelet-leukocyte aggregates or platelet aggregation, SDF-1α 
significantly elevated platelet migration compared to vehicle control and platelets 
fixed with 4% PFA prior to stimulation to provide a suitable control for chemokine 
stimulation (Veh: 1.00 ± 0.00 vs. 0.1µg/ml SDF-1α: 1.37 ± 0.26; 0.5µg/ml SDF-1α: 
1.48 ± 0.23; 1µg/ml SDF-1α: 2.49 ± 0.24, P < 0.001 and PFA treated 1µg/ml SDF-
1α: 1.11 ± 0.07, figure 5.1F). 




Figure 5. 1. Investigating the effects of the CXCR4 chemokine SDF-1α on 
parametres of platelet activation 
Stimulation with 0.1, 1 or 10μg/ml SDF-1 on gel filtered platelets isolated from 
human venous blood exposed to showed increased P-selectin activity (A: %, B: 
MFI), on platelet leukocyte conjugation in human venous whole blood (C: %, D: 
MFI), platelet aggregation in gel filtered platelets (E) and platelet migration with 
washed platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * 
= P < 0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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MDC  stimulates platelet CCR4 receptors, and has been shown to induce 
intracellular Ca
2+
 mobilisation and in some cases an elevation in P-selectin 
expression (Kowalska et al., 2000; Gear, 2001). Using the aforementioned assays of 
platelet function, the role of MDC on both the inflammatory and haemostatic 
parameters of platelet activation was investigated. 
Similar to the effects seen by SDF-1α stimulation, MDC stimulation was unable to 
induce elevations in platelet surface P-selectin expression compared to vehicle 
controls in either percent expression (Veh 4.01 ± 0.33% vs. 0.1µg/ml MDC: 4.36 ± 
0.46%; 1µg/ml MDC: 5.55 ± 1.14% and 10µg/ml MDC: 5.98 ± 1.27%, figure 5.2A) 
or MFI on P-selectin expression (Veh: 0.48± 0.08 vs. 0.1µg/ml MDC: 0.50 ± 0.06; 
1µg/ml: 0.56 ± 0.10 and 10µg/ml MDC: 0.57 ± 0.10, figure 5.2B). 
MDC also failed to induce a significant increase in the formation of platelet-
leukocyte conjugates in human venous whole blood, however a trend depicting a 
small increase in conjugate formation is visible in the total circulating numbers (Veh: 
1.05 ± 0.04 vs. 0.1µg/ml MDC: 1.02 ± 0.07; 1µg/ml MDC: 1.04 ± 0.03 and 10µg/ml 
1.30 ± 0.19, figure 5.2C) but not the MFI on platelet leukocyte conjugates (Veh: 
4.09 ± 1.83 vs. 0.1µg/ml MDC: 3.64 ± 1.63; 1µg/ml MDC: 3.62 ± 1.62 and 10µg/ml 
MDC: 3.64 ± 1.63, figure 5.2D). 
Stimulation of gel filtered isolated platelets failed to induce any significant platelet 
aggregation, however once again, a small trend appeared to show a small increase in 
MDC induced platelet aggregation compared to negative controls (Veh: 11.52 ± 
5.06% vs. 0.1µg/ml MDC: 11.67 ± 9.17; 1µg/ml MDC: 15.67 ± 2.88 and 10µg/ml 
MDC: 23.50 ± 2.85, figure 5.2E). 
160 Chapter V: Results III 
 
 
Finally, stimulation of washed platelets isolated from citrated blood induced 
significant platelet migration compared to vehicle and fixed platelet controls 
(Veh:1.00 ± 0.06 vs. 0.1µg/ml MDC: 0.94 ± 0.13; 1µg/ml MDC: 1.83 ± 0.13, P < 
0.01; 10µg/ml MDC: 1.39 ± 0.00 and PFA treated 10µg/ml MDC: 0.58 ± 0.00, 
figure 5.2F). 




Figure 5. 2 Investigating the effects of the CCR4 chemokine MDC on 
parameters of platelet activation 
Stimulation with 0.1, 1 or 10μg/ml MDC on gel filtered platelets isolated from 
human venous blood exposed to showed increased P-selectin activity (A: %, B: 
MFI), on platelet leukocyte conjugation in human venous whole blood (C: %, D: 
MFI), platelet aggregation in gel filtered platelets (E) and platelet migration with 
washed platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * 
= P < 0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
162 Chapter V: Results III 
 
 
f-MLP stimulates functional formyl peptide receptors (FPRs) on human platelets, 
and has previously been implicated in platelet chemotaxis (Czapiga et al., 2005). 
Using the aforementioned assays of platelet function, the role of MDC on both the 
inflammatory and haemostatic parameters of platelet activation was investigated. 
f-MLP stimulation was unable to induce elevations in platelet surface P-selectin 
expression compared to vehicle controls in either percent expression (Veh 4.73 ± 
0.90% vs. 0.1µM f-MLP: 5.57 ± 1.37%; 1µM f-MLP: 4.54 ± 0.69% and 10µM f-
MLP: 4.26 ± 0.67%, figure 5.3A) or MFI on P-selectin expression (Veh: 0.50 ± 0.08 
vs. 0.1µM f-MLP: 0.52 ± 0.08; 1µM: 0.49 ± 0.08 and 10µM: 0.43 ± 0.04, figure 
5.3B). Furthermore, f-MLP stimulation failed to induce an increase in the formation 
of platelet-leukocyte conjugates in human venous whole blood, both in terms of a 
fold increase compared to vehicle control (Veh: 1.05 ± 0.04 vs. 0.1µM f-MLP: 1.34 
± 0.19; 1µM f-MLP: 1.44± 0.22 and 10µM f-MLP: 1.41 ± 0.14, figure 5.3C) and 
MFI on platelet leukocyte conjugates (Veh:4.14 ± 0.30 vs. 0.1µM f-MLP: 4.18 ± 
0.45; 1µM f-MLP: 4.50 ± 0.32 and 10µM f-MLP: 4.62 ± 0.43, figure 5.3D). 
Stimulation of gel filtered isolated platelets also failed to induce any visible changes 
in platelet aggregation, compared to negative controls (Veh: 0.00 ± 0.00% vs. 0.1µM 
f-MLP: 0.00 ± 0.00; 1µM f-MLP: 0.00 ± 0.00 and 10µM f-MLP: 0.00 ± 0.00, figure 
5.3E). 
Finally, washed platelets isolated from citrated blood demonstrated significant 
platelet migration towards f-MLP compared to vehicle and fixed platelet controls 
(Veh: 1.00 ± 0.00 vs. 0.1µM f-MLP: 1.72 ± 0.22, P < 0.05; 1µM f-MLP: 1.68 ± 0.22, 
P < 0.05; 10µM f-MLP: 1.45 ± 0.25 and PFA treated 10µ f-MLP: 1.14 ± 0.00, figure 
5.3F). 




Figure 5. 3. Investigating the effects of the FPR receptor chemokine f-MLP on 
parameters of platelet activation 
Stimulation with 0.1, 1 or 10μM f-MLP on gel filtered platelets isolated from human 
venous blood exposed to showed increased P-selectin activity (A: %, B: MFI), on 
platelet leukocyte conjugation in human venous whole blood (C: %, D: MFI), 
platelet aggregation in gel filtered platelets (E) and platelet migration with washed 
platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * = P < 
0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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Interlukin-1β (IL-1β) stimulates the IL-R1 receptor on platelets and has previously 
been shown to induce platelet activation in vitro (Brown et al., 2013). 
Platelet stimulation with IL-1β failed to induce any increases in surface P-selectin 
expression in vitro compared to vehicle controls, both in terms of the percent of 
platelets expressing P-selectin (Veh: 3.47 ± 0.93% vs. 0.1µg/ml IL-1β: 3.49 ± 
0.88%; 1µg/ml IL-1β: 3.88 ± 1.06% and 10µg/ml IL-1β: 3.60 ± 1.06%, figure 5.4A) 
or platelet MFI on P-selectin expression (Veh: 0.60 ± 0.07 vs. 0.1µg/ml IL-1β: 0.61 
± 0.08; 1µg/ml IL-1β: 0.63 ± 0.08 and 10µg/ml IL-1β: 0.62 ± 0.09, figure 5.4B). 
Stimulation of citrated whole blood with IL-1β was also unable to induce significant 
elevation of platelet-leukocyte conjugate formation compared to vehicle controls, 
however a trend is visible suggesting that Il-1β induced a small but non-significant 
increase in the incidence of platelet leukocyte conjugates (Veh: 1.00 ± 0.35 vs. 
0.1µg/ml IL-1β: 1.36 ± 0.48; 1µg/ml IL-1β: 1.56 ± 0.52 and 10µg/ml IL-1β: 1.15 ± 
0.52, figure 5.4C), but not MFI on platelet-leukocyte conjugates (Veh: 3.92 ± 0.51 
vs. 0.1µg/ml IL-1β: 4.29 ± 0.39; 1µg/ml IL-1β: 4.02 ± 0.19 and 10µg/ml IL-1β: 3.75 
± 0.41, figure 5.4D). 
Platelet aggregation remained unaffected following stimulation of gel filtered 
isolated platelets with IL-1β when compared to vehicle controls (Veh: 13.03 ± 
3.92% vs. 0.1µg/ml IL-1β: 14.00 ± 4.04%; 1µg/ml IL-1β: 24.67 ± 0.88% and 
10µg/ml IL-1β:  24.50 ± 0.50, figure 5.4E). 
Finally, washed platelets isolated from human venous blood failed to demonstrate 
any significant migration towards IL-1β when compared to vehicle controls (Veh: 
1.00 ± 0.06 vs. 0.1μg/ml IL-1β: 0.38 ± 0.01; 1μg/ml IL-1β: 1.02 ± 0.31; 10μg/ml IL-
1β: 1.18 ± 0.43; 10μg/ml IL-1β + PFA: 0.93 ± 0.27, figure 5.4F). 




Figure 5. 4. Investigating the effects of the IL-R1 receptor chemokine IL-1β on 
parameters of platelet activation 
Stimulation with 0.1, 1 or 10μg/ml IL-1β on gel filtered platelets isolated from 
human venous blood exposed to showed increased P-selectin activity (A: %, B: 
MFI), on platelet leukocyte conjugation in human venous whole blood (C: %, D: 
MFI), platelet aggregation in gel filtered platelets (E) and platelet migration with 
washed platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * 
= P < 0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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5-HT stimulates the 5-HT2A receptor present on platelets, which has previously 
been described to induce platelet activation through a Gαq dependent mechanism. 5-
HT stimulation was therefore investigated on a number of parameters of platelet 
activation. Platelet P-selectin expression was unaffected by 5-HT stimulation at all 
tested doses, both in terms of the incidence of platelets expressing P-selectin (Veh: 
6.87 ± 2.22% vs. 0.1µg/ml 5-HT: 7.40 ± 3.52%; 1µg/ml 5-HT: 7.70 ± 2.73% and 
10µg/ml 5-HT: 7.66 ± 2.77, figure 5.5A) and platelet MFI on P-selectin expression 
(Veh: 0.62 ± 0.08 vs. 0.1µg/ml 5-HT: 0.65 ± 0.09; 1µg/ml 5-HT: 0.61 ± 0.08 and 
10µg/ml 5-HT: 0.62 ± 0.07, figure 5.5B). 
The formation of platelet-leukocyte conjugates was also unaffected by stimulation of 
5-HT at any tested dose in citrated whole blood compared to vehicle controls, both in 
the elevation of total platelet –leukocyte conjugates present (Veh: 1.00 ± 0.00 vs. 
0.1µg/ml 5-HT: 1.38 ± 0.23; 1µg/ml 5-HT: 1.40 ± 0.23 and 10µg/ml 5-HT: 1.74 ± 
0.34, figure 5.5C) and MFI on platelet-leukocyte conjugates (Veh: 3.92 ± 0.51 vs. 
0.1µg/ml 5-HT: 4.48 ± 0.19; 1µg/ml 5-HT: 4.35 ± 0.21 and 10µg/ml 5-HT: 4.24 ± 
0.17, figure 5.5D). Interestingly, whilst not significant a potential trend 
demonstrating a small increase was observed in the incidence of platelet-leukocyte 
conjugates but not MFI on platelet-leukocyte conjugates. 
5-HT stimulation induced no platelet aggregation when compared with vehicle 
controls (Veh: 0.00 ± 0.00% vs. 0.1µg/ml 5-HT: 0.52 ± 0.52%; 1µg/ml 5-HT: 0.22 ± 
0.22% and 10µg/ml 5-HT: 0.98 ± 0.48%, figure 5.5E), nor was there any observed 
increase in platelet migration compared to vehicle controls or stimulation of fixed 
platelets (Veh: 1.00 ± 0.00 vs. 0.1µg/ml 5-HT: 1.17 ± 0.25; 1µg/ml 5-HT: 1.18 ± 
0.22; 10µg/ml 5-HT: 1.34 ± 0.36 and PFA treated 10µg/ml 5-HT: 0.96 ± 0.00, figure 
5.5F). 




Figure 5. 5. Investigating the effects of 5-HT on parameters of platelet 
activation 
Stimulation with 0.1, 1 or 10μg/ml 5-HT on gel filtered platelets isolated from 
human venous blood exposed to showed increased P-selectin activity (A: %, B: 
MFI), on platelet leukocyte conjugation in human venous whole blood (C: %, D: 
MFI), platelet aggregation in gel filtered platelets (E) and platelet migration with 
washed platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * 
= P < 0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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Lipopolysaccharide (LPS), a pro-inflammatory glycol-lipid component of the 
bacterial cell wall of gram-negative bacteria has previously been described as a 
potent platelet agonist and has been shown to induce platelet activation through 
stimulation of platelet toll-like receptor 4 (TLR4) (Brown et al., 2013), therefore 
LPS stimulation was investigated on the panel of platelet activation assays. 
Platelets stimulated with LPS in vitro failed to demonstrate any increase in P-selectin 
expression, in either the incidence of platelets expression P-selectin (Veh:6.24 ± 
1.81% vs. 1µg/ml LPS: 6.37 ± 1.88%; 10µg/ml LPS: 7.28 ± 2.48% and 100µg/ml 
LPS: 7.32 ± 2.26%, figure 5.6A) or platelet MFI on P-selectin expression (Veh: 0.53 
± 0.10 vs. 1µg/ml LPS: 0.50 ± 0.07; 10µg/ml LPS: 0.51 ± 0.09 and 100µg/ml LPS: 
0.53 ± 0.09, figure 5.6B). 
LPS stimulation also failed to induce elevations in the formation of platelet-
leukocyte conjugates in citrated whole blood, both in the incidence of the conjugates 
formation (Veh: 1.09 ± 0.06% vs. 1µg/ml LPS: 1.69 ± 0.21%; 10µg/ml LPS: 1.56 ± 
0.31 and 100µg/ml LPS: 2.72 ± 0.08, figure 5.6C) and the MFI on platelet-leukocyte 
conjugates (Veh: 4.22 ± 0.52 vs. 1µg/ml LPS: 4.47 ± 0.68; 10µg/ml LPS: 4.38 ± 
0.48 and 100µg/ml LPS: 3.88 ± 0.49, figure 5.6D), interestingly however, whilst the 
not significant a potential trend demonstrating an increase in the incidence of platelet 
leukocyte conjugates but not the MFI can be seen with increasing concentrations of 
LPS. 
LPS stimulation of isolated gel filtered platelets failed to induce platelet aggregation 
compared to vehicle controls (Veh: 0.00 ± 0.00% vs. 1µg/ml LPS: 0.52 ± 0.52%; 
10µg/ml LPS: 0.00 ± 0.00% and 100µg/ml LPS: 0.50 ± 0.50%, figure 5.6E). 
Similarly, platelets demonstrated no significant migration towards LPS at any tested 
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dose, indeed, 100µ/ml LPS appeared to attenuate basal levels of random platelet 
migration (Veh: 1.00 ± 0.00 vs. 1µg/ml LPS: 1.43 ± 0.27; 10µg/ml LPS: 1.20 ± 0.24; 
100µg/ml LPS: 0.02 ± 0.01 and PFA treated 100µg/ml LPS: 0.67 ± 0.00, figure 
5.6F). 
 




Figure 5. 6. Investigating the effects of LPS on parameters of platelet activation 
Stimulation with 1, 10 or 100μg/ml LPS on gel filtered platelets isolated from human 
venous blood exposed to showed increased P-selectin activity (A: %, B: MFI), on 
platelet leukocyte conjugation in human venous whole blood (C: %, D: MFI), 
platelet aggregation in gel filtered platelets (E) and platelet migration with washed 
platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * = P < 
0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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5.3 An Investigation in to Effects of Classical Platelet Agonist Stimulation on 
Platelet Function 
 
Adrenaline stimulates platelets via the α2A adrenoceptor coupled to Gαi, but has 
also been shown to stimulate platelets via the Gαs coupled β2 adrenoceptor 
(Benovic, 2002). The effects of adrenaline on the different paramaters of platelets 
were subsequently investigated. 
Stimulation of isolated gel-filtered platelets induced an increase in P-selectin 
expression in both the incidence of platelets expressing P-selectin (Veh: 5.22 ± 
1.38% vs. 1µM adrenaline: 4.68 ± 2.43%; 10µM adrenaline: 9.62 ± 2.82%; and 
100µM adrenaline: 13.54 ± 3.34%, figure 5.7A) and platelet MFI on P-selectin 
expression (Veh: 0.62 ± 0.08; 1µM adrenaline: 0.75 ± 0.12; 10µM adrenaline: 0.85 ± 
0.16 and 100µM adrenaline: 0.87 ± 0.34, figure 5.7B), however these elevations 
were not significantly different to vehicle levels. 
Adrenaline stimulation also induced elevations in the formation of platelet-leukocyte 
conjugates in citrated whole blood, with increases observed in both the incidence of 
platelet leukocyte conjugates (Veh: 1.00 ± 0.00 vs. 1µM adrenaline: 1.55 ± 0.35%; 
10µM adrenaline: 1.98 ± 0.43% and 100µM adrenaline: 2.24 ± 0.61, figure 5.7C) 
and MFI on platelet-leukocyte conjugates (Veh: 3.92 ± 0.51 vs. 1µM adrenaline: 
3.56 ± 0.23; 10µM adrenaline: 4.49 ± 0.41 and 100µM adrenaline: 4.88 ± 0.36, 
figure 5.7D), although these elevations were not significant compared to vehicle 
controls. 
Platelet stimulation with Adrenaline also induced platelet aggregation compared to 
vehicle control (Veh: 5.28 ± 2.89% vs. 1µM adrenaline: 2.43 ± 0.76%; 10µM 
adrenaline: 21.00 ± 10.78% and 100µM adrenaline: 21.32 ± 10.21%, figure 4.7E), 
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although aggregation induced by 100µM adrenaline was still substantially lower than 
aggregation induced by the positive control of 10µM ADP (42.20 ± 12.17%). No 
platelet migration was observed to adrenaline, with all tested concentrations 
remaining similar to vehicle and fixed platelet stimulated samples (Veh: 1.00 ± 0.00 
vs. 1µM adrenaline: 1.06 ± 0.09; 10µM adrenaline: 1.18 ± 0.13; 100µM adrenaline: 
1.03 ± 0.19 and PFA treated 100µM adrenaline: 1.08 ± 0.27, figure 5.7F). 




Figure 5. 7. Investigating the effects of adrenaline on parameters of platelet 
activation 
Stimulation with 1, 10 or 100μM Adrenaline on gel filtered platelets isolated from 
human venous blood exposed to showed increased P-selectin activity (A: %, B: 
MFI), on platelet leukocyte conjugation in human venous whole blood (C: %, D: 
MFI), platelet aggregation in gel filtered platelets (E) and platelet migration with 
washed platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * 
= P < 0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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Stimulation of platelets with ADP results in the activation of both the P2Y1 and 
P2Y12 receptors, which when stimulated together triggers platelet granule release 
resulting in increases in expression of surface adhesion molecules, Ca
2+
 mobilisation, 
integrin αIIbβ3 activation, and platelet aggregation. The effects of ADP on the 
parameters of platelet activation were investigated. 
Stimulation of platelets with ADP as expected induced a significant elevation in P-
selectin expression, both in terms of the incidence of platelets expressing P-selectin 
(Veh: 3.52 ± 0.45% vs. 0.1µM ADP: 3.83 ± 0.41%; 1µM ADP: 10.62 ± 5.53% and 
10µM ADP: 30.21 ± 5.32%, P < 0.001, figure 5.8A) and MFI on P-selectin 
expression (Veh: 0.51 ± 0.08 vs. 0.1µM ADP: 0.52 ± 0.08; 1µM ADP: 0.69 ± 0.09 
and 10µM ADP: 1.59 ± 0.27, P < 0.001, figure 5.8B). 
ADP stimulation also induced significant increases in the formation of platelet 
leukocyte conjugates, but only in terms of the incidence of platelet-leukocyte 
conjugates (Veh: 1.00 ± 0.45% vs. 0.1µM ADP: 1.28 ± 0.74%; 1µM ADP: 1.88 ± 
1.08% and 10µM ADP: 2.83 ± 1.27%, P < 0.05, figure 5.8C) and not the MFI on 
platelet-leukocyte conjugates which remained similar to that seen in vehicle treated 
samples (Veh: 3.68 ± 0.65 vs. 0.1µM: 3.62 ± 0.61; 1µM: 3.28 ± 0.27 and 10µM 
ADP: 3.59 ± 0.70, figure 5.8D). 
ADP stimulation also induced significant platelet aggregation compared to vehicle 
controls (Veh: 2.83 ± 1.74% vs. 0.1µM ADP: 2.65 ± 1.61%; 1µM ADP: 19.40 ± 
13.41% and 10µM ADP: 42.20 ± 12.17%, P < 0.01, figure 5.8E), however no 
significant platelet migration was observed towards ADP at any tested concentration 
(Veh: 1.00 ± 0.00; 0.1µM ADP: 1.14 ± 0.06; 1µM ADP: 1.24 ± 0.23; 10µM ADP: 
1.19 ± 0.21 and PFA treated 10µM ADP: 1.06 ± 0.21, figure 5.8F). 




Figure 5. 8. Investigating the effects of the purinergic agonist ADP on 
parameters of platelet activation 
Stimulation with 0.1, 1 or 10μM ADP on gel filtered platelets isolated from human 
venous blood exposed to showed increased P-selectin activity (A: %, B: MFI), on 
platelet leukocyte conjugation in human venous whole blood (C: %, D: MFI), 
platelet aggregation in gel filtered platelets (E) and platelet migration with washed 
platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * = P < 
0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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U46619 is a synthetic analogue of the platelet agonist thromboxane A2 known to 
stimulate platelet activation through the TP receptors on the platelets surface (Li et 
al., 2010). In this section the impact of TP receptor stimulation on a wide range of 
platelet activation parameters, both haemostatic and inflammatory were investigated. 
Platelet stimulation with U46619 induced significant elevations in surface P-selectin 
expression, both in terms of the incidence of platelets expressing P-selectin (Veh: 
8.94 ± 2.06% vs. 10nM U46619: 7.52 ± 2.09%; 100nM U46619: 18.93 ± 0.65% and 
1000nM U46619nM: 53.70 ± 5.40%, P < 0.001, figure 5.9A) and platelet MFI on P-
selectin expression (Veh: 0.67 ± 0.09 vs. 10nM U46619: 0.65 ± 0.12; 100nM 
U46619: 1.04 ± 0.12 and 1000nM U46619: 3.93 ± 0.65, P < 0.001, figure 5.9B). 
U46619 stimulation also resulted in significant increases in the formation of platelet-
leukocyte conjugates, however increases were only observed in the incidence of 
platelet leukocyte conjugates (Veh: 1.00 ± 0.00% vs. 10nM U46619: 1.11 ± 0.16%; 
100nM U46619: 1.32 ± 0.19% and 1000nM U46619: 2.75 ± 0.26%, P < 0.001, 
figure 5.9C) and not MFI on platelet-leukocyte conjugates (Veh: 3.53 ± 0.74 vs. 
10nM U46619: 2.82 ± 0.47; 100nM U46619: 2.80 ± 0.34 and 1000nM U46619: 3.02 
± 0.74, figure 5.9D). 
In addition, platelet stimulation with U46619 induced substantial platelet 
aggregation compared to vehicle controls (Veh: 2.04 ± 1.59%; 10nM U46619: 5.50 
± 4.27%; 100nM U46619: 52.09 ± 9.31%, P < 0.001 and 1000nM U46619: 81.76 ± 
8.97%, P < 0.001, figure 5.9E), with significantly elevated aggregation observed 
towards 1000nM U46619 compared to the 10µM ADP positive control (10µM ADP: 
42.20 ± 12.17% vs. 1000nM U46619: 1000nM U46619: 81.76 ± 8.97%, P < 0.001). 
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No significant migration was observed towards U46619 at any tested dose, with 
levels of migration remaining within ranges observed for vehicle control and 
stimulation of fixed platelets (Veh: 1.00 ± 0.00 vs. 10nM U46619: 1.24 ± 0.14; 
100nM: 1.08 ± 0.19; 1000nM U46619: 1.23 ± 0.20 and PFA treated 1000nM 
U46619: 1.15 ± 0.22, figure 5.9F). 
 




Figure 5. 9. Investigating the effects of the TxA2 analogue U46619 on 
parameters of platelet activation 
Stimulation with 10, 100 or 1000nM U46619 on gel filtered platelets isolated from 
human venous blood exposed to showed increased P-selectin activity (A: %, B: 
MFI), on platelet leukocyte conjugation in human venous whole blood (C: %, D: 
MFI), platelet aggregation in gel filtered platelets (E) and platelet migration with 
washed platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * 
= P < 0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
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Thrombin receptor activating peptide (TRAP) is a platelet agonist stimulating 
platelet aggregation through stimulation of the Gαq coupled PAR receptors (Soh et 
al., 2010). TRAP induced platelet activation was investigated further through the use 
of both haemostatic and inflammatory assays of platelet activation. 
As expected, platelet stimulation with TRAP resulted in a significant increase in both 
the incidence of platelets expressing P-selectin (Veh: 7.58 ± 2.67% vs. 0.1µM 
TRAP: 13.30 ± 6.53%; 1µM TRAP: 27.91 ± 5.74% and 10µM TRAP: 78.13 ± 7.18, 
P < 0.001, figure 5.10A) and platelet MFI on P-selectin expression (Veh: 0.64 ± 
0.13 vs. 0.1µM TRAP: 0.60 ± 0.08; 1µM TRAP: 0.71 ± 0.15 and 10µM TRAP: 9.42 
± 1.99, p < 0.001, figure 5.10B) compared to vehicle controls. 
Furthermore, stimulation of citrated whole blood induced a significant increase in the 
formation of platelet-leukocyte conjugates (Veh: 1.00 ± 0.00% vs. 0.1µM TRAP: 
1.31 ± 0.16%; 1µM TRAP: 1.49 ± 0.52% and 10µM TRAP: 3.05 ± 0.78%, P < 0.01, 
figure 4.10C) but not MFI on platelet-leukocyte conjugates (Veh: 3.68 ± 1.65 vs. 
0.1µM TRAP: 3.24 ± 1.45; 1µM TRAP: 3.61 ± 1.62 and 10µM TRAP: 3.85 ± 1.74, 
figure 5.10D). 
Platelet aggregation was significantly elevated following stimulation with increasing 
concentrations of TRAP compared to vehicle controls (Veh: 3.31 ± 2.54% vs. 0.1µM 
TRAP: 1.41 ± 1.11%; 1µM TRAP: 33.41 ± 10.11%, P < 0.05 and 10µM TRAP: 
69.35 ± 8.54%, P < 0.001, figure 4.10E), with 10µM TRAP inducing significantly 
higher levels of platelet aggregation compared to aggregation induced by 10µM 
ADP as the positive control (10µM ADP: 42.20 ± 12.17% vs. 10µM TRAP: 69.35 ± 
8.35%, P < 0.001). 
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Finally, no platelet migration was observed to TRAP at any tested concentration 
(Veh: 1.00 ± 0.00 vs. 0.1µM TRAP: 1.25 ± 0.24; 1µM TRAP: 1.10 ± 0.24; 10µM 
TRAP: 1.10 ± 0.19 and PFA treated 10µM TRAP: 1.01 ± 0.17, figure 5.10F). 
 
 




Figure 5. 10. Investigating the effects of the PAR receptor agonist TRAP on 
parameters of platelet activation 
Stimulation with 0.1, 1 or 10μM TRAP on gel filtered platelets isolated from human 
venous blood exposed to showed increased P-selectin activity (A: %, B: MFI), on 
platelet leukocyte conjugation in human venous whole blood (C: %, D: MFI), 
platelet aggregation in gel filtered platelets (E) and platelet migration with washed 
platelets isolated from human venous blood (F) Data: Mean ± SEM, N = 5. * = P < 
0.05, ** = P < 0.01, *** = P < 0.001 compared to vehicle controls. 
182 Chapter V: Results III 
 
 
5.4 A Summary of the Dichotomy in Platelet Function 
 
As the previous studies have demonstrated, the 3 inflammatory chemokines SDF-1α,  
MDC and f-MLP demonstrated significant increases in platelet chemotactic ability, 
however no significant change was observed in other platelet activation markers 
such as P-selectin expression, Platelet-leukocyte conjugation or platelet aggregation. 
In contrast the classical platelet agonists including TxA2, ADP, adrenaline and 
TRAP all demonstrated elevations in P-selectin expression, Platelet-Leukocyte 
conjugation and platelet aggregation. 
Interestingly 5-HT, IL-1β and LPS all failed to produce signs of platelet activation in 












SDF-1       √ 
MDC       √ 
f-MLP       √ 
IL-1β   X     
5-HT   X     
LPS   X     
Adrenaline √ √ √   
ADP √ √ √   
U46 √ √ √   
TRAP √ √ √   
 
Table 4. Summarising a dichotomy in platelet function 




183 Chapter V: Results III 
 
 
The inability of the chemokines SDF-1α and MDC as well as the other inflammatory 
stimuli to modulate typical platelet function was surprising, but a explanation may 
rely in observed synergism between chemokine stimulation and sub-threshold doses 
of ADP(Gear, 2001; Suttitanamongkol and Gear, 2001).  
5.5 An Investigation into the Potential Potentiation of ADP induced Platelet 
Activation with MDC Co-Stimulation 
 
Under normal conditions as it is demonstrated that primary agonists induce platelet 
activation as seen through platelet aggregation, P-selectin and Platelet-Leukocyte 
aggregate experiments, whilst other agonists such as adrenaline can play important 
amplify agonist induced platelet aggregation. Given that platelets expresses the 
MDC chemokine receptor CCR4, combined with the previously described platelet 
induced PMN chemotaxis assays, it stood to reason that MDC may be capable of 
inducing platelet activation or at least modulate ADP induced platelet activation.  
The ability of MDC to either directly induce platelet activation or modulate ADP 
induced platelet activation through an in vitro platelet-leukocyte aggregate assay was 
therefore investigated. Washed platelets were isolated from citrated blood collected 
via cardiac puncture and subsequently stimulated with MDC, ADP or a co-
stimulation of both MDC and ADP. Following stimulation, washed platelets were 
mixed with bone marrow derived PMN cells and platelet-PMN aggregates measured 
by flow cytometry as a measure of platelet activation (figure 3.45). 
Platelets stimulated with 10µM ADP induced significant formation of platelet-PMN 
aggregates ( 58.02 ± 9.80% above basal, P < 0.001). In contrast, stimulation with 
0.1µM MDC failed to induce any significant elevation of platelet-PMN conjugation 
above basal levels (Basal: 0.00 ± 3.66% vs. 4.04 ± 3.76%). Co-stimulation of 
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platelets with both 10µM ADP and 0.1µM MDC further enhanced  platelet-PMN 
aggregate formation with a 21.8% increase in platelet-aggregates observed in co-
stimulated samples compared to ADP stimulation alone (79.79 ± 5.12%, P < 0.05), 
indicating that whilst stimulation with MDC alone was insufficient to induce platelet 
activation, in combination with a primary agonist it was capable of potentiating 
platelet activation, which is in agreement with published work (Clemetson et al., 








































Figure 5. 11. Potential MDC potentiation of ADP induced platelet-leukocyte 
conjugate formation 
Platelets and PMNs were isolated from citrated blood and bone marrow from female 
Balb/c mice. Platelets were stimulated with 0.1µM MDC, 10µM ADP or co 
stimulation with both 0.1µM MDC and 10µM ADP before mixing with PMN cells. 
Platelet-leukocyte conjugation was subsequently measured via flow cytometry. Data 
expressed as mean ± SEM of % above basal. * = P < 0.05, *** = P < 0.001. # = P < 
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6.1 The Role of Purines in an Acute Model of Allergic Inflammation 
The role of purines and the platelet purinergic receptors in platelet activation has 
been extensively documented. Stimulation of platelet P2Y1 and P2Y12 receptors has 
been observed to induce increases in P-selectin expression whilst the P2X1 receptor 
involvement has been implicated in platelet shape change. All 3 purinergic receptors 
are implicated in platelet aggregation (Sun et al., 1998; Storey et al., 2000, 2002; 
Leon et al., 2003; Hechler et al., 2005; Gachet, 2006; Mahaut-Smith et al., 2011). 
Furthermore, recent research has implicated platelet purinergic receptor stimulation 
in allergic inflammation (Idzko et al., 2007; Paruchuri et al., 2009). Whilst currently, 
the importance of purines in platelet activation in the context of allergic 
inflammation remains unclear, it is becoming an area of increasing interest. Indeed at 
the time of writing a clinical trial has commenced investigating the impact of 
clopidogrel treatment on sputum eosinophil levels following allergen challenge in 
patients with asthma (http://clinicaltrials.gov/ct2/show/record/NCT01955512). In 
this thesis, evidence of a distinct mechanism of platelet activation within the context 
of allergic inflammation leading to pulmonary leukocyte recruitment is provided. 
Initial experiments were performed using the enzyme apyrase responsible for 
hydrolysing active ATP & ADP into inactive AMP. Treatment of mice sensitised 
and challenged to the allergen OVA with 100U/ml apyrase intravenously 
demonstrated significant attenuation of pulmonary macrophage, neutrophil, 
lymphocyte and eosinophil recruitment, thus agreeing with work demonstrating 
inhibition of neutrophil chemotaxis in vitro following apyrase treatment (Chen et al., 
2006). This suggests a role of purine stimulation in the context of allergic 
inflammation. Whilst this study implicates purines generally, later experiments 
specifically investigated the role of the 3 purinergic receptors expressed on the 
187 Chapter VI: Discussion 
 
 
surface of platelets (P2X1, P2Y1 and P2Y12). Whilst administration of the P2X1 
receptor specific suramin analogue NF-279 failed to inhibit allergen induced 
pulmonary leukocyte recruitment, treatment with both the P2Y1 specific receptor 
antagonists MRS2179 and MRS2500 significantly attenuated pulmonary leukocyte 
recruitment as measured in BALF in a dose-dependent manner. Interestingly, P2Y12 
receptor antagonism with MRS2395, AR-C66096 or Clopidogrel demonstrated no 
attenuation of allergen induced pulmonary leukocyte recruitment at any tested 
dosage. We confirmed that, the inability of the P2Y12 receptor antagonists was not a 
result of insufficient biological activity in this model as the highest doses of both 
AR-C66096 and Clopidogrel continued to suppress platelet aggregation towards 
ADP 6 hours post allergen challenge ex vivo. Elevated numbers of circulating 
platelet-leukocyte conjugates have previously been demonstrated in asthmatic 
patients following allergen provocation as well as within the murine model of 
allergic inflammation used in these investigations (Gresele et al., 1993; Pitchford et 
al., 2003a, 2005; Kowal et al., 2006; Johansson et al., 2012), with these circulating 
complexes believed to 'prime' leukocytes for efficient adhesion the vascular 
endothelium prior to transmigration into inflamed tissue. In this investigation, 
antigen exposure demonstrated significant elevations in circulating platelet-
leukocyte complexes at 6 hours post allergen challenge, with levels returning to 
basal levels at 24 hours, in agreement with the literature.  P2Y1 receptor antagonist 
treatment (P2Y1) suppressed allergen induced elevations in conjugate formation at 6 
hours; however this was not replicated by P2Y12 receptor antagonist treatment (AR-
C66096). This combined with pulmonary leukocyte recruitment the data suggests 
that platelet activation during the inflammatory response to allergen is mediated via 
the P2Y1 receptor. 
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Given the accepted role of the P2Y12 receptor in platelet aggregation to all platelet 
activating stimuli (Gachet, 2006), the failure of P2Y12 receptor antagonism to 
modulate allergen induced leukocyte recruitment or the formation of platelet-
leukocyte conjugates came as a surprise. Indeed, this is of particular interest given 
that previous studies have demonstrated decreased formation of platelet-leukocyte 
conjugates and P-selectin expression in Clopidogrel treated mice (Evangelista et al., 
2005) and their importance in leukocyte recruitment in numerous inflammatory 
diseases (Hayward et al., 1999; Jawieñ et al., 2002; Pitchford et al., 2005; Zarbock et 
al., 2007; Kornerup et al., 2010). Whilst in these studies P2Y12 receptor antagonism 
was not involved in pulmonary leukocyte recruitment and failed to attenuate allergen 
induced elevations in circulating platelet-leukocyte conjugates, other laboratories 
have demonstrated conflicting impacts of the P2Y12 receptor in inflammatory 
disorders with both protective (Garcia et al., 2011; Liverani et al., 2014) and 
potentiating roles (Paruchuri et al., 2009) observed in inflammatory cell recruitment. 
It is possible that the conflicting roles of P2Y12 receptors may be dependent on the 
provocation stimuli used in each study. In this model platelets were activated via an 
IgE-dependent mechanism following antigen (OVA) challenge in contrast to direct 
stimulation of platelets by leukotrienes (LTD4/LTE4) or Lipopolysaccharide (LPS) 
that has been presented in alternate models (Paruchuri et al., 2009; Liverani et al., 
2014).  
Platelet activation of purinergic receptors under haemostatic conditions is typically 
instigated by initial activation of the high affinity platelet P2Y1 ADP receptor 
promoting internal Ca
2+
 mobilisation and α-granule secretion. This leads to platelet 
derived ADP release triggering subsequent activation of the lower affinity P2Y12 
ADP receptor (Jin et al., 1998; Fabre et al., 1999; Kunapuli, 2003). This secondary 
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activation of P2Y12 receptors then promotes dense granule secretion inducing local 
generation of thrombin and TxA2 promoting integrin activation and platelet 
aggregation (Storey et al., 2000; Kauffenstein et al., 2001). With the understanding 
that under haemostatic conditions P2Y1 activation triggers subsequent P2Y12 
activation promoting platelet aggregation, it remains unclear as to why platelet 
activation by inflammatory mediators promoting leukocyte recruitment via P2Y1 
receptor stimulation does not ultimately lead to thrombosis and coagulation in vivo. 
One hypothesis is that following allergen sensitisation, alterations in the surface 
expression of the purinergic receptors might occur. However, studies investigating 
P2Y1 and P2Y12 receptor expression post allergen challenge demonstrated no 
modulation in either receptors’ expression profile. The P2Y1 and P2Y12 receptors 
demonstrate different affinities for ADP, with the P2Y1 receptor demonstrating a 
much higher affinity compared to the P2Y12 receptor (Kunapuli, 2003). It is 
therefore possible that in regions under inflammatory stress the local concentration 
of ADP is lower when compared to regions of thrombosis which are unable to 
induce P2Y12 receptor activation.  
As the formation of platelet-leukocyte complexes post allergen challenge is P-
selectin dependent (Hayward et al., 1999; Jawieñ et al., 2002; Schober, 2002; 
Pitchford et al., 2005; Zarbock et al., 2006; Kornerup et al., 2010) and is affected by 
P2Y1 receptor signalling it was possible that the dependency on P2Y1 receptor 
activation mediating engagements with leukocytes in vivo might stimulate the 
expression of leukocyte adhesion molecules enhancing leukocyte transmigration into 
inflamed tissue. To measure this a functional assay of platelet induced PMN cell 
migration previously described by Kornerup et al., 2010 towards a MDC, SDF-1α 
and f-MLP and its dependency on P-selectin, and the impact of the purinergic 
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receptors was investigated following stimulation with low dose (sub-threshold for 
aggregation, 100nM) ADP.  This potentially indentifies a source of cross-over 
signalling between separate GPCRs (i.e. CXCR4 and P2Y1 or CCR4 and P2Y1), 
allowing ADP at concentrations below the threshold for the initiation of platelet 
aggregation (100nM) to trigger platelet activation and stimulate the migration of 
leukocytes towards a chemotactic stimulus. Indeed, MDC is known to activate 
platelets in an ADP-dependent manner and MDC has previously been demonstrated 
to be present in elevated levels in asthmatic patients (Gear, 2001; Hirata et al., 2003). 
This potential cross-talk between receptors is particularly important given production 
of second messengers can be amplified by coincidental receptor activation. Cross-
talk between the Gi and Gq signalling pathways can potentiate smooth muscle 
contraction when stimulated by low (almost threshold) concentrations of agonists 
(Selbie and Hill, 1998), whilst other studies have shown cross-talk between the Gq 
linked P2Y1 and the Gi linked P2Y12 receptor in Ca
2+
 mobilisation and PI3-K activity 
(Hardy et al., 2004). This mechanism of receptor cross-talk potentially demonstrates 
a mechanism by which chemokines such as MDC and SDF-1α can induce platelet 
activation following co-stimulation with ADP and sub-threshold concentrations. 
Experiments confirmed that platelets were critical for PMN cell migration towards 
both MDC and SDF-1. Furthermore, platelet-induced PMN migration was 
significantly attenuated by pre-incubation of platelets with antagonists of either the 
CCR4 (AMD3100) or CXCR4 (C-021) receptors which are known to be expressed 
on the platelets surface antagonists (Clemetson et al., 2000), thus confirming that 
direct chemokine stimulation of platelets was critical in the instigation of PMN cell 
migration. The assay was also confirmed to be dependent upon P-selectin 
interactions with PSGL-1 through the use of an anti—P-selectin antibody proving its 
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relevance to the in vivo P-selectin dependent model of pulmonary leukocyte 
recruitment (Pitchford et al., 2003a, 2005). 
Sensitisation to OVA demonstrated significant increases in platelet induced PMN 
chemotaxis when compared to sham controls. This suggests that allergen sensitised 
platelets potentially become ‘primed’ for more efficient activation. Indeed, previous 
studies have demonstrated platelets are amongst a number of cells capable of being 
activated by allergen, with subsequent increases in cell motility and migration 
observed (Pitchford et al., 2008; Kuehn et al., 2010). Furthermore, allergen challenge 
resulted in a mild but significant state of systemic thrombocytopenia between 3 and 
24 hours, presumably as a result of the migration of platelets attached to leukocytes 
into the tissue but also potentially through direct recruitment and tissue accumulation 
(Pitchford et al., 2008). Whilst re-infusion of thrombocytopenic mice with platelets 
isolated from allergen sensitised mice demonstrated greater restoration of allergen 
induced pulmonary eosinophilia when compared to platelets isolated from naive 
mice (Pitchford et al., 2003a). This potentially describes a mechanism by which 
allergen can 'prime' platelets for efficient interactions with leukocytes contributing to 
elevated PMN migration in this assay. 
Pre-incubation of platelets with the P2Y1 receptor antagonists MRS2179 or 
MRS2500 significantly inhibited PMN chemotaxis in a dose-dependent manner to 
both MDC and f-MLP, however neither the P2Y12 receptor antagonists MRS2395 or 
AR-C66096 nor the P2X1 receptor antagonists inhibited platelet-induced PMN 
chemotaxis towards any measured chemokine. Interestingly, the P2Y1 antagonists 
failed to inhibit platelet-induced PMN chemotaxis towards SDF-1α, suggesting that 
PMN chemotaxis towards SDF-1α was independent of ADP, whilst platelet 
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activation via f-MLP and MDC initiated PMN migration in an ADP dependent 
manner. 
P2Y1 receptor expression is not solely restricted to platelets and has also been 
measured on epithelial, endothelial, immune cells and osteoclasts (Burnstock, 2007). 
Given the apparent regulatory role in P-selectin dependent PMN migration in vitro, 
the formation of platelet-leukocyte conjugates ex vivo post allergen challenge and 
pulmonary leukocyte recruitment in vivo, it was determined that the requirement of 
P2Y1 receptors for pulmonary leukocyte recruitment was platelet specific and not 
through activation of systemic P2Y1 receptors. To investigate the requirement of 
platelet specific P2Y1 receptors, OVA sensitised mice were rendered 
thrombocytopenic through a previously documented dosing regimen with the bone 
marrow depleting toxin Busulfan (Pitchford et al., 2003a, 2004, 2005, 2008).  
Thrombocytopenia can be induced using both immune and non-immune techniques, 
through either treatment with the bone marrow depleting toxin Busulfan, or through 
administration of anti-platelet antibodies i.e. APAS. For the purpose of these 
investigations, thrombocytopenia was induced through Busulfan treatment, as this 
enabled the investigation of the specific platelet purinergic receptors through 
reinfusion of drug treated platelets. In this investigation, 3 separate administrations 
of 20mg/kg Busulfan induced a severe state of thrombocytopenia characterised by an 
80% decrease in circulating platelets. Importantly, the busulfan dosing profile did 
not demonstrate any toxicity towards leukocytes and no significant decreases in 
circulating leukocytes were observed. Furthermore, previous studies have shown that 
busulfan treatment had no effect on IgE titres in allergen sensitised mice following 
acute or chronic treatment (Pitchford et al., 2003a, 2004). Neither have any effects 
been observed on the production of the Th2 cytokines IL-4 and IL-5 which are 
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critical for the development of the allergic response in this model (Pitchford, 2003). 
Moreover, any non-specific actions of busulfan treatment can be ruled out through 
the restoration of the inflammatory response following platelet replenishment of 
thrombocytopenic mice. These investigations demonstrated attenuated allergen 
induced pulmonary leukocyte recruitment in busulfan treated mice, combined with a 
restoration of leukocyte recruitment following platelet replenishment in agreement 
with previous studies (Pitchford et al., 2003a, 2005). Replenishment of platelets 
isolated from donor mice treated with saturating concentrations of the P2Y1 
antagonist MRS2500 continued to result in significant suppression of pulmonary 
leukocyte recruitment, whilst reinfusion of AR-C66096 treated platelets 
demonstrated full restoration of allergen induced pulmonary leukocyte recruitment. 
This data combined with the previous experiments provides conclusive evidence of a 
role of the platelet specific P2Y1 receptor in propagating pulmonary leukocyte 
recruitment but not the P2Y12 receptor. 
 




Figure 6. 1. A Potential dichotomy in platelet function through the P2Y1 
receptor 
 
It remains unclear as to why platelet activation of the P2Y1 receptor does not lead to 
subsequent activation of the P2Y12 receptor promoting aggregation or coagulation. 
Indeed, rather than showing increased platelet aggregation asthmatic patients display 
a mild haemostatic defect manifested by increased bleeding times (Szczeklik et al., 
1986; Ind, 1991). As previously discussed, normal activation of the P2Y12 receptor 
signals through its associated Gi G protein inhibiting adenylyl cyclase activation 
through the α subunit decreasing cAMP production (Leon et al., 2003) or promoting 
dense granule secretion through phosphatidylinositol-3-kinase (PI3-K) activation 
mediated by the β/γ subunits (Hardy et al., 2004; Gachet, 2006). In contrast, the 
P2Y1 receptor activation initiates signalling through its associated Gα G protein, 
typically signalling through PLCβ triggering Ca2+ mobilisation and PKC activation 
critical in the instigation of platelet shape change, granule secretion and initiating 
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aggregation (Hardy et al., 2004; Gachet, 2006). Interestingly however, the P2Y1 
receptor also appears to be able to couple to and activate the small GTPase RhoA 
which in other cells has been demonstrated to be involved in cell polarity and 
chemotaxis (Sakumura et al., 2005; Mong and Wang, 2009; Palani et al., 2012; 
Pleines et al., 2012; Aslan and McCarty, 2013; Sauzeau et al., 2013). The widely 
accepted role of the Rho family of GTP binding proteins is that of signalling 
switches through the hydrolysis of GTP to GDP. Small GTPase's mediation of signal 
transduction is homologous to the Gα subunits of heterotrimeric G proteins. In 
platelets they are responsible for the amplification of signals from platelet surface 
receptors. The 3 key members of the Rho GTPase family are RhoA, cdc42 and Rac1 
(Aslan and McCarty, 2013), all of which have emerged as major regulators of actin 
cytoskeleton dynamics, platelet aggregation, granular secretion, spreading and 
thrombus formation (Aslan and McCarty, 2013; Ridley, 2013a). In its active form, 
RhoA mediates the activation of Rho Kinase (ROCK). Two ROCK isoforms exist, 
ROCK1 and ROCK2 sharing an overal 64% sequence identity with 89% identity in 
the catalytic domain on the N terminus with a functional redundancy observed 
between the 2 isoforms (Mong and Wang, 2009). RhoA can mediate its effects 
through either Gα13 or Gαq. Through Gα13 stimulation, RhoA mediated activation of 
ROCK inactivates myosin light chain (MLC) phosphatase increasing MLC 
phosphorylation. This triggers subsequent actomyosin contractions and promotes 
platelet shape change. Alternatively, Gαq signalling can directly activate MLC kinase 
activation promoting direct phosphorylation of MLC promoting shape change and 
centralisation of secretory granules. (Mong and Wang, 2009; Pleines et al., 2012; 
Aslan and McCarty, 2013).  
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In this murine model of allergic inflammation, platelet activation downstream of 
P2Y1 but not P2Y12 was demonstrated to phosphorylate RhoA at residue Ser188 6 
hours post allergen challenge in vivo. Furthermore, through inhibition of Rho 
associated kinase (ROCK) with the specific receptor antagonist GSK429286 and the 
RhoA inhibitor C3 exoenzyme, RhoA appears necessary for platelet-induced PMN 
chemotaxis in vitro downstream of specific P2Y1 receptor activation with the P2Y1 
agonist MRS2365. 
The impact of RhoA phosphorylation at the Serine 188 residue remains unclear. On 
the one hand, phosphorylation of S188 is believed to inactivate RhoA (Ellerbroek et 
al., 2003; Rolli-Derkinderen et al., 2010), trapping it in a complex with guanine 
dissociation inhibitor α (GDIα), locking the inactive RhoA within the cytosol. 
However, phosphorylation of RhoA has not been shown to induce full aggregation in 
response to ADP or other primary agonists. 
Interestingly, recent studies have demonstrated that this phosphorylation mediated 
inactivation of RhoA induces the dissociation of Rac1 from GDIα allowing 
translocation of Rac1 from the cytosol to the membrane (figure 6.2). This allows its 
activation by Rac guanine exchange factors (Rac-GEFs) including Vav proteins or P-
Rex proteins, thus initiating the Rac1 signalling pathway (Rolli-Derkinderen et al., 
2010; Aslan et al., 2011). Indeed, full platelet Rac1 activation requires direct Gq 
signalling through receptors as stimulation with ADP or combined ADP and TxA2 
treatments fail to activate Rac1 in the absence of Gαq receptors (Rolli-Derkinderen et 
al., 2010). Furthermore Rac activation has previously been shown to be activated via 
the P2Y1 receptor independent of the P2Y12 and P2X1 receptors (Soulet et al., 2005; 
Aslan and McCarty, 2013). 
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Figure 6. 2. RhoA mediated activation of Rac1 
The Rac signalling pathway has also been implicated in the modulation of cell 
adhesion and migration in vascular smooth muscle cells (VSM) and human cancer 
cells (Rolli-Derkinderen et al., 2010; Valderrama et al., 2012; Carr et al., 2013). 
Rac1 signalling has also been shown to play a key role in the regulation of 
pulmonary neutrophil infiltration and tissue injury through regulating CXC 
chemokines (i.e. CXCL1 and CXCL2) and TNFα production in a murine model of 
abdominal sepsis (Hwaiz et al., 2013). Indeed, Rac1 inhibition was shown to 
decrease neutrophil accumulation in the lung, histology scores and  Mac-1 
expression on neutrophils,  expression which is typically upregulated by CXC 
chemokines (Hwaiz et al., 2013). The apparent P2Y1 dependent activation of Rac1, 
and the involvement of Rac1 in cell adhesion and migration demonstrates a potential 
separate pathway by which P2Y1 receptor stimulation in inflammation may initiate 
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the inflammatory response without triggering full platelet aggregation. However 
these studies have demonstrated that inhibition of a RhoA dependent kinase as well 
as direct inhibition of RhoA inhibits pulmonary leukocyte recruitment in vivo as well 
as platelet-dependent leukocyte migration in vitro. It is therefore important to 
consider alternative mechanisms, as RhoA activation has also been implicated in 
inflammatory processes (Li et al., 2013; Ridley, 2013b; Sauzeau et al., 2013). 
Indeed, Platelets isolated from RhoA deficient mice demonstrate a normal phenotype 
under normal conditions. However, shape change was completely abolished to G13 
agonists and severely impaired to Gq agonists such as ADP. Granule secretion to a 
wide range of platelet agonists is also severely impaired in RhoA deficient mice, as 
demonstrated by significant decreases in P-selectin expression following ADP 
stimulation and significantly increased bleeding times (Pleines et al., 2012). Rho and 
Rho associated kinase activation has previously been detected downstream of P2Y1 
signalling in vascular myocytes (Sauzeau et al., 2013). 
 
Figure 6. 3. P2Y1 mediated activation of RhoA 
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It is also possible that the elevation in RhoA phosphorylation at S188 that has been 
detected 6 hours post allergen challenge is an indirect result of increased RhoA 
activity as described by Rho dependent activation of ROCK. If Rho activity is 
elevated post allergen challenge, over time a consequence of this will be elevations 
in pRhoA for its subsequent inactivation, as has been observed in this model of 
allergic inflammation. RhoA activation downstream of Gαq has previously been 
shown to be independent of PLCβ activation and is suspected to be activated though 
activation of Rho-guanine nucleotide exchange factors (Rho-GEFS) (Pleines et al., 
2012), whilst RhoA mediated platelet shape change is known to function through 
inhibitory actions of MLC phosphatase allowing promoting rearrangement of the 
actin cytoskeleton (Pleines et al., 20120) (figure 6.3). However, whilst it is possible 
that rearrangement of the actin cytoskeleton through regulation of MLC prepares 
centralised granules for secretion the signalling mechanisms behind granule 
secretion remains unclear. 
Within this context, the role of a ROCK inhibitor GSK429286 and the RhoA 
inhibitor C3 exoenzyme have been used to inhibit Rho activity both in the in vitro 
model of platelet-induced-PMN migration, as well as in the murine model of allergic 
pulmonary inflammation. In both cases, GSK429286 demonstrated significant 
inhibition of leukocyte recruitment both in vitro and in vivo, whilst C3 exoeznzyme 
and GSK429286 inhibited P2Y1 specific stimulation of platelet induced PMN cell 
migration in vitro. Importantly, reinfusion of GSK429286 treated platelets into 
busulfan induced thrombocytopenic mice confirmed that platelet specific RhoA 
activity was involved. It is important however to clarify the exact mechanism by 
which modulation of RhoA signalling is involved in inflammatory cell recruitment, 
as both Rac1 and RhoA activation both exhibit the potential to increase cell motility 
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and migration. It is therefore important to investigate the activity of both platelet 
RhoA and Rac1 in allergen sensitised and challenged mice and the effects of the 
P2Y1 specific receptor antagonist MRS2500 has on their activity states. 
Nevertheless, this research suggests that the mechanism of platelet activation as a 
result of inflammatory stimuli, whilst requiring addition ADP stimulation of platelet 
P2Y1 receptors is fundamentally different to mechanisms of platelet activation to 
‘classical platelet agonists’ in hemostasis where additional co-stimulation of the 
P2Y12 receptors by ADP is critical (Gachet, 2006, 2008). Modulation of RhoA 
signalling downstream of platelet P2Y1 receptors therefore demonstrates a potential 
signalling pathway differentiating platelet activation towards inflammatory stimuli 
over classical platelet agonists. 
6.2 Describing a Potential Dichotomy in Platelet Function 
 
In Chapter V, experiments were performed to investigate the potential role of 
differential stimuli on platelet functions. Platelets express a large array of different 
receptors including receptors for hemostatic stimuli PAR1, PAR4, α2A 
adrenoceptor, β2 adrenoceptor, TPα, P2Y1, P2Y12 and P2X1  (Quinton et al., 2004; 
Gachet, 2006, 2008; Li et al., 2010; Soh et al., 2010). Platelets also express a large 
array of receptors for inflammatory stimuli including the f-MLP receptor FPR 
(Czapiga et al., 2005), the LPS receptor TLR-2, TLR-4 and TLR-9 (Aslam et al., 
2006; Semple and Freedman, 2010), the IL-1β receptor IL-1R1 (Brown et al., 2013), 
5-HT2A (Li et al., 2010), the SDF-1α receptor CXCR4, the MDC receptor CCR4, 
the MIP-3 receptor CCR1, and the eotaxin receptor CCR3 (Clemetson et al., 2000) 
(figure 6.4). This produces scope for large differences in platelet activation leading 
to potential differences in platelet function. Chapter V describes the differential 
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impact of both inflammatory and haemostatic parameters of platelet function using 
inflammatory stimuli (SDF-1α, MDC, f-MLP, IL-1β, 5-HT, LPS) and hemostatic 
stimuli (Adrenaline, ADP, U46619 and TRAP1). 
Using an in vitro assay of platelet chemotaxis, it was identified that stimulation of 
platelets with the chemokines SDF-1α, MDC and f-MLP induced significant 
chemotaxis compared to negative controls, a process that was not replicated by any 
hemostatic stimuli (Adrenaline, ADP, U46619, TRAP 1) or other inflammatory 
stimuli (IL-1β, 5-HT, LPS). In contrast however, IL-1β, 5-HT and LPS all 
demonstrated a potential (albeit not significant) increase in platelet-leukocyte 
conjugation, importantly none of the tested inflammatory stimuli were able to induce 
platelet aggregation. 
All haemostatic stimuli induced significant platelet aggregation, significant 
elevations in platelet P-selectin expression and significant increases in the formation 
of platelet leukocyte conjugates, however none were capable of inducing platelet 
migration. This suggests fundamental differences in platelet function depending on 
which platelet receptors are stimulated. As expected, the haemostatic stimuli studied 
(ADP, Adrenaline, U46619 and TRAP-1) all induced significant platelet activation 
through stimulation of Gαq coupled receptors (ADP, U46619 and TRAP-1) (Gachet, 
2006; Li et al., 2010; Soh et al., 2010) or the Gαs (adrenaline) (Rivera et al., 2009) 
inducing granule secretion and positive feedback of platelet activation through 
further release of platelet agonists. This was confirmed by the observed increases in 
P-selectin expression and formation of platelet-leukocyte conjugates following 
stimulation with ADP, TRAP, U46619 and adrenaline in agreement with the 
literature (Storey et al., 2002; Leon et al., 2004; Evangelista et al., 2005; Franks et 
al., 2010; Totani and Evangelista, 2010). 
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Whilst IL-1β, 5-HT and LPS demonstrated a potential increase in the formation of 
platelet leukocyte conjugates, this rise was not significant. This suggests that the 
current assay of platelet-leukocyte aggregate formation is not sensitive enough to 
detect the more subtle changes potentially induced by the weaker inflammatory 
stimulation of platelets. That said, the inability of IL-1β and LPS to induce an 
increase in P-selectin expression is not surprising. Previous studies investigating LPS 
and IL-1β stimulation of platelets have confirmed platelet activation post 
stimulation, but have demonstrated that this activation is not characterised by 
elevations in P-selectin expression (Schaufelberger et al., 1994; Brown et al., 2013) 
implying that platelet α-granules are not being secreted from the platelet. Indeed, 
previous work in murine platelets has demonstrated the LPS stimulation of platelets 
operates through an IL-1β autocrine loop resulting in the production of IL-1β mRNA 
amplifying platelet activation through ligation of TLR4 (Brown et al., 2013). 
Additional studies have also demonstrated potentiation of aggregation towards 
collagen and fibrinogen when co-stimulated with IL-1β (Beaulieu et al., 2014), 
further adding to the possibility of receptor cross-talk in the inflammatory actions of 
platelets. 
The ability of the chemokines SDF-1α, MDC and f-MLP to induce platelet migration 
is consistent with reports in the literature suggesting platelets can undergo 
chemotaxis (Czapiga et al., 2005; Kraemer et al., 2010). Platelets express functional 
CXCR4, CCR4 and FPR receptors on their surface (Clemetson et al., 2012), whilst 
platelet activation has been demonstrated towards both SDF-1α and MDC 
(Clemetson et al., 2000; Abi-Younes et al., 2001; Gear, 2001). Importantly, these 
studies also demonstrate increases in P-selectin expression (Gear, 2001), with f-MLP 
stimulation inducing Ca
2+
 mobilisation in the platelet (Czapiga et al., 2005). Here, no 
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elevation in P-selectin was detected following stimulation with SDF-1α, MDC or f-
MLP. It is possible this difference is a result in different protocols for P-selectin 
measurement, as Gear et al. 2001 measured P-selectin expression following 
agitation, an additional variable capable of contributing to platelet activation (Gear, 
2001). It is also possible that the measurement of platelet activation through 
quantification of P-selectin expression is not a suitable assay as small elevations may 
not be detectable. Therefore, other assays investigating markers of platelet activation 
should be considered including measurements of platelet shape change, Ca
2+
 
mobilisation and potentially CD40L expression. The suggestion that the assay of P-
selectin expression demonstrates poor sensitivity as a marker of chemokine induced 
platelet activation is further supported by the ability of these chemokines (SDF-1α, 
MDC and f-MLP) to induce platelet migration. Indeed previous studies have 
demonstrated platelet migration to f-MLP and SDF-1α (Czapiga et al., 2005; 
Kraemer et al., 2010), thus demonstrating functional activity of platelets following 
stimulation by chemokines. Importantly, platelets stimulated with SDF-1α, MDC 
and f-MLP, whilst inducing significant chemotaxis had no effect on platelet 
aggregation, highlighting a potential mechanism by which platelet activation by 
inflammatory stimuli differs from platelet activation through hemostatic stimuli. 
This is interesting as chapter IV depicts a mechanism through ADP stimulation of 
the P2Y1 receptor triggering inflammatory events (pulmonary leukocyte recruitment) 
without proceeding through to platelet aggregation, in agreement with heightened 
levels of platelet activation markers in asthmatic patients with a phenotype of mild 
hemostatic defects (Moritani et al., 1998; Sullivan et al., 2000; Pitchford et al., 
2003a; Kowal et al., 2006). Given that ADP receptor P2Y1 and the chemokines SDF-
1α and MDC all signal through receptors coupled to the Gαq G protein (Gear, 2001; 
204 Chapter VI: Discussion 
 
 
Gachet, 2006; Clemetson et al., 2012), it is possible that co-operation between the 
signalling pathways exists. Indeed, studies have previously demonstrated that 
chemokine dependent aggregation or adhesion of platelets under flow conditions was 
dependent on low levels of primary agonists such as ADP, at sub-threshold 
concentrations required for aggregation alone (Gear, 2001). This being considered, 
initial preliminary experiments were performed investigating potential synergy 
between chemokine and ADP stimulation in vitro. Co-stimulation with ADP and 
MDC demonstrated synergy in the formation of platelet-leukocyte complexes in 
human whole blood potentially demonstrating a pathway by which inflammatory 
receptors combined with the P2Y1 receptor could contribute to inflammatory actions 
of platelets without platelet aggregation. In chapter IV, inhibition of ROCK was 
demonstrated to inhibit platelet-induced PMN chemotaxis in vitro whilst also 
inhibiting pulmonary leukocyte recruitment in vivo. Given the ability of the Gαq 
coupled P2Y1 receptor to modulate the signalling of RhoA seen here and reported 
RhoA signalling downstream of Gαq coupled receptors (Mong and Wang, 2009; 
Pleines et al., 2012; Aslan and McCarty, 2013), it is possible that chemokine 
receptors such as the SDF-1α receptor CXCR4 and the MDC receptor CCR4 also 
signal through RhoA and synergise with subthreshold concentrations of ADP 
stimulating the high affinity P2Y1 receptor inducing platelet activation which is 
fundamentally different to aggregation with no secondary phase aggregation 
observed (figure 6.1). Therefore, the impact of chemokine stimulation of RhoA 
activity, or investigations should be performed to detect if inflammatory mediator 
stimulation of platelet migration is sensitive to inhibition of ROCK. 
 
 




6.3 Future Work 
In chapter IV, a particular role of the ADP activated P2Y1, but not the P2Y12 or 
P2X1, receptors was discovered to be critical in pulmonary leukocyte recruitment in 
vivo, platelet-leukocyte conjugation in vitro and platelet-induced-PMN migration in 
vitro. Whilst modulation of RhoA signalling downstream of the P2Y1 receptor is 
evident, it still remains unclear as to why activation of the P2Y1 receptor under 
inflammatory conditions does not signal the same way as activation to haemostatic 
stimuli demonstrated by granule secretion and subsequent activation of the P2Y12 
receptor critical in the amplification of P2Y1 initiated platelet aggregation. 
Therefore, further work needs to investigate in more detail how RhoA activity is 
modulated following allergen challenge and the effects on other signalling events 
mediated by the P2Y1 receptor. Furthermore, if RhoA is becoming activated which 
specific proteins are involved? Is the Gq associated G protein directly responsible for 
the production of active GTP bound RhoA? If so, is this process independent of Gαq 
activation of PLCβ and subsequent elevations in intracellular Ca2+, PKC activation 
and α-granule secretion?  
In the in vitro model of platelet-induced PMN chemotaxis, platelets become 
activated following stimulation with 0.1µM ADP and chemokine (MDC, SDF-1α, f-
MLP). 0.1µM ADP is incapable of inducing platelet aggregation and is such 
considered to be a sub-threshold concentration. However, in combination with 
additional chemokine stimulation, significant platelet-induced leukocyte chemotaxis 
is observed. Furthermore, costimulation of platelets with MDC and 10µm ADP 
demonstrates elevated platelet-leukocyte conjugation greater than the summation of 
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stimulation with either MDC or ADP alone. When this is combined with evidence in 
the literature demonstrating significant potentiation of platelet function induced by 
MDC, TARC and SDF-1α when constimulated with low dose ADP (0.1µM) (Gear, 
2001), it becomes clear that there is potential co-operation between ADP receptors 
and other receptors such as the chemokine receptors. However, work needs to be 
investigated on a range of different receptors to investigate if co-operation is limited 
to Gq coupled receptors such as the CXCR4 and CCR4 receptors or whether it is a 
more generic phenomenon involving other inflammatory receptors such as TLR’s, 5-
HT receptors, IL-1R1 etc. Therefore using a similar experimental plan to those used 
in experiments described in chapter V, co-operation of low dose ADP with the 
inflammatory stimuli SDF-1α, MDC, IL-1β, f-MLP, 5-HT, LPS needs to be 
investigated. 
Finally, at the outset of this research the aim was to investigate the differential role 
of platelet ADP receptors in pulmonary leukocyte recruitment. This mechanism of 
platelet involvement in inflammation may be more widespread than solely allergen 
induced leukocyte recruitment. Indeed, platelets have previously been implicated in 
non-allergic conditions of inflammation including COPD, RA, IBS and 
atherosclerosis (Ott I, Neumann FJ, Gawaz M, Schmitt M, 1996; Ferroni P, Basili S, 
Martini F, Vieri M, Labbadia G, Cordova C, Alessandri C, 2000; Bunescu et al., 
2004). Platelets have also more recently been implicated in inflammation associated 
with bacterial infection. Indeed, platelet dysfunction has been observed in cystic 
fibrosis (CF), with increased platelet activation observed towards gram-negative 
infection with increased elevations in platelet derived mediators, platelet-monocyte 
interactions, platelet-neutrophil interactions and P-selectin expression (O’Sullivan et 
al., 2005; O’Sullivan and Michelson, 2006). It is therefore important to investigate 
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whether the P2Y1 specific role in pulmonary leukocyte recruitment observed in this 
murine model of acute allergic inflammation is replicated in additional models such 
as LPS induced pulmonary leukocyte recruitment and in a model of respiratory 
infection with Pseudomonas aeruginosa in the rat mimicking pulmonary 
inflammation typical of CF (Growcott et al., 2011). 
6.4 Final Remarks 
The conjugation of platelets with leukocytes and their subsequent recruitment to the 
lungs is dependent on the expression of platelet P-selectin and its interactions with 
its counter ligand PSGL-1 (Sanctis et al., 1997; Lukacs et al., 2002; Pitchford et al., 
2005), furthermore a number of studies have demonstrated that activation of both the 
P2Y1 and P2Y12 receptors induced elevations in P-selectin expression through 
granule secretion (Storey et al., 2002; Leon et al., 2003). It was therefore somewhat 
surprising that in these studies P2Y12 receptor activation does not appear to be 
involved in the P-selectin-dependent mechanism of pulmonary leukocyte 
recruitment. It stands to reason that the mechanism of platelet activation by 
inflammatory mediators is fundamentally different to the mechanism of platelet 
activation induced by the 'classical' platelet agonists, where co-activation of the 
P2Y12 receptor by ADP is involved, even when the end result (P-selectin) is similar 
but ultimately results in differences in platelet function. This ability of inflammatory 
stimuli to induce platelet activation without altering haemostasis highlights a 
fundamental dichotomy in platelet activation (Page, 1988). This has far reaching 
implications for a wide range of inflammatory disorders associated with heightened 
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